

CURRICULUM VITAE

Date prepared: July 8, 2019

NAME: Gregory J. Tsongalis, Ph.D., H.C.L.D., F.A.C.B., C.C.

ADDRESS: Office
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756
Tel: (603) 650-5498
Email: Gregory.J.Tsongalis@Hitchcock.org

I. EDUCATION:

<u>DATES</u>	<u>INSTITUTION</u>	<u>DEGREE</u>
1980 – 1984	University of Massachusetts at Amherst	B.S., Major: Zoology, Minor: Chemistry
1984 – 1986	Quinnipiac College Hamden, CT	M.H.S., Pathology Assistant Training Program
1986 – 1990	Rutgers Graduate School of Biomedical Sciences (formerly UMDNJ), Newark, NJ	Ph.D., Pathology

II. POSTDOCTORAL TRAINING

<u>DATES</u>	<u>INSTITUTION</u>	<u>SPECIALTY</u>
6/85 – 10/85	West Haven Veterans' Administration, Medical Center, West Haven, CT,	Surgical and Autopsy Pathology Internship
10/85 – 2/86	Saint Vincent's Medical Center, Bridgeport, CT,	Surgical and Autopsy Pathology Internship
2/86 – 5/86	Norwalk Community Hospital, Norwalk, CT,	Surgical and Autopsy Pathology Internship
1990 – 1992	University of North Carolina, Chapel Hill, NC,	Postdoctoral Research Associate, Molecular Carcinogenesis, Dept. of Pathology (David Kaufman)
1992 – 1994	University of North Carolina Hospitals, Chapel Hill, NC,	Clinical Research Fellow, Clinical Chemistry Training Program, Dept. of Hospital Laboratories, Division of Molecular Pathology and Clinical Chemistry (Lawrence Silverman)

III. ACADEMIC APPOINTMENTS

<u>DATE</u>	<u>INSTITUTION</u>	<u>TITLE</u>
1995 – 2003	University of Connecticut, Storrs, CT,	Adjunct Assistant Professor of Pathobiology
1995 – 2003	University of Connecticut Health Center, Farmington, CT,	Adjunct Assistant Professor of Laboratory Medicine and of Pediatrics

1996 – 2003	Quinnipiac University, Hamden, CT, Adjunct Professor of Graduate Program Medical Laboratory Sciences
2002 – 2003	School of Allied Health, University of Connecticut, Storrs, CT, Assistant Professor
2002 – 2014	University of Connecticut, Storrs, CT, Adjunct Associate Professor of Pathobiology
2004 – 2005	Dartmouth Medical School, Hanover, NH, Assistant Professor of Pathology
2005 – 2010	Dartmouth Medical School, Hanover, NH, Associate Professor of Pathology
2010 – present	The Geisel School of Medicine at Dartmouth, Hanover, NH (Formerly DMS), Professor of Pathology

IV. LICENSURE AND CERTIFICATION (IF APPLICABLE):

<u>DATE</u>	<u>LICENSURE/CERTIFICATION</u>
1997	High Complexity Clinical Laboratory Director (HCLD), American Board of Bioanalysis (#7296)
1997	Clinical Laboratory Specialist in Molecular Biology (CLSpMB), National Certification Agency for Medical Laboratory Personnel
2002	Fellow Academy of Clinical Biochemistry
2012	Clinical Consultant (CC), American Board of Bioanalysis (#7296)

V. HOSPITAL APPOINTMENTS (IF APPLICABLE):

<u>DATES</u>	<u>INSTITUTION</u>	<u>POSITION/TITLE</u>
1994 – 2004	Hartford Hospital, Hartford, CT, Director, Molecular Pathology and Associate Director, Clinical Chemistry, Hartford Pathology Associates and the Department of Pathology and Laboratory Medicine	
1994 - 2010	Hartford Hospital, Hartford, CT, Consulting Staff, Department of Pathology and Laboratory Medicine	
2004 – 2015	Dartmouth-Hitchcock Medical Center, Lebanon, NH, Director, Molecular Pathology, Dept. of Pathology	
2005 –	Dartmouth-Hitchcock Medical Center and The Geisel School of Medicine at Dartmouth, Lebanon, NH, Co-Director, Pharmacogenomics Program	
2005 –	Norris Cotton Cancer Center, Lebanon, NH, Clinical Oncology Affiliate Member	
2007 – 2009	Dartmouth-Hitchcock Medical Center, Lebanon, NH, Interim Director, Clinical Chemistry Laboratory, Dept. of Pathology	
2007 – 2015	Dartmouth-Hitchcock Medical Center and The Geisel School of Medicine at Dartmouth, Lebanon, NH, Co-Director, Pathology Translational Research Core Facility	

2007 – 2018	Norris Cotton Cancer Center, Lebanon, NH, Member, Molecular Therapeutics Research Program
2014-	Norris Cotton Cancer Center, Lebanon, NH, Breast Cancer Program Team member
2014-	Norris Cotton Cancer Center, Lebanon, NH, Gastrointestinal Cancer Program Team member
2015-2017	Mt. Ascutney Hospital, Ascutney, VT, Medical Director of Clinical Laboratories
2015-	Dartmouth-Hitchcock Health System and The Geisel School of Medicine at Dartmouth, Lebanon, NH, Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
2019-	Norris Cotton Cancer Center, Lebanon, NH, Member, Cancer Biology and Developmental Therapeutics Program
2019-	Vice Chair for Research, Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Health System and The Geisel School of Medicine at Dartmouth, Lebanon, NH

VI. OTHER PROFESSIONAL POSITIONS (NON-DARTMOUTH):

<u>DATES</u>	<u>INSTITUTION</u>	<u>POSITION/TITLE</u>
1985	Office of the Chief Medical Examiner, State of Connecticut, Farmington, CT,	Medicolegal Autopsy Pathology
1985 – 1986	West Haven Veterans' Administration Medical Center, West Haven, CT,	Research Associate, Department of Pathology
1985 – 1986	Diagnostic Medical Laboratories, Branford, CT,	Surgical Pathology
1986 - 1988	Saint Barnabas Medical Center, Livingston, NJ,	Clinical Microbiology, Department of Pathology
2009 – 2011	Baystate Health Systems, Springfield, MA,	Consulting Director, Molecular Pathology Laboratory
2/2014-9/2014	Baystate Health Systems, Springfield, MA,	Consulting Director, Molecular Pathology Laboratory
8/2014-4/2016	JAX Genomic Medicine Center, Farmington, CT,	Interim Director, Clinical Genomics Laboratory

VII. TEACHING ACTIVITIES:

Please append course reviews or other metrics (e.g., eVal) with your CV.

A. UNDERGRADUATE (COLLEGE) EDUCATION

<u>DATES</u>	<u>INSTITUTION</u>	<u>COURSE TITLE</u>	<u>ROLE</u>	<u>HOURS/YR</u>
2004-2014	Dartmouth-Hitchcock Medical Center, UNH Medical Technology Program,		Lecturer,	3 hours/year
2013	Dartmouth College,	Biology,	Lecturer,	2 hours/year
2018	Dartmouth College Thayer School of Engineering (ENGS56),	Lecture-Clinical Genomics		(1 hour)

B. GRADUATE EDUCATION (List classes taught for Ph.D. and Masters students):

<u>DATES</u>	<u>INSTITUTION</u>	<u>COURSE TITLE</u>	<u>ROLE</u>	<u>HOURS/YR</u>
1996-2003	Quinnipiac University, Hamden, CT,	Molecular Pathology,	Lecturer and Course Organizer	
1999-2000	Univ. of Connecticut School of Allied Health, Storrs, CT,	Molecular Diagnostics,	Lecturer and Course Organizer	
9/2015-	Dartmouth College,	Program in Experimental and Molecular Medicine (PEMM),	Member	

C. UNDERGRADUATE MEDICAL EDUCATION:

i. CLASSROOM TEACHING

<u>DATES</u>	<u>INSTITUTION</u>	<u>COURSE TITLE</u>	<u>ROLE</u>	<u>HOURS/YR</u>
1994-1998	Univ. of Connecticut Medical School, Farmington, CT,	Year One Medical Genetics Course,	Lecturer, Problem-based Learning Group Leader	
1997-2003	Univ. of Connecticut School of Allied Health, Storrs, CT,	Diagnostic Genetic Sciences Program,	Lecturer and Clinical Site Director	
2000-2003	Univ. of Connecticut School of Allied Health, Storrs, CT,	Molecular Diagnostic Technologies,	Lecturer and Course Organizer	
2003-present	Univ. of Medicine and Dentistry of New Jersey, Newark, NJ	Introduction to Molecular Genetics,	Online course "Molecular Diagnostics"	
2005-2016	The Geisel School of Medicine at Dartmouth (formerly DMS),	General Pathology Course	Lecturer, Once per Year, 2 hours	
2008	Dartmouth Medical School,	Scientific Basis of Medicine,	Year 2 Lecturer	

D. GRADUATE MEDICAL EDUCATION (Inclusive of instruction of residents and fellows during clinical practice):

<u>DATES</u>	<u>INSTITUTION</u>	<u>COURSE TITLE</u>	<u>ROLE</u>	<u>HOURS/YR</u>
2009-present	Dartmouth-Hitchcock Medical Center	Pathology Fellowship Programs: Cytopathology, Dermatopathology, Hematopathology, Transfusion Medicine,	Teaching Faculty	

2010	Dartmouth-Hitchcock Medical Center Faculty	Anesthesia Resident rotation in Pathology, Teaching	
2018-present	DHMC	DNA extraction Polymerase chain reaction HIV/HCV VL Pharmacogenomics Identity testing	1hr/yr 1 hr/yr 1 hr/yr 1 hr/yr 1 hr/yr

VIII. ADVISING/MENTORING:**A. UNDERGRADUATE STUDENTS**

e.g., Dartmouth College Arts and Sciences students

<u>DATES</u>	<u>STUDENT'S NAME</u>	<u>PROGRAM (e.g., WISP, Presidential Scholar)</u>
June-Dec 2005	Kelly Gilbert	Supervisor, Student Affiliation, Univ. of Conn (Storrs)
Jan-June 2008	Angela Marcghetti	Supervisor, Diagnostic Genetic Sciences Program Clinical Internship, Univ. of Conn (Storrs)
Jan-June 2008	Nicole Nintean	Supervisor, Diagnostic Genetic Sciences Program Clinical Internship, Univ. of Conn (Storrs)
May-Aug. 2008	Nathaniel Hicks	Supervisor, Summer student research fellow from Univ. of Vermont
July 2008-Jan. 2009	Kyle Peras	Supervisor, Diagnostic Genetic Sciences Program Clinical Internship from Univ. of CT
June 2010-Aug. 2010	Brendan Wood	Supervisor, Summer Student Research Fellow from Univ. of NH
Jan. 2011-March 2011	Kristine M. Abo	Supervisor, Undergraduate Research Internship, Dartmouth College
Jan. 2011-June 2011	Minh-Hang Hoang	Supervisor, Diagnostic Genetic Sciences Program Clinical Internship, Univ. of Conn (Storrs)
June 2011-Aug 2011	Brendan Wood	Supervisor, Summer Student Research Fellow from Univ. of NH
June-Aug 2013	Courtney Lancor	Supervisor, Undergraduate summer research fellowship, University of New Haven, "Establishing an anonymized DNA bank"
June-August 2015 August 2016	Rachel Alibozek	Sponsor, Precision Summer internship (Elmira June-College)
June-August 2015	Anghad Singh	Sponsor, Precision Summer internship (McGill University)
June-August 2015	Peter Tsongalis	Sponsor, Precision Summer internship (Virginia Tech)
June-August 2015	Christopher Wells	Sponsor, Precision Summer internship (Skidmore College)
May-August 2016	Mackenzie Kegan	Supervisor, Precision Summer internship (Northeastern University)
June-August 2016	John He	Supervisor, Summer student internship (Hanover High School)
January-June 2017	Courtney Studwell	Supervisor, University of Connecticut, Diagnostic Genetic Sciences Program Clinical Internship
January-June 2017	Jennifer Kilbourn	Supervisor, Graduate Internship, Professional Science Masters in Applied Genomics, University of Connecticut, Storrs
June-August 2017	James Dinulos	Supervisor, Precision Summer Internship (Dartmouth College)

June-August 2017,2018	Rachael Barney	Supervisor, Precision Summer Internship (University of Vermont)
August-Dec. 2017	Kelly Goodwin	Supervisor, University of Connecticut, Diagnostic Genetic Sciences Program Clinical Internship
June-August 2018	Alicia Finney	Supervisor, Precision Summer Internship (University of New Hampshire)
Augsut-October 2018	Stanley Rozentsvit	Supervisor, Research Internship (Dartmouth College)
January-June 2019	Anna Mackay	Supervisor, University of Connecticut, Diagnostic Genetic Sciences Program Clinical Internship

B. GRADUATE STUDENTS

<u>DATES</u>	<u>STUDENT'S NAME</u>	<u>PROGRAM NAME</u>	<u>DEGREE</u>
1993-1998	Salvatore Frasca, Jr.	Veterinary Pathology, Univ. of Conn (Storrs), Resident	and PhD student
1994-1999	Richard C. Johnson	Univ. of Conn (Storrs)	PhD student
2000-2006	Andrew Draghi II	Univ. of Conn (Storrs)	PhD Student
2000-2007	Judith D. Brown	Univ. of Conn (Storrs)	PhD Student
2001-2006	Bruce E. Blanchard	Univ. of Conn (Storrs)	PhD Student
2002-2007	Daniel H. Best	Univ. of North Carolina (Chapel Hill),	PhD Student
Feb.-April 2013	Jason Peterson	Professional Science Masters in Applied Genomics, University of Connecticut, Storrs, Graduate Internship,	
Sept. 2017-	Amogha Tadimety	Thayer School of Engineering, Dartmouth College, Hanover, NH,	PhD candidate

C. MEDICAL STUDENTS

<u>DATES</u>	<u>STUDENT'S NAME</u>	<u>PROGRAM NAME (if applicable)</u>
Jan.-June 2007	Constantinos T. Spyris,	Howard Hughes Medical Institute Fellow, Dartmouth College
Jan.-June 2007	Rashmi Agarwal	Howard Hughes Medical Institute Fellow, Dartmouth College
June 2007-May 2008	Constantinos T. Spyris,	James O. Freedman Presidential Scholar Award, Dartmouth College
June-Aug. 2008	Gabriel Belanger	Summer student research fellow, Dartmouth Medical School
2011	Ziev Moses,	Post-Sophomore Fellow in Pathology, Dartmouth Medical School

D. RESIDENTS/FELLOWS

<u>DATES</u>	<u>MENTEE'S NAME</u>	<u>SPECIALTY</u>
2007-2010	Claudine L. Bartels	Molecular Pathology and Translational Research training program, DHMC, Post-doctoral Fellow
2007-2010	Joel Lefferts	Molecular Pathology and Translational Research training program, DHMC, Post-doctoral Fellow
2011-2013	Soya Sam	Molecular Pathology and Translational Research training program, DHMC, Post-doctoral Fellow
2011-2013	Ahmad N. Abou Tayoun	Molecular Pathology and Translational Research training program, DHMC, Post-doctoral Fellow
2012-2014	Francine de Abreu	Molecular Pathology and Translational Research training program, DHMC, Post-doctoral Fellow
April 2014-June 2016	Scott A. Turner	Molecular Pathology and Translational Research training

Sept. 2015-May 2017	Hou-Sung Jung	program, DHMC, Post-doctoral Fellow Clinical Genomics and Advanced Technology training program, DHMC and Geisel School of Medicine, Post-doctoral Fellow
August 2016-July 2018	Aaron Atkinson	Clinical Genomics and Advanced Technology training program, DHMC and Geisel School of Medicine, Post-doctoral Fellow
August 2017-	M. Rabie Al Turkmani	Clinical Genomics and Advanced Technology training program, DHMC and Geisel School of Medicine, Post-doctoral Fellow
July 2017-	Lauren Petersen	Clinical Genomics and Advanced Technology training program, DHMC and Geisel School of Medicine, Post-doctoral Fellow

IX. COMMUNITY SERVICE, EDUCATION, AND ENGAGEMENT:

List activities relevant to your professional roles

<u>DATES</u>	<u>INSTITUTION</u>	<u>COURSE TITLE</u>	<u>ROLE</u>	<u>HOURS/YR</u>
2012	Dartmouth Medical School, Dartmouth Community	Medicine Series, Lecturer,	1 hr/yr	
2012-2013	Science Cafe	Presenter	1 hr/yr	
2017	Hanover Senior Center	Presenter	1 hr/yr	
2019	The Prouty-NCCC Fundraiser	Co-Chair	Annual	
2019	Lyme Elementary School	Science fair	1.5 hrs/yr	

X. RESEARCH FUNDING:

A. CURRENT SUPPORT

DATES: 10/1/2016-9/30/2019
PROJECT TITLE/NUMBER: NCI MATCH Trial
ROLE / % EFFORT: PI
SPONSOR: NCI-Leidos
ANNUAL DIRECT COSTS: \$452,870

Dates: 12/01/14-11/30/19
PROJECT TITLE/NUMBER: Cancer Center Support Grant/P30 CA023108
ROLE/% EFFORT: Director Pathology Shared Resource/5%
SPONSOR: NCI

B. PAST SUPPORT

DATES: 1/2/2017-12/30/2018
PROJECT TITLE/NUMBER: Cervical Cancer Screening Using Viral DNA Analysis and Telepathology
as a Global Health Strategy in LMICs
ROLE/ % EFFORT: PI
SPONSOR: Munck-Pfefferkorn Novel and Interactive Grant
ANNUAL DIRECT COSTS: \$145,077

DATES: 10/1/2016-9/30/2017

PROJECT TITLE/NUMBER: ctDNA in pancreatic cancer patients as a marker of disease progression

ROLE / % EFFORT: PI

SPONSOR: GI COG

ANNUAL DIRECT COSTS: \$50,000

DATES: 01/2016-12/30/2016

PROJECT TITLE/NUMBER: Bench to Community: Fast Track to Global Health Strategy to ID Women with High Risk HPV

ROLE / % EFFORT: PI

SPONSOR: Munck-Pfefferkorn Novel and Interactive Grant

ANNUAL DIRECT COSTS: \$63,378

DATES: 01/2014-12/30/16

PROJECT TITLE/NUMBER: Molecular profiling of tumor and ctDNA

ROLE / % EFFORT: PI

SPONSOR: Friends of NCCC Scholar

ANNUAL DIRECT COSTS: \$50,000

DATES: 06/2011-05/2015

PROJECT TITLE/NUMBER: PCR sample preparation simplified for developing world point-of-care diagnostics & quantitative PCR (qPCR) amplification and detection. Global Health Grant #OPP1028794

ROLE / % EFFORT: Collaborator

SPONSOR: Bill & Melinda Gates Foundation

(Grant awarded to Axel Scherer at the California Institute of Technology)

ANNUAL DIRECT COSTS: \$289,292

DATES: 03/01/13-01/31/2018

PROJECT TITLE/NUMBER: 1P20GM104416

ROLE / % EFFORT: Investigator / 2%

SPONSOR: COBRE Center for Molecular Epidemiology

ANNUAL DIRECT COSTS: Federal Direct Costs: \$1,793,732

DATES: 1986 – 1990

PROJECT TITLE/NUMBER: Predoctoral Training Fellowship, Dept. of Laboratory Medicine and Pathology

ROLE / % EFFORT:

SPONSOR: Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey

ANNUAL DIRECT COSTS:

DATES: 1990 - 1992

PROJECT TITLE/NUMBER: Postdoctoral Fellowship, Environmental Pathology Training Program, University of NC at Chapel Hill, National Research Service Award

ROLE / % EFFORT:

SPONSOR: NIEHS

ANNUAL DIRECT COSTS:

DATES: 07/01/1994 – 06/30/1996

PROJECT TITLE/NUMBER: Molecular Alterations in Human Breast Cancer
ROLE / % EFFORT:
SPONSOR: Hartford Hospital Research Office
ANNUAL DIRECT COSTS:

DATES: 10/1995 – 09/1997
PROJECT TITLE/NUMBER: Apolipoprotein E genotypes of adults and elders with Down Syndrome.
#121024
ROLE / % EFFORT:
SPONSOR: Hartford Hospital Research Office
ANNUAL DIRECT COSTS:

DATES: 08/1996 – 07/1997
PROJECT TITLE/NUMBER: DNA Fingerprinting for identification of urine specimen donors by the
PM+DQA1 PCR amplification and typing kit.
ROLE / % EFFORT:
SPONSOR: Medical Review Officer Certification Council, Arlington Heights, IL
ANNUAL DIRECT COSTS:

DATES: 07/1996 – 01/1998
PROJECT TITLE/NUMBER: Clinical outcome of patients exhibiting gene mutation of coagulation factor
V during and following discharge from the ICU. #1017-20-063
ROLE / % EFFORT:
SPONSOR: Hartford Hospital Research Office
ANNUAL DIRECT COSTS:

DATES: 01/1998 – 01/1999
PROJECT TITLE/NUMBER: Genetic and epigenetic abnormalities in the development and progression
of sporadic breast cancer.
ROLE / % EFFORT:
SPONSOR: Hartford Hospital Research Office
ANNUAL DIRECT COSTS:

DATES: 01/2002 – 01/2003
PROJECT TITLE/NUMBER: Comparison of FISH and immunohistochemical technologies for
determining HER2 gene amplification in primary breast cancer. #01-045
ROLE / % EFFORT:
SPONSOR: Hartford Hospital Research Office
ANNUAL DIRECT COSTS:

DATES: 06/2004 – 06/2005
PROJECT TITLE/NUMBER: Comparison of the aneuploidy invader assay to traditional cytogenetics for
the analysis of products of conception. Dartmouth CPHS #16971
ROLE / % EFFORT:
SPONSOR: Collaboration with Third Wave Technologies, Madison, WI
ANNUAL DIRECT COSTS:

DATES: 04/2005-04/2006
PROJECT TITLE/NUMBER: Sample procurement for the evaluation of reagents for the detection of
high risk types of human papillomavirus (HPV). Dartmouth CPHS#17403.
ROLE / % EFFORT:

SPONSOR: Collaboration with Third Wave Technologies, Madison, WI
ANNUAL DIRECT COSTS:

DATES: 06/2005-06/2006

PROJECT TITLE/NUMBER: Molecular markers in breast cancer. Dartmouth CPHS#17540

ROLE / % EFFORT:

SPONSOR: Collaboration with Abbott-Vysis, Des Plaines, IL

ANNUAL DIRECT COSTS:

DATES: 07/2005-12/2008

PROJECT TITLE/NUMBER: Assessing clinically relevant markers of biological pathways.

ROLE / % EFFORT:

SPONSOR: Research agreement with Luminex Corporation, Austin, TX

ANNUAL DIRECT COSTS: \$45,000

DATES: 09/2005-09/2006

PROJECT TITLE/NUMBER: Evaluation of the Abbott-Vysis breast aneusomy multicolor probe set.
Dartmouth CPHS#17685

ROLE / % EFFORT:

SPONSOR: Collaboration with Abbott-Vysis, Des Plaines, IL

ANNUAL DIRECT COSTS:

DATES: 12/2005-11/2010

PROJECT TITLE/NUMBER: Alternative Breast Cancer Imaging Modalities. PO1 080139-06A2

ROLE / % EFFORT: Core B Investigator

SPONSOR: National Cancer Institute

ANNUAL DIRECT COSTS:

DATES: 06/2006-06/2007

PROJECT TITLE/NUMBER: Evaluation and comparison of the Nanosphere Verigene System to a currently used method for genotyping the Factor II, Factor V, and MTHFR single nucleotide polymorphisms. Dartmouth CPHS#320264

ROLE / % EFFORT:

SPONSOR: HF Contract with Nanosphere, Inc., Northbrook, IL

ANNUAL DIRECT COSTS:

DATES: 08/2006-08/2007

PROJECT TITLE/NUMBER: Validation of the Veridex GeneSearch breast lymph node assay – Clinical trial BLN-US-DH-2006.00. Dartmouth CPHS#20365

ROLE / % EFFORT:

SPONSOR: HF Contract with Veridex, Inc., Warren, NH

ANNUAL DIRECT COSTS: \$17,000

DATES: 10/2006-10/2007

PROJECT TITLE/NUMBER: Comparison of the performance of the Bayer System 340 and System 440.

ROLE / % EFFORT:

SPONSOR: HF Contract with Bayer Healthcare, LLC

ANNUAL DIRECT COSTS:

DATES: 10/2006

PROJECT TITLE/NUMBER: A multicenter study to evaluate the reproducibility of the InPlex CF Molecular test for detection of CFTR mutations.

ROLE / % EFFORT:

SPONSOR: HF Contract with TWT, Inc., Madison, WI

ANNUAL DIRECT COSTS:

DATES: 11/2006-11/2007

PROJECT TITLE/NUMBER: The evaluation of miRNA profiling in pancreatic cancer. Dartmouth CPHS#20438

ROLE / % EFFORT:

SPONSOR: HF Contract with Asuragen, Inc., Austin, TX

ANNUAL DIRECT COSTS:

DATES: 01/2007-03/2007

PROJECT TITLE/NUMBER: Evaluation of the Verigene system and hypercoagulation panel clinical protocol – FDA Trial.

ROLE / % EFFORT:

SPONSOR: HF Contract with Nanosphere, Inc., Northbrook, IL

ANNUAL DIRECT COSTS: \$33,000

DATES: 02/2007-02/2008

PROJECT TITLE/NUMBER: Nanosphere Verigene Warfarin Metabolism Nucleic Acid test evaluation – FDA trial.

ROLE / % EFFORT:

SPONSOR: HF Contract with Nanosphere, Inc., Northbrook, IL

ANNUAL DIRECT COSTS: \$19,000

DATES: 08/2008-07/2010

PROJECT TITLE/NUMBER: MicroRNAs as novel biomarkers for pancreatic ductal adenocarcinoma. R21CA133715-1A01

ROLE / % EFFORT: 3%

SPONSOR: National Cancer Institute

ANNUAL DIRECT COSTS: \$157,500

DATES: 09/2008-06/2010

PROJECT TITLE/NUMBER: CD154 CA repeat polymorphisms and RA pathogenesis.

ROLE / % EFFORT: 5%

SPONSOR: American College of Rheumatology Research and Education Foundation

ANNUAL DIRECT COSTS: \$185,185

DATES: 07/2009-12/2011

PROJECT TITLE/NUMBER: Variations in colonoscopy: A population based study.

ROLE / % EFFORT: 3%

SPONSOR: NCI-APRC

ANNUAL DIRECT COSTS: \$203,826

DATES: 01/2010-12/2010

PROJECT TITLE/NUMBER: MicroRNAs in delineating prognostic risk groups in chronic lymphocytic leukemia.

ROLE / % EFFORT: PI

SPONSOR: Norris Cotton Cancer Center Developmental Funds

ANNUAL DIRECT COSTS: \$23,860

DATES: 01/2012-12/2013

PROJECT TITLE/NUMBER: MicroRNA expression in patients with myelodysplastic syndrome treated with hypomethylating drugs.

ROLE / % EFFORT: Co-PI

SPONSOR: Norris Cotton Cancer Center Development Funds (Pilot Projects)

ANNUAL DIRECT COSTS: Total Directs: \$49,657

XI. PROGRAM DEVELOPMENT (List any educational, clinical or research entities at Dartmouth that were created or notably advanced by your efforts):

1. Pathology Translational Research Program (Co-Founder, 2013)
2. Topics in Molecular Pathology lecture series (Coordinator, 2013-2015)
3. Molecular Tumor Board (Co-Founder, 2014)
4. Molecular Pathology Sign out and Case Review (Founder, 2014)
5. Clinical Genomics and Advanced Technology (Founder, 2015)
6. The Genomic Analysis Consortium (Founder, 2015)
7. @DHMC_CGAT (Founder, 2015)
8. CGAT eJournal (Founder, 2015)
9. The Molecular Twist (Founder and editor, 2016)

XII. MAJOR COMMITTEE ASSIGNMENTS:

National/International

<u>DATES</u>	<u>COMMITTEE</u>	<u>ROLE</u>	<u>INSTITUTION</u>
1996	SSRF Review Committee	Member	American Heart Association (CT Affiliate)
1996	Molecular Advisory Committee	Member	National Certification Agency for Medical Laboratory Personnel
1998 – 2002	Committee of Molecular Biology Techniques		Member, International Federation of Clinical Chemistry (IFCC)
1999	Clinical Molecular Biology Consultant		Promega Corporation
1999 – 2003	Molecular/Clinical Genetics Devices Panel of the Medical Device Advisory Committee	Member	FDA
1999 – 2002	PCR Advisory Board	Member	Roche Diagnostics
1999 – 2005	Genetics Training Consultant		Centers for Disease Control
2000 – 2014	External Grant Referee		Canadian Institutes of Health Research
2000 – 2014	External Grant Referee, Natural Sciences and Engineering Research Council of Canada		
2003	Subcommittee on Determining Clinical Utility of Genetic Tests, Advisor		NCCLS
2004 – 2009	Molecular/Clinical Genetics Devices Panel of the Medical Device Advisory Committee	Member	FDA
2004 – 2005	Executive Review Board	Member	Annual Pharmaceutical Achievement Awards, Boston, MA
2004 – 2008	NAD Scientific Advisory Board	Chair	Siemens (Bayer Diagnostics)
2005 – 2006		Consultant	Fujiribio Diagnostics
2005 – 2006	Advisory Board	Member	Third Wave Technologies
2005 – 2007	Advisory Board	Member	Osmetech Inc.

2006 – 2007	Global Clinical Customer Advisory Board		Member, Applied Biosystems
2006 – 2009	Healthcare Consultant		ThermoFisher
2006 – 2009	Advisory Board	Member	GenProbe Inc.
2006 – 2008		Consultant	Mirus Inc.
2007 – 2009	Consulting Life Sciences	Advisor	Navigant
2008	FVL Analysis	Member	Federal Agency for Healthcare Research and Quality
2008 – 2009	North American HPV Advisory Board,	Member	Gen Probe Inc.
2008 – 2010	Medical Advisory Board	Member	OpGen Inc, Madison, WI
2008 – 2009	Scientific Advisory Board	Member	Philips-Molecular Diagnostics, Eindhoven, Netherlands
2009	ARRA RC1 Challenge Grant Applications (Cancer Biomarkers),	Stage 1 Reviewer	National Institutes of Health
2009 – 2010	Advisory Board	Member	Althea Diagnostics
2009	External Grant Referee		The Danish National Advanced Technology Foundation
2009 – 2014	Molecular Advisory Board	Member	Roche
2009 – 2013		Consultant	Abbott-Vysis
2010 – 2013	Scientific Advisory Board	Member	Primera Dx
2011	Molecular and Clinical Genetics Advisory Panel:	DTC Genetics Testing	FDA
2011 – 2012	Scientific Advisory Board	Member	T2 Bio
2011 – 2012	Scientific Advisory Board	Member	Gentura Dx
2011	South Carolina Experimental Program to Stimulate Institutional Development Awards (EPSCoR/IDeA)		Competitive Research and Reviewer
2012 –	Scientific Advisory Board	Member	ChromaCode Inc.
2013 – 2015	Pathology Advisory Board	Member	Foundation Medicine
2013 - 2016	Scientific Advisory Board	Member	Physician Choice Labs
2016-	Scientific Advisory Board	Member	Seracare Inc.
2016-2018	Scientific/Medical Advisory Board	Member	Theranos
2017-	Scientific Advisory Board	Member	Astrazeneca
2017-	Scientific Advisory Board	Member	Loxo
2017 (Oct)-	Scientific Advisory Board	Chair	Wavesense
2018	Commercial Advisory Board	Member	Roche (Automation)
2019-	Committee for Translational Omics	Chair	International Federation of Clinical Chemistry
2019-	Center for Devices and Radiological Health	Sp Gov Empl	Food and Drug Administration

Regional

<u>DATES</u>	<u>COMMITTEE</u>	<u>ROLE</u>	<u>INSTITUTION</u>
1997	School of Allied Health Diagnostic Genetic Sciences Program	Advisory Board, Member	University of Connecticut
1997	Connecticut Cancer Genetics Advisory Group,	Member,	University of Connecticut
1998	UCONN Health Center Faculty Research Grant Program,	Ad Hoc Reviewer	, University of Connecticut
2004 - 2012	School of Allied Health Diagnostic Genetic Sciences Program	Advisory Board	Member University of Connecticut

2015- Health Care Genetics Professional Science Master's Degree Program Advisory Board, Member, University of Connecticut

Institutional

<u>DATES</u>	<u>COMMITTEE</u>	<u>ROLE</u>	<u>INSTITUTION</u>
1994	Mary Mulready Sullivan Oncology Symposium Organizing Committee, Member,		Hartford Hospital
1996	CAP Inspection Team, Corning Clinical Laboratories, Baltimore, MD, Member,		Hartford Hospital
1997	CAP Inspection Team, Dianon Laboratories, Stamford, Ct, Member,		Hartford Hospital
1997	Hartford Hospital Task Force on Customer Relations, Member,		Hartford Hospital
1999	Clinical Microbiology Task Force/Search Committee, Member,		Hartford Hospital
2002	Endowed Chair Cancer Genetics Search Committee, Member,		Connecticut Children's Medical Center
2002 – 2004	MT Program Advisory Board (introduced molecular diagnostics course/lab; program expansion), Chair,		Hartford Hospital
2003	MLT Advisory Committee, Member,		Manchester Community College
2004	CAP Inspection Team, Fletcher Allen Medical Center, Burlington, VT, Member,		Hartford Hospital
2004 – present	Department of Pathology Quality Council, Member,		Dartmouth-Hitchcock Medical Center
2004 – 2006	Department of Pathology Research Committee, Member,		Dartmouth-Hitchcock Medical Center
2004 – present	SuperCoSA (Supervisors/Coordinators of Specialty Areas) Workgroup, Member,		Dartmouth-Hitchcock Medical Center
2004 – 2005	Department of Pathology Technical Seminar Series, Coordinator,		Dartmouth-Hitchcock Medical Center
2004	CAP Inspection Team, Mt. Sinai Medical Center, NY, Member,		Dartmouth-Hitchcock Medical Center
2005	Department of Pathology Hematopathologist Search Committee, Member,		Dartmouth-Hitchcock Medical Center
2005	Department of Pathology Clinical Chemistry Assistant Director Search Committee, Member,		Dartmouth-Hitchcock Medical Center
2005	Department of Pathology Surgical Pathologist Search Committee, Member,		Dartmouth-Hitchcock Medical Center
2005 – 2007	Department of Pathology Residency Committee, Member,		Dartmouth-Hitchcock Medical Center
2005 – 2006	Department of Pathology Operations Committee, Member,		Dartmouth-Hitchcock Medical Center
2006	Department of Pathology Search Committee for Director of Cell Labeling Laboratory, Member,		Dartmouth-Hitchcock Medical Center
2006 – 2007	Pharmacogenomics Symposium, Faculty and Organizing Committee,		Dartmouth-Hitchcock Medical Center
2006 – present	Department of Pathology Translational Research Program, Member,		Dartmouth-Hitchcock Medical Center
2007 – present	Norris Cotton Cancer Center Integrative Biology Program, Member,		Dartmouth-Hitchcock Medical Center
2007 – present	Norris Cotton Cancer Center Experimental and Translational Models Group, Member,		Dartmouth-Hitchcock Medical Center

- 2008 – present The Dartmouth Center for Clinical & Translational Science, Development of Novel Clinical and Translational Methodologies Section, Member, Dartmouth-Hitchcock Medical Center
- 2009 Department of Pathology Cytopathologist Search Committee, Member, Dartmouth-Hitchcock Medical Center
- 2009 Department of Pathology Clinical Chemistry Director Search Committee, Member, Dartmouth-Hitchcock Medical Center
- 2010 Genomic Medicine Exploratory Committee, Member, Dartmouth-Hitchcock Medical Center
- 2010 Novel Translational Technology Committee (CTSA), Co-Director, Dartmouth-Hitchcock Medical Center
- 2010 Department of Pathology aCGH Technology Assessment Committee, Chair, Dartmouth-Hitchcock Medical Center
- 2010 – present The Hitchcock Foundation Scientific Review Committee, Member, Dartmouth-Hitchcock Medical Center
- 2011 – present Molecular Pathology Post-doctoral Fellowship Committee, Chair, Dartmouth-Hitchcock Medical Center
- 2011 – present Department of Pathology Promotions Committee, Member, Dartmouth-Hitchcock Medical Center
- 2011 Norris Cotton Cancer Center Strategic Planning Workshop, Member, Dartmouth-Hitchcock Medical Center
- 2012 – 2015 Topics in Molecular Pathology Seminar Series, Coordinator, Dartmouth-Hitchcock Medical Center
- 2012 – 2013 Department of Pathology Cytogenetics Director Search Committee, Chair Dartmouth-Hitchcock Medical Center
- 2012 - present Department of Pathology Test Utilization Committee, Member, Dartmouth-Hitchcock Medical Center
- 2013 Global Health Initiative – Honduras, Team Leader, Dartmouth-Hitchcock Medical Center
- 2013 CAP Inspection Team, Baylor College of Medicine, Houston, TX, Member, Dartmouth-Hitchcock Medical Center
- 2017 CAP Inspection Team – Porter Hospital, Team Leader, Middlebury, VT
- 2017 - CGAT Operations Committee, Member, Dartmouth-Hitchcock Medical Center
- 2018 NCCC Strategic Planning Leader of Research Working Group
- 2018 Department of Pathology and Laboratory Medicine CGAT Assitant Director Director Search Committee, Chair, Dartmouth-Hitchcock Medical Center
- 2019 Department of Pathology and Laboratory Medicine Clinical Chemistry Assitant Director Search Committee, Chair, Dartmouth-Hitchcock Medical Center

XIII. MEMBERSHIPS, OFFICE AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

<u>DATES</u>	<u>SOCIETY</u>	<u>ROLE</u>
	American Association for the Advancement of Science	Member
1992-	American Association for Clinical Chemistry	Member
1991-	American Society for Investigative Pathology	Member
1995-	Association for Molecular Pathology	Member
1993-	American Association for Cancer Research	Member
1996-	American Society of Human Genetics	Member
1996-2104	American Society for Microbiology	Member

- 1994 American Association for Clinical Chemistry (AACC), Molecular Pathology Division, Nominating Committee
- 1995 American Association for Clinical Chemistry, Clinical Laboratory News, Editorial Advisory Board
- 1995 American Association for Clinical Chemistry, CliniChem '96 Organizing Committee
- 1996 American Association for Clinical Chemistry, Molecular Pathology Division Chair-Elect
- 1996 American Association for Clinical Chemistry, Student Research Award Judge
- 1996 American Association for Clinical Chemistry, San Diego Conference Abstract Review Committee
- 1996 Association for Molecular Pathology (AMP) Nominating Committee
- 1997 American Association for Clinical Chemistry Molecular Pathology Division Chair
- 1998 American Association for Clinical Chemistry, National Meeting Abstract Reviewer
- 1998 American Association for Clinical Chemistry, Connecticut Valley Section Chair
- 1998 American Association for Clinical Chemistry, National Meeting Organizing Committee for New Orleans 1999
- 1998 American Association for Clinical Chemistry, Organizing Committee for Symposium on Viral Testing in the Clinical Laboratory (Atlanta)
- 1998 Association for Molecular Pathology (AMP), Training and Education Committee (Genetics Subdivision)
- 1999 – 2001 American Association for Clinical Chemistry Nominating Committee
- 1999 American Association for Clinical Chemistry, Task Force on the San Diego Conference
- 2000 – 2002 American Association for Clinical Chemistry Awards Committee
- 2000 – 2003 American Society for Investigative Pathology (ASIP), Program Committee
- 2001 American Association for Clinical Chemistry, Pharmacogenomics Conference Organizing Committee
- 2001 Association for Molecular Pathology (AMP), Training and Education Committee (Solid Tumors Subdivision)
- 2002 American Association for Clinical Chemistry, Fellow Academy of Clinical Biochemistry
- 2002 – 2004 American Association for Clinical Chemistry Chair, Awards Committee
- 2003 Association for Molecular Pathology (AMP) Clinical Practice Committee (Infectious Disease Subdivision)
- 2003 – 2008 American Society for Investigative Pathology (ASIP), Publications Committee
- 2004 Association for Molecular Pathology (AMP), Chair-elect, Program Committee
- 2005 Association for Molecular Pathology (AMP) Chair, Program Committee
- 2005 – 2007 American Association for Clinical Chemistry, Annual Meeting Organizing Committee
- 2006 – 2017 American Society for Investigative Pathology (ASIP), Joint Journal Oversight Committee (Am J Pathol and J Molec Diagn)
- 2006 – 2007 United States and Canadian Academy of Pathology (USCAP), Scientific abstract review board
- 2007 United States and Canadian Academy of Pathology (USCAP), Session Moderator, USCAP Annual meeting, San Diego, CA
- 2007 American Association for Clinical Chemistry, Lecturer, Professional Practice in Clinical Chemistry Review course
- 2007 Association for Molecular Pathology (AMP) President-elect
- 2007 American Society for Investigative Pathology (ASIP), Session moderator, ASIP Annual meeting, Washington, DC
- 2007 – 2008 American Society for Investigative Pathology (ASIP), American Journal of Pathology Editor-in-Chief Search Committee
- 2007 – 2008 American Society for Investigative Pathology (ASIP), Organizing Committee, 29th National Congress of the Italian Society of Pathology
- 2007 – 2016 American Association of Bioanalysts (AAB) Board of Scientific Advisors

2007 – 2016 American Board of Bioanalysis (ABB) Board Member
 2007 – 2009 Association for Molecular Pathology (AMP), Professional Society Services Oversight Committee
 2007 – Alliance for Clinical Trials in Oncology (previously Cancer and Leukemia Group B) Pathology Committee
 2008 Association for Molecular Pathology (AMP) President
 2008 American Association for Clinical Chemistry, Lecturer, Molecular Pathology Essentials course
 2008 College of American Pathologists (CAP) Abstract Reviewer
 2009 Association for Molecular Pathology (AMP) Past-President
 2009 Association for Molecular Pathology (AMP) Nominating Committee Chair
 2009 American Association for Clinical Chemistry, Lecturer, Professional Practice in Clinical Chemistry Review course
 2009 American Society for Investigative Pathology (ASIP), Co-Organizer, Summer Academy: “Solid Tumors: Transcripts, Tyrosine Kinases and Therapeutics”, Arlington, VA
 2009 American Society for Investigative Pathology (ASIP), Journal of Molecular Diagnostics Editor-in-Chief Search Committee
 2009 United States and Canadian Academy of Pathology (USCAP), Session Moderator, USCAP Annual meeting, Boston, MA
 2010 Association for Molecular Pathology (AMP), Finance Committee
 2010 – 2012 American Association for Clinical Chemistry Board of Directors
 2010 American Association for Clinical Chemistry, Liaison to the College of American Pathologists
 2010 American Association for Clinical Chemistry, Joint AACC-NACB Awards Task Force
 2010 College of American Pathologists (CAP), CAP Inspection Team, Baltimore, MD
 2010 – 2012 College of American Pathologists (CAP) AACC Liaison
 2011 American Association for Clinical Chemistry, Executive Vice President Search Committee
 2011 American Association for Clinical Chemistry, Representative to the NCCN Oncology Policy Summit on Molecular Testing – Effectiveness, Efficiency, and Reimbursement
 2011 – 2014 American Society for Investigative Pathology (ASIP), Meritorious Awards Committee
 2012 American Society for Investigative Pathology (ASIP), Abstract reviewer, XXXI Congress of the Societa Italiana di Patologia e Medicina Traslazionale
 2013 American Society of Human Genetics (ASHG), 8th Annual DNA Day essay contest, Judge
 2013 American Society for Investigative Pathology (ASIP), Chair, Joint Journal Oversight Committee for Journal of Molecular Diagnostics and the American Journal of Pathology
 2013-2016 Federation of American Societies for Experimental Biology (FASEB), Board of Directors
 2013 FASEB, Bioart judge
 2013-2015 FASEB, Science Policy Committee and Clinical and Translational Research Subcommittee
 2013-2015 American Association for Clinical Chemistry, NIH/NHGRI Inter-Society Coordinating Committee for Physician Proficiency in genomics
 2013- Alliance for Clinical Trials in Oncology Executive Committee, Translational Research Program
 2014-2016 American Board of Bioanalysis (ABB), Liason to APC Committee on Pathology Workforce
 2014-2015 Association for Molecular Pathology, Representative to APC Committee on Pathology Workforce
 2015- American Society for Investigational Pathology, Chair, Molecular Diagnostic Pathology Scientific Interest Group
 2016- Targeted Agent and Profiling Utilization Registry (TAPUR) Study, ASCO-Molecular Tumor Board

- 2016-2017 Association for Molecular Pathology, Infectious disease advisory board
2017- Association for Molecular Pathology, Molecular genetic Pathology Review Course Director

XIV. EDITORIAL BOARDS:

<u>DATES</u>	<u>JOURNAL NAME</u>
1998 – 2007	Clinica Chimica Acta
1998 – 2007	Clinical Biochemistry
1999 – 2002	Critical Reviews in Clinical Laboratory Sciences
1999 – present	Experimental and Molecular Pathology
2006 – present	Archives of Pathology and Laboratory Medicine
2009 – present	Journal of Clinical Virology
2009 – present	American Journal of Translational Research
2009 – present	International Journal of Clinical and Experimental Pathology
2010 – present	Journal of Molecular Diagnostics
2010 – 2016	Clinical Chemistry and Laboratory Medicine
2012 – present	Clinical Chemistry
2012 – present	Current Pathobiology Reports
2014-2015	MethodsX
2017-present	Surgical and Experimental Pathology
2018-present	Advances in Molecular Pathology (Editor in Chief, New Elsevier Journal)

XV. JOURNAL REFEREE ACTIVITY:

<u>DATES</u>	<u>JOURNAL NAME</u>
Ad hoc	American Journal of the Medical Sciences
Ad hoc	Applied Cancer Research
Ad hoc	Clinical Cancer Research
Ad hoc	Clinical Chemistry
Ad hoc	Infectious Diseases in Obstetrics and Gynecology
Ad hoc	Journal of Clinical Microbiology
Ad hoc	JCO Precision Oncology
Ad hoc	Laboratory Investigation
Ad hoc	Molecular Cancer Therapeutics
Ad hoc	Molecular Diagnosis and Therapy
Ad hoc	Nature Reviews Drug Discovery
Ad hoc	Pancreatology
Ad hoc	Thrombosis Haemostasis
Ad hoc	Thyroid

XVI. AWARDS AND HONORS:

<u>DATES</u>	<u>AWARD NAME</u>
1984	Zoology Departmental Honors in Research, University of Massachusetts, Amherst, MA
1993	Experimental Pathologist in Training Merit Award, American Society for Investigative Pathology

- 1993 – present Ad hoc reviewer: BBA, Clin Chem, Arch Pathol Lab Med, Am J Clin Pathol, Molec Diagn, J Forensic Sci, CCA
- 1994 Young Investigator Award, Academy of Clinical Laboratory Physicians and Scientists
- 1995 AACC Summer Fellowship Award for Participating Graduate Student
- 1995 George Grannis Award, National Academy of Clinical Biochemistry
- 1995 AACC Connecticut Valley Section Best Submitted Abstract Award
- 1996 IFCC-AVL National Award for “Significant Advances in Critical Care Testing”
- 1996 Association of Clinical Scientists, Young Scientist Award
- 1997 AACC Young Investigator Award
- 1999 IFCC-AVL National Award for “Significant Advances in Critical Care Testing”
- 1999 Outstanding Clinician Award, Diagnostic Genetic Sciences Program, UCONN SAH
- 2004 Outstanding Speaker Award, AACC
- 2006 AACC – SYCL Mentor of the Month (December)
- 2006 Outstanding Speaker Award, AACC
- 2007 Distinguished Alumni Award, University of Medicine and Dentistry of New Jersey – Graduate School of Biomedical Sciences
- 2008 AACC Molecular Pathology Division Featured Member (July)
- 2009 Outstanding Speaker Award, AACC
- 2010 International Federation of Clinical Chemistry (IFCC) Award for Significant Contributions to the Field of Molecular Diagnostics, Seoul, Korea (Oct.)
- 2010 AACC Outstanding Speaker Award
- 2011 AACC Outstanding Speaker Award
- 2012 AACC Outstanding Speaker Award
- 2013 Rowe Scholars Lectureship, University of Connecticut at Storrs
- 2013 AACC and National Academy of Clinical Biochemistry Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research
- 2013 AACC Outstanding Speaker Award
- 2014 AACC New York Metropolitan Section Van Slyke Award
- 2014 ACB/AACC European Federation for Laboratory Medicine Transatlantic Lectureship Award
- 2014 Friends of Norris Cotton Cancer Center Scholar Award
- 2016 CCLM Award of the Most Cited Paper Recently Published (Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Published in Clin Chem Lab Med 2014; 52:707-14; DOI: 10.1515/cclm-2013-0883)
- 2016 Cancer Genetics Certificate for Highly Cited Research for Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth Jr RJ, Suriawinata AA, Tsongalis GJ. MicroRNAs as Diagnostic Markers for Pancreatic Ductal Adenocarcinoma and Its Precursor, Pancreatic Intraepithelial Neoplasm. Cancer Genetics, 2013 Jun; 206(6):217-21. PMID:23933230
- 2016 Norris Cotton Cancer Center Award for Excellence
- 2017 Association for Molecular Pathology (AMP) Jeffrey A. Kant Leadership Award
- 2019 American Society for Investigative Pathology Robbins Distinguished Educator Award

XVII. INVITED PRESENTATIONS:

A. International:

<u>DATE</u>	<u>TOPIC/TITLE</u>	<u>ORGANIZATION</u>	<u>LOCATION</u>
November 1998	Clinical applications of molecular biology: Case reports.	2nd Greek Congress on Clinical Chemistry, Athens, Greece	
September 1999	Mutation detection in laboratory medicine.	Congress of Pathology and Laboratory Medicine, Sao Paulo, Brazil	

September 2003	The future of molecular oncology testing. International Meeting of the Athena society, Samos, Greece
October 2003	SNP analysis in clinical practice. Nanogen webcast (Oct.) (See Nanogen.com)
April 2004	The role of molecular diagnostics in anatomic pathology. Pathology Assistants of New England Regional Meeting, Montreal, Quebec, Canada
September 2006	Microarray technologies in the clinical laboratory. International Meeting of the Athena Society, Mykonos, Greece
October 2007	Identifying the next test out of the molecular pathology chute: which developing assays to watch. Executive Edge Conference, Toronto, Ontario, Canada
January 2008	Moving Forward in Molecular Oncology, La Sociedad Mexicana De Oncologia y El Colegio De Patólogos, Guadalajara, Mexico
September 2008	In search of metastatic tumor cells. 29th Congress of the Italian Society of Pathology, University of Calabria, Rende, Italy
September 2009	miRNA as New Biomarkers. 5th Meeting of the Athena Society, Porto Heli, Greece
October 2009	Molecular Oncology: Better patient selection for breast cancer biotherapy. Chinese Society for Clinical Oncology, Xiamen, China
October 2009	Molecular Oncology: Patient selection for optimal targeted therapy using FISH assays. Chinese Society for Clinical Oncology, Xiamen, China
June 2010	What if the human genome could... R.E. Bell Memorial Lectureship, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
August 2010	miRNA: A new biomarker in human cancer. XIII Pathology Meeting of the Hospital A.C. Camargo and III International Meeting on Investigative Pathology, Sao Paulo, Brazil
August 2010	KRAS mutation detection: Looking at an old gene in a new way. XIII Pathology Meeting of the Hospital A.C. Camargo and III International Meeting on Investigative Pathology, Sao Paulo, Brazil
August 2010	Molecular Pathology: Where are we headed. XIII Pathology Meeting of the Hospital A.C. Camargo and III International Meeting on Investigative Pathology, Sao Paulo, Brazil
October 2010	HER2: A model for targeted therapy. Oncology Society, Taipei, Taiwan
October 2010	HER2: A target in breast and gastric cancers. Pathology Society, Seoul, Korea
October 2010	HER2 and EGFR: targets in breast and lung cancer. Department of Pathology, Singapore General Hospital, Singapore
October 2010	HER2: A role in Breast and gastric cancer. 27th HUGO-IABCR Congress, Biopolis, Singapore
August 2011	Molecular hematology: Finding the clone. XIV Pathology Meeting of the Hospital A.C. Camargo and IV International Meeting on Investigative Pathology, Sao Paulo, Brazil
August 2011	Multiplex Analyses: How many targets do we need? XIV Pathology Meeting of the Hospital A.C. Camargo and IV International Meeting on Investigative Pathology, Sao Paulo, Brazil
August 2011	Molecular Pathology: From Bench to Bedside. XIV Pathology Meeting of the Hospital A.C. Camargo and IV International Meeting on Investigative Pathology, Sao Paulo, Brazil
Sept. 26, 2011	Advances in molecular diagnosis of infectious diseases. Department of Pathology, Singapore General Hospital, Singapore
Sept. 26, 2011	Bringing new molecular tests into the clinical laboratory. Department of Pathology, Singapore General Hospital, Singapore

Sept. 27, 2011	Molecular pathology using paraffin-embedded tissue and cytological samples. Department of Pathology, Singapore General Hospital, Singapore
Sept. 27, 2011	Molecular diagnostics and targeted therapies in solid tumors – current status. Department of Pathology, Singapore General Hospital, Singapore
Sept. 27, 2011	Updates in molecular hematology. Department of Pathology, Singapore General Hospital, Singapore
Sept. 28, 2011	Molecular diagnostics and targeted therapies – future targets. Department of Laboratory Medicine, National University Hospital, Singapore
Sept. 28, 2011	Validation and verification of diagnostic molecular tests. Department of Laboratory Medicine, National University Hospital, Singapore
Sept. 29, 2011	Role of molecular diagnostics in genetic testing and pharmacogenomics. Department of Pathology, Singapore General Hospital, Singapore
Sept. 29, 2011	HER2 FISH and IHC testing. Department of Pathology, Singapore General Hospital, Singapore
Sept. 29, 2011	Quality control and monitoring of molecular tests. Department of Pathology, Singapore General Hospital, Singapore
Sept. 30, 2011	Overview of current molecular diagnostic methods and emerging molecular technologies. Department of Pathology, Singapore General Hospital, Singapore
June 2012	MiRNAs: Not part of the junk in our genome. XXXIII Nordic Congress in Clinical Chemistry, Reykjavik, Iceland
September 2012	Why I should have my genome sequenced. 6th Meeting of the Athena Society, Messinia, Greece
March 2013	Genomics: What you cannot see under the microscope. Department of Pathology, School Hospital, Tegucigalpa, Honduras
June 2013	Profiling miRNAs in renal cancers for diagnosis and biomarker discovery. Department of Pathology, Maisonneuve-Rosemont Hospital, Montreal, Canada
June 2013	Is the clinical laboratory ready for miRNAs: Potential role in diagnosis, prognosis and therapy. 27th World Congress of the World Association of Societies of Pathology and Laboratory Medicine, Quebec City, Canada
August 2013	Personalized medicine: implementing genotyping studies into routine clinical practice. 1st International Symposium on Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
October 2014	22 and you: the impact of genomics on patient care. EuroLab Focus- 3rd EFLM-UEMS Congress, Liverpool, UK
June 2015	Genetic testing for the masses. 7th Meeting of the Athena Society, Crete, Greece
June 2015	Clinical utility of miRNAs in diagnosis and prognosis. 21st IFCC-EFLM European Congress on Clinical Chemistry and Laboratory Medicine, Paris, France
August 2015	miRNAs in Clinical Practice, 2nd International Symposium on Personalized Medicine, Albert Einstein Hospital, Sao Paulo, Brazil
August 2015	The New Pharmacogenomics: From Near Patient to Whole Genome Sequencing. 2nd International Symposium on Personalized Medicine, Albert Einstein Hospital, Sao Paulo, Brazil
October 2015	Molecular Diagnostics: How small to medium size labs can deliver value. Executive Edge Conference, Toronto, Canada

B. National:

<u>DATE</u>	<u>TOPIC/TITLE</u>	<u>ORGANIZATION</u>	<u>LOCATION</u>
1994	DNA: Beyond mutations, genes, and PCR machines.	Department of Hospital Laboratories Continuing Education, UNC Hospitals,	Chapel Hill, NC

- July 1994 DNA diagnostics in the clinical chemistry laboratory. Roundtable discussion group, AACC National meeting, New Orleans, LA
- March 1995 Cancer: An old disease with a new twist. North and South Carolina Association of Medical Technologists, Myrtle Beach, SC
- July 1995 In situ amplification of nucleic acid sequences. AACC National meeting, Anaheim, CA
- March 1996 Cancer genetics in the post-human genome era. University of Louisville Cancer Center, Louisville, KY
- March 1996 Hero for a day: Applications of molecular biology to laboratory medicine. Department of Pathology, University of Louisville, Louisville, KY
- May 1996 A new clinical dilemma for laboratory testing of the hypercoagulable patient. Association of Clinical Scientists, Chapel Hill, NC
- July 1996 Human DNA Repair Mechanisms. Roundtable, AACC National Meeting, Chicago, IL
- March 1998 Determination of clonality in lymphoid malignancies: Understanding the gold standard. Workshop on standards for nucleic acid diagnostic testing, National Institutes of Standards and Technology, Gaithersburg, MD
- March 1999 Factor VII genotyping and risk for myocardial infarction. Beaumont Conference on DNA Technology in the Clinical Laboratory, Royal Oak, MI
- July 2000 Molecular Diagnostic Clinical Applications. AACC Workshop, AACC National Meeting, San Francisco, CA
- May 2001 Clinical applications of forensic identity testing. Association of Clinical Scientists, Chapel Hill, NC
- May 2001 Nucleic acid manipulation. Association of Genetic Technologists, Minneapolis, MN
- June 2001 What is the Future of Molecular Diagnostics CHILdX and ARUP. Salt Lake City, UT
- June 2001 Identity testing: Translation to the clinical laboratory. ARUP Laboratories, Salt Lake City, UT
- September 2001 A Review of Laboratory Practices in Pharmacogenomics. International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Washington, DC
- July 2002 Oncogenomics: A Focus on Prostate Cancer. AACC National meeting, Orlando, FL
- September 2002 Personalized Medicine: It's in Our Genes. Abbott Breast Cancer Patient Advocacy Summit, Chicago, IL
- October 2002 Molecular Diagnostics: An Emerging Science? University of Maryland, Baltimore, MD
- March 2003 Clinical Laboratory Medicine: An Alternative Career and Research Forum, University of North Carolina, Chapel Hill, NC
- April 2003 Evaluation and performance of the BD Viper system. Clinical Virology Symposium, Clearwater, FL
- April 2003 Approaches to extraction of viral nucleic acids. Clinical Virology Workshop, Clearwater, FL
- March 2004 TAT, reimbursement and molecular diagnostics. Cepheid Corporation, Sunnyvale, CA
- April 2004 Clinical laboratory medicine: An alternative career in diagnostics and research. American Society for Investigative Pathology, Washington, DC
- April 2004 Molecular Pathology: A case report on laboratory development. Executive War College, New Orleans, LA
- June 2004 Has molecular diagnostics arrived for human cancers? Academy of Clinical Laboratory Physicians and Scientists (ACLPS), Denver, CO

July 2004 Molecular quantification for HIV-1 viral disease. Bayer Diagnostics Molecular Made Easy Program, AACC Annual Meeting, Los Angeles, CA

July 2004 The present and future of molecular diagnostics. 8th Annual Presentation for Financial Analysts, AACC Annual Meeting, Los Angeles, CA

October 2004 Using a conventional technology in a not so conventional way. 13th Annual Symposium on Molecular Pathology: DNA Technology in the Clinical Laboratory, William Beaumont Hospital, Troy, MI

October 2004 DHMC Molecular Pathology, Beckman Coulter Corporation, Indianapolis, IN

November 2004 HSV 1 and 2 assay development and validation. 10th Annual Meeting of the Association for Molecular Pathology, Los Angeles, CA

December 2004 Molecular Diagnostics: The Why's and Why Not's, GenProbe Corporation, San Diego, CA

December 2004 Building a Molecular Diagnostics Lab, Washington G-2 Reports, Audioconference

January 2005 Cancer Diagnostics: The Bcr-Abl Model. National Corporate Meeting, Cepheid, Napa Valley, CA

January 2005 Reimbursement Issues for the Molecular Diagnostics Laboratory. National Corporate Meeting, Cepheid, Napa Valley, CA

February 2005 New diagnostic and translational applications of frozen tissues: The frozen section ain't what it used to be. USCAP Meeting, San Antonio, TX

April 2005 Molecular diagnostic testing is not just for reference laboratories. Indiana Society for Clinical Laboratory Sciences, Syracuse, IN

May 2005 Practical issues in molecular diagnostics: methods and instrumentation. Annual Clinical Virology Symposium, Clearwater, FL

May 2005 A molecular diagnostics update. Clinical Ligand Assay Society annual meeting, San Diego, CA

May 2005 Bringing molecular diagnostics into the clinical laboratory. Clinical Ligand Assay Society annual meeting, San Diego, CA

May 2005 A new era in the war on cancer. Clinical Ligand Assay Society annual meeting, San Diego, CA

June 2005 Molecular diagnostics: A strategic plan. Bio-Rad Diagnostics Division, Hercules, CA

June 2005 Maximizing your laboratory business opportunities. Innovation in the Real World Program, Chicago, IL

July 2005 Cystic Fibrosis: Molecular diagnostics and associated issues. 12th Annual Progress in Clinical Pathology Symposium (Sponsored by UT Southwestern Medical Center), Keystone, CO

July 2005 Pharmacogenomics: Target specific therapies for the cancer patient. 12th Annual Progress in Clinical Pathology Symposium (Sponsored by UT Southwestern Medical Center), Keystone, CO

July 2005 Validation of a nanoparticle array assay for Factor II and V SNPs. Nanosphere Inc., Chicago, IL

August 2005 Diagnostic testing for bcr/abl: The clinical implications. Cepheid Scientific Advisory Board, Nashville, TN

October 2005 Molecular revolution: Short and long term impact on labs. Washington G2 Reports 23rd Annual Lab Institute, Arlington, VA

January 2006 Overview of pharmacogenomics. TWT Board of Directors Meeting, Miami, FL

January 2006 Validation of Molecular Assays. TWT National Sales/Marketing Meeting, Miami, FL

January 2006 Molecular testing personnel: hire or retrain existing workers. Washington G-2 Reports: Building a Molecular Diagnostics Laboratory, Miami, FL

February 2006 Pharmacogenomic testing platforms. Osmetech-Triton Scientific/Market Review Meeting, Pasadena, CA

April 2006 Molecular pathology in an era of personalized medicine. Department of Clinical Pathology, University of Texas Southwestern Medical Center, Dallas, TX

June 2006 Creating or expanding lab services in a time of decreasing resources. Bayer Molecular Symposium, Los Angeles, CA

July 2006 AACC University: Molecular Pathology Technology Review AACC Annual Meeting, Chicago, IL

July 2006 Novel applications of genomic profiling in human cancers. AACC Annual Meeting, Chicago, IL

September 2006 Detection of microsatellite instability in the analysis of colorectal cancers. 15th Symposium on Molecular Pathology, Beaumont Pathology Conference, Troy, MI

September 2006 Clinical implementation of pharmacogenomics testing. 15th Symposium on Molecular Pathology, Beaumont Pathology Conference, Troy, MI

November 2006 An overview of molecular diagnostics for the community pathologist. Association for Molecular Pathology Annual Meeting, Orlando, FL

November 2006 Maintaining a quality assurance program for the molecular diagnostics laboratory. Association for Molecular Pathology Annual Meeting, Orlando, FL

November 2006 Multiplex mononucleotide repeat assay for MSI in paraffin embedded rectosigmoid cancers. Association for Molecular Pathology Annual Meeting, Orlando, FL

November 2006 Molecular oncology: Quantification of the bcr-abl transcript. Association for Molecular Pathology Annual Meeting, Orlando, FL

December 2006 Quantification of the bcr-abl fusion transcript using the GeneXpert. ACL Illinois Central Laboratory, Chicago, IL

January 2007 Introduction to molecular diagnostics. ThermoFisher National Sales Meeting, Tampa, FL

April 2007 Nucleic acid probes and amplification techniques. AACC Professional Practice in Clinical Chemistry Review Course, Washington, DC

April 2007 Pharmacogenomics and targeted therapies. ASIP Annual Meeting, Washington, DC

May 2007 Use of miRNA in a clinical setting. Mirus Inc., Madison, WI

May 2007 Qualitative molecular testing: A story of an outbreak. Washington University School of Medicine, St. Louis, MO

June 2007 Moving forward in oncolecular testing. Washington G-2 Reports From Bench to Bedside, San Francisco, CA

July 2007 Overview of molecular technologies for pharmacogenomics. Interactive Workshop, AACC Annual Meeting, San Diego, CA

July 2007 Molecular Pathology Methods. AACC University, AACC Annual Meeting, San Diego, CA

September 2007 Next generation amplification methods for molecular diagnostics. In Vivo Technology Webinar (www.invivotechnology.com)

November 2007 An overview of molecular diagnostics. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 Cystic fibrosis mutation analysis. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 miRNA as a novel biomarker for human cancers. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 miRNA Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 Multiplexing analysis for genetics and hematology/oncology: applications and issues. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 Bordetella pertussis: A multicenter study. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 The sentinel lymph node. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

November 2007 DHMC-Warfarin sensitivity. Association for Molecular Pathology Annual Meeting, Los Angeles, CA

March 2008 miRNAs in human cancers. Department of Pathology, Visiting Professor Seminar Series, Medical College of Wisconsin, Milwaukee, WI

April 2008 Molecular Pathology: Bridging the Clinical Gap, American Society for Investigative Pathology, Experimental Biology Meeting, San Diego, CA

April 2008 In search of the metastatic cancer cell. American Society for Investigative Pathology, Experimental Biology Meeting, San Diego, CA

April 2008 STAT molecular testing: From infectious diseases to oncology. Bay Area On-Demand Molecular Diagnostics Symposium, San Francisco, CA

May 2008 Molecular Pathology: past, present and future. AACC and AMP Molecular Pathology Essentials: Principles and Practices Review Course, Baltimore, MD

May 2008 Coming to your lab soon: New molecular assays and automated systems. 13th Annual Executive War College on Lab and Pathology Management, Miami, FL

June 2008 Bordetella pertussis: Anatomy of an outbreak. 108th Annual Meeting of the American Society for Microbiology, Boston, MA

July 2008 Molecular pathology methods. Principles and Practices of Molecular Diagnostics and Pharmacogenomics Workshop, AACC Annual Meeting, Washington, DC

July 2008 An overview of pharmacogenomics. Case Studies in Pharmacogenomics Workshop, AACC Annual Meeting, Washington, DC

July 2008 Status of molecular diagnostic testing and what it takes to set up a laboratory. North American Chinese Clinical Chemistry Association, AACC Annual Meeting, Washington, DC

September 2008 How hospitals and health system labs can profit from new must-have molecular tests and technologies. The Dark Report Audioconference

November 2008 An overview of molecular diagnostics. AMP Outreach Course, Association for Molecular Pathology Annual Meeting, Grapevine, TX

January 2009 A Vision for the future of pathology. Institute of Pathology and Laboratory Medicine, Cleveland, OH

March 2009 Molecular Pathology: Implementation and billing. American Pathology Foundation Annual Meeting, Las Vegas, NV

March 2009 Molecular Pathology: where are we going and where have we been. Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH

June 2009 Molecular genetics of human cancer. ASIP Summer Academy: "Molecular Mechanisms of Human Disease – Solid Tumors: Transcripts, Tyrosine Kinases and Therapeutics", Arlington, VA

June 2009 Cancer Pharmacogenomics, ASIP Summer Academy: "Molecular Mechanisms of Human Disease – Solid Tumors: Transcripts, Tyrosine Kinases and Therapeutics", Arlington, VA

July 2009 Molecular pathology methods. Principles and Practices of Molecular Diagnostics and Pharmacogenomics Workshop, AACC Annual Meeting, Chicago, IL

November 2009 An overview of molecular diagnostics. AMP Outreach Course, Association for Molecular Pathology Annual Meeting, Orlando, FL

November 2009 Technical Troubles: What would you do? Workshop, Association for Molecular Pathology Annual Meeting, Orlando, FL

December 2009 Molecular Pathology and the Human Genome: More Applications than the iPhone. Department of Pathology, Montefiore Medical Center, New York, NY

February 2010 SWOT Analysis for esoteric testing. TriCore Laboratories, Albuquerque, NM
February 2010 Molecular Pathology: Where are we headed. Department of Pathology, TriCore Laboratories, Albuquerque, NM

April 2010 Bringing a new molecular test into the clinical laboratory. College of American Pathologists' Audioconference

July 2010 Base-ics of nucleic acid testing. AACC National Meeting, Anaheim, CA
July 2010 The liability associated with not doing PGX testing. AACC National Meeting, Anaheim, CA

July 2010 Personalized medicine in oncology. AACC National Meeting, Anaheim, CA
September 2010 Personalized Medicine: A new role for the pathologist. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL

November 2010 Writing a scientific manuscript. AMP National Meeting, San Jose, CA
November 2010 FISH Analysis, AMP National Meeting, San Jose, CA
November 2010 Molecular technologies in clinical practice. AMP National Meeting, San Jose, CA
July 2011 Introduction to nucleic acid biochemistry and molecular diagnostic technologies. American Association for Clinical Chemistry National Meeting, Atlanta, GA

July 2011 Molecular pathogenesis of cancer: Identifying diagnostic and therapeutic targets. American Association for Clinical Chemistry National Meeting, Atlanta, GA
July 2011 Personalized medicine: Fantasy or reality: The essential phases of implementation and practical challenges facing the era of personalized medicine. American Association for Clinical Chemistry National Meeting, Atlanta, GA

July 2011 Applications of miRNAs in clinical practice. American Association for Clinical Chemistry National Meeting, Atlanta, GA

August 2011 Translating basic science to active patient management. CHI 3rd Annual Next Generation Dx Summit, Washington, DC

October 2011 Update in molecular diagnostics. Advance Virtual Conference Webinar
November 2011 An overview of molecular diagnostics. AMP Outreach Course, Association for Molecular Pathology Annual Meeting, Grapevine, TX

November 2011 Multiplexing made simple. AMP Corporate Workshop, Association for Molecular Pathology Annual Meeting, Grapevine, TX

March 2012 The elusive cancer cell: How personal can we get? Institute for Molecular Diversity and Drug Development, University of Louisville, Louisville, KY

April 2012 Clinical biomarkers for targeted breast cancer treatment: A personal approach. Experimental Biology 2012, American Society for Investigative Pathology, San Diego, CA

June 2012 Personalized medicine: Pharmacogenomics and targeted therapies. Keynote Address, 37th Annual Meeting of the Association of Genetic Technologists, Atlanta, GA

July 2012 Pharmacogenomics: Beyond metabolomics. American Association for Clinical Chemistry Annual Meeting, Los Angeles, CA
July 2012 No vel biomarkers in human cancer. American Association for Clinical Chemistry Annual Meeting, Los Angeles, CA
July 2012 Pharmacogenomics and the era of personalized medicine: Essential phases of implementation and practical challenges. American Association for Clinical Chemistry Annual Meeting, Los Angeles, CA

October 2012 Introducing whole genome sequencing into pathology practice. Understanding Your Genome Conference, San Diego, CA
October 2012 An overview of molecular diagnostics. AMP Outreach Course, Association for Molecular Pathology Annual Meeting, Long Beach, CA
October 2012 So you want to start a molecular pathology lab. Workshop presentation, Association for Molecular Pathology Annual Meeting, Long Beach, CA

- November 2012 The Omics-era: An introduction to molecular diagnostics. ASCP Annual meeting, Boston, Ma
- February 2013 Pharmacogenomics and the era of personalized medicine. AACC Webcast
- April 2013 The continuing evolution of molecular diagnostics. Symposium on Molecular Diagnostics and Genomic Medicine, University of Medicine and Dentistry of New Jersey, Newark, NJ
- April 2013 Pathobiology for Basic Scientists: Neoplasia: Fundamental Themes in Neoplasia – When Good Cells Go Bad. American Society for Investigative Pathology, EB 2013, Boston, MA
- April 2013 Profiling miRNAs in Renal Neoplasms for Diagnosis and Biomarker Discovery. American Society for Investigative Pathology, EB 2013, Boston, MA
- April 2013 Companion diagnostics for HER2+ breast cancer. Breast Cancer Workshop: HER2+ Breast Cancer: Biology, Diagnostics and Therapeutics, American Society for Investigative Pathology, EB 2013, Boston, MA
- May 2013 Introducing whole genome sequencing into pathology practice. Understanding Your Genome (UYG) Conference, San Diego, CA.
- June 2013 Emerging technologies in molecular diagnostics: Here we go again! G2 Intelligence: MDx-Gaining ground in molecular testing and genomic medicine, Las Vegas, NV
- July 2013 The new pharmacogenomics: From near patient to whole genome sequencing. AACC Annual meeting, Houston, TX
- April 2014 Assessing mutations in human cancer: what we think we know and what we definitely do not know. Translational Medicine Symposium, University of North Carolina, Chapel Hill, NC
- April 2014 An overview of triple negative breast cancer Breast Cancer Workshop, American Society for Investigative Pathology, EB 2014, San Diego, CA
- April 2014 Biobanking, Stowell Symposium, American Society for Investigative Pathology, EB 2014, San Diego, CA
- May 2014 Clinical consultation and results reporting. AACC Molecular testing Course, Washington, DC
- April 2015 Implications of Massively Parallel Sequencing in Clinical Practice. Department of Pathology, University of New Mexico, Albuquerque, NM
- May 2015 How small to medium sized clinical labs can provide diagnostic value using molecular techniques. Executive War College, New Orleans, LA
- August 2015 Precision Medicine-Challenges Associated with Annotation and Interpretation of Somatic mutation Data. Cambridge Healthtech NGS Diagnostics Symposium, Washington, DC
- November 2015 Disruptive Technology and Its Implications for Diagnostics. Association for Molecular Pathology, Austin, TX
- November 2015 Disruptive Technologies and their Effect on the Traditional Molecular Diagnostics Laboratory. AMP- 2015 Analyst Day, Austin, TX
- April 2016 Career Development and Diversity Workshop: Molecular diagnostics and clinical chemistry. ASIP 2016 (EB 2016), San Diego, CA
- April 2016 Target Discovery Through Next Gen Sequencing of Triple Negative Breast Cancers. ASIP 2016 (EB 2016), San Diego, CA
- August 2016 Making Sense of the Chaotic World of Precision Medicine: Why NGS Is Not the End of the Game. FDA Genetics and Genomic Team Symposium Lecture series, Silver Spring, MD
- October 2016 The revolving door of somatic mutation analysis. Department of Pathology, University of Virginia, Charlottesville, VA

January 2017 QC: Where the rubber meets the road. Precision Medicine World Congress 2017, Silicon Valley, CA

Januray 2017 Somatic Mutation. Department of Laboratory Medicine, University of California at San Francisco, San Francisco, CA

April 2017 The future of molecular testing in breast DCIS. Breast Cancer Workshop, American Society for Investigative Pathology and Experimental Biology 2017, Chicago, IL

April 2017 PhDs in clinical chemistry and molecular diagnostics. XVII Annual Workshop on Graduate Education in Pathology: The PhD Workforce, American Society for Investigative Pathology and Experimental Biology 2017, Chicago, IL

April 2017 Applications of next generation sequencing technology. Pathobiology for research scientists: Next generation genomics for the basic/translational. Clinical scientist, American Society for Investigative Pathology and Experimental Biology 2017, Chicago, IL

May 2017 The role of disruptive technology in precision medicine. DxMA 2017 Global Marketing Summitt, New Orleans, LA

May 2017 What labs at academic centers and community hospitals need to know about molecular and genetic testing opportunities. Executive War College, New Orleans, LA

May 2017 Strategic overviews of the molecular and genetic testing market. Executive War College, New Orleans, LA

May 2017 Molecular Biology Review: The BASEics. American Association of Bioanalysts annual meeting, Houston, TX

May 2017 Molecular Biology Review: Southern blots and PCR. American Association of Bioanalysts annual meeting, Houston, TX

May 2017 Molecular Biology Review: FISH and DNA sequencing. American Association of Bioanalysts annual meeting, Houston, TX

May 2017 Molecular Biology Review: Precision Medicine-Hematology and Oncology. American Association of Bioanalysts annual meeting, Houston, TX

May 2017 Molecular Biology Review: Moleular Genetics and Infectious Diseases. American Association of Bioanalysts annual meeting, Houston, TX

July 2017 The past, present and future of genomics in the clinical laboratory. AACC Annual meeting, San Diego, CA

August 2017 Next generation sequencing: Logistics from the trenches. Next Generation Dx Summitt, Washington, DC

September 2017 Disruptive or revolutionary? The role of new technologies in molecular diagnsotics. Beaumont 26th Annual Symposium on Molecular Pathology, Troy, Michigan

September 2017 Cancer genomics in the era of next generation sequencing. PISA -Pathobiology for Investigators, Students and Academicians annual meeting, Pittsburgh, PA

October 2017 Precisiapon Oncology Roundtable: Ask the experts about NGS-based tumor profiling. GenomeWeb webinar: <https://genomeweb.webex.com/genomeweb/lsr.php?RCID=b40da5ac1ca6a03650a5eb15e9ac983e>

April 2018 Beyond academia: Some alternative career options. American Society for Investigative Pathology and Experimental Biology 2018, San Diego, CA

August 2018 Implementation of cervical cancer screening: A laboratory perspective. AACC Annual meeting, Chicago, IL

August 2018 Validation of NGS-based somatic mutation assays for routine clinical use. AACC Annual meeting, Chicago, IL

August 2018 Disruptive technologies in laboratory medicine – Panel discussion.10th Next generation Dx Summit, Washington, DC

September 2018	Trends in clinical NGS QC management: Expert insights to ensure quality results for your lab. Genomeweb webinar session moderator.
October 2018	Translating basic science to clinical medicine: A view from the trenches. Grand Rounds, Department of Pathology and Laboratory Medicine, Rutgers-New Jersey Medical School, Newark, NJ
October 2018	Who you are is in your DNA. Annual Research Symposium, Department of Pathology and laboratory Medicine, University of North Carolina, Chapel Hill, NC
October 2018	The trek from Lebanon to Honduras. PISA, University of Michigan, Ann Arbor, MI
October 2018	Molecular diagnostics overview: key trends. Financial analyst Day, Annual meeting of the Association for Molecular Pathology, San Antonio, TX
October 2018	Q...what? Seracare Corporate Workshop, Annual meeting of the Association for Molecular Pathology, San Antonio, TX
October 2018	Tissue Stewardship and the Role of Liquid Biopsy for Biomarker Testing in Lung Cancer. AstraZeneca Corporate Workshop, Annual meeting of the Association for Molecular Pathology, San Antonio, TX
October 2018	Multiplex Testing with ChromaCode's High-Definition PCR Technology. Chromacode Corporate Workshop, Annual meeting of the Association for Molecular Pathology, San Antonio, TX
April 2019	Somatic Mutation testing: Beyond the FFPE section. USCAP, Baltimore, MD
April 2019	Living the best of both worlds: Clinical careers for biomedical scientists. American Society for Investigative Pathology, EB'19, Orlando, FL.
April 2019	Moving beyond next generation sequencing: The role of STAT DNA testing. American Society for Investigative Pathology, EB'19, Orlando, FL.
April 2019	Translating science into clinical medicine. American Society for Investigative Pathology, EB'19, Orlando, FL.

C. Regional/Local:

<u>DATE</u>	<u>TOPIC/TITLE</u>	<u>ORGANIZATION</u>	<u>LOCATION</u>
1993	Diagnostic Tools in Molecular Pathology,	Hartford Hospital,	Hartford, CT
1993	ATGC: The Genetic Code in Laboratory Medicine,	University of Connecticut Medical Center,	Farmington, CT
1994	The molecular pathology of cancer.	University of Connecticut Medical Center,	Farmington, CT
September 1994	Molecular Pathology: DNA diagnostics in the clinical laboratory.	Medicine Grand Rounds,	Hartford Hospital, Hartford, CT
September 1994	DNA diagnostics in the clinical chemistry laboratory.	Department of Laboratory Medicine,	Yale University School of Medicine, New Haven, CT
October 1994	Genomic Instability,	Department of Pathobiology,	University of Connecticut, Storrs, CT
January 1995	Current genetic techniques for evaluating hereditary cancers.	Department of Pediatrics, Division of Medical Genetics,	Univ. of Connecticut Medical Center, Farmington, CT
April 1995	DNA on Trial.	Waterbury Association of Legal Secretaries,	Watertown, CT
April 1995	Molecular genetic applications: Searching for cancer genes.	Mary Mulready Sullivan Oncology Symposium,	Hartford Hospital, Hartford, CT
April 1995	The cystic fibrosis paradigm shift.	Pathobiology Department,	Univ. of Connecticut, Storrs, CT
October 1994	Genomic Instability,	Department of Pathobiology,	University of Connecticut, Storrs, CT

- July 1995 Molecular analysis of activated protein C resistance. Department of Pediatrics, Univ. of Connecticut, Farmington, CT
- May 1996 Molecular diagnostic testing and the CAP inspection. Maine Medical Center, Portland, ME
- February 1998 Molecular diagnostics for the pediatric patient. Grand Rounds, Rockville Hospital, Rockville, CT
- February 1998 Molecular diagnostics in laboratory medicine. Department of Laboratory Medicine, UCONN, Farmington, CT
- April 1998 Applications of molecular genetics in clinical practice. New England Regional Genetics Group Annual Meeting, Baystate Medical Center, Springfield, MA
- June 1998 Cell surface markers in lymphoma as molecular diagnostic models. AACC Northeast Section Symposium on: Cancer and the Clinical Laboratory, Boston, MA
- June 1998 Alternative in vitro amplification technologies. Molecular Diagnostics Review Course, UCONN, Storrs, CT
- October 1998 Molecular mechanisms of hereditary thrombophilia. Baystate Medical Center, Springfield, MA
- January 1999 Hereditary Hemochromatosis, Intercity GI Rounds, Hartford Hospital, Hartford, CT
- March 1999 Chlamydia: It really is not a flower. Infectious Disease Seminar Series, New York, NY
- April 1999 Is it or isn't it: identity testing for the clinical pathologist. Baystate Medical Center, Springfield, MA
- January 2000 Molecular Diagnostic Applications for GI, GI Rounds, UCONN Health Center, Farmington, CT
- March 2000 Applications of human genome technologies in clinical practice. Grand Rounds, Midstate Medical Center, Meriden, CT
- June 2001 Identification of infectious agents using molecular techniques. Society for Applied Immunohistochemistry, New York, NY
- June 2001 DNA fingerprinting in tissue specimens. Society for Applied Immunohistochemistry, New York, NY
- October 2001 Stem Cells, Capitol Region Education Council, Trinity College, Hartford, CT
- October 2001 HER2 as a marker for breast cancer. LabMed 2001, New York, NY
- October 2001 FISH Technology, LabMed 2001, New York, NY
- October 2001 Future impact of pharmacogenomics in laboratory medicine. LabMed 2001, New York, NY
- March 2002 The future of molecular diagnostic testing. Audioconference
- September 2002 Molecular Diagnostic Testing: Issues in the Clinical Laboratory. Waters Functional Genomics Forum, Milford, MA
- October 2002 Molecular Diagnostics: Personalized Medicine is Based on Your Identity. LabMed 2002, New York, NY
- November 2002 Our Health is in Our Genes, UCONN-SAH Sandra Evans Alumni Brunch, CT
- April 2003 Human Genomics with Respect to Molecular Oncology. AACC Northeast Regional Conference, Boxborough, MA
- April 2003 Pharmacogenomics: Applications to Clinical Oncology, Wachovia Investment Securities, New York, NY
- May 2003 Quality assurance and the microarray: The leap into a clinical laboratory. Cambridge Healthtech Institute's Macroresults for Microarrays, Needham, MA
- June 2003 Identity testing and molecular oncology cross paths. Department of Laboratory Medicine, Univ. of Connecticut Health Center, Farmington, CT

September 2004 The role of molecular pathology in the diagnosis of pancreatic cancer. 4th Annual Dartmouth Conference on Liver, Pancreas and Biliary Disease, Dartmouth-Hitchcock Medical Center, Lebanon, NH

September 2004 The DNA fingerprint: From the crime lab to the clinical lab. Department of Pathology, Annual Genetic Technology Symposium, Dartmouth-Hitchcock Medical Center, Lebanon, NH

September 2004 bDNA and the Fit into the Clinical Laboratory. NAD Sales Meeting, Bayer Diagnostics, Tarrytown, NY

October 2004 Cystic fibrosis mutation analysis: How, when and where? Department of Pathology, Clinical Pathology Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

January 2005 Clinical Applications of Quantitative Molecular Analysis, Department of Pathology, Clinical Pathology Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

March 2005 An update on molecular tools for anatomic applications: clinical, research and development. Department of Pathology, Anatomic Pathology Conference, Dartmouth-Hitchcock Medical Center, Lebanon, NH

March 2005 Molecular Pathology: An array of possibilities. Department of Pathology, Clinical Pathology Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

March 2005 Molecular Diagnostics: What will it take to expand the market more broadly? SG Cowen & Co., 25th Annual Health Care Conference, Boston, MA

May 2005 An Overview of the Polymerase Chain Reaction (PCR). Bone Marrow Transplant Conference, Dartmouth-Hitchcock Medical Center, Lebanon, NH

June 2005 Molecular Pathology: In search of novel markers of disease. Department of Pathology Research Forum, Dartmouth-Hitchcock Medical Center, Lebanon, NH

July 2005 Novel markers in the diagnosis of pancreatic cancer. Dartmouth Pancreas Club, Dartmouth-Hitchcock Medical Center, Lebanon, NH

August 2005 The pharmacogenomics of UGT1A1: Hitting close to home. GI Tumor Board, Dartmouth-Hitchcock Medical Center, Lebanon, NH

August 2005 A Molecular Pathology Update, DHMC Alliance Managers Group, Dartmouth-Hitchcock Medical Center, Lebanon, NH

September 2005 Drug-diagnostic combinations in clinical use. (Panel Discussion), IBC 4th Annual Conference on Molecular Diagnostics and Personalized Medicine, Boston, MA

September 2005 The changing paradigm of cancer diagnostics. 31st Annual Meeting of the American Association of Pathologist's Assistants, Cambridge, MA

September 2005 The ABCs of DNA (3 hour workshop), 31st Annual Meeting of the American Association of Pathologist's Assistants, Cambridge, MA

September 2005 Molecular Pathology: New Tools for New Questions. NCCC Clinical Cancer Care Committee Meeting, Dartmouth-Hitchcock Medical Center, Lebanon, NH

September 2005 Applications of molecular pathology/diagnostics to pancreatic cancer. 5th Annual Dartmouth Conference on Liver, Pancreas and Biliary Disease, Dartmouth-Hitchcock Medical Center, Lebanon, NH

October 2005 Molecular genetics: Fragile X Syndrome. Department of Pathology, Clinical Pathology Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

October 2005 Molecular pathology: Current and future directions. Beth Israel Deaconess Medical Center, Boston, MA

November 2005 Creating a molecular diagnostics laboratory. LabMed 2005, New York, NY

December 2005 Hematopathology: The gene rearrangement. Department of Pathology, Clinical Pathology Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

January 2006 A Molecular Pathology Update, Department of Pathology, Anatomic Pathology Conference, Dartmouth-Hitchcock Medical Center, Lebanon, NH

- March 2006 Opportunities and challenges in clinical molecular diagnostics. S.G. Cowen & Co. 26th Annual Healthcare Conference, Boston, MA
- March 2006 Molecular oncology: new initiatives in cancer diagnostics. Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY
- March 2006 Microsatellite instability in colorectal cancer. Agencourt Bioscience Corporation, Beverly, MA
- March 2006 Molecular assessment of the sentinel lymph node. Johnson & Johnson – Veridex, Warren, NJ
- April 2006 NIHGR National DNA Day presentation. Hartford High School, Hartford, VT
- April 2006 NIHGR National DNA Day presentation. Outtaquechee Elementary School, Quechee, VT
- May 2006 Translational research through molecular pathology. Department of Pathology and Laboratory Medicine, UMDNJ New Jersey Medical School, Newark, NJ
- June 2006 Creating or expanding lab services in a time of decreasing resources. Bayer Molecular Symposium, Short Hills, NJ
- October 2006 The evolving field of disease biomarkers. AACC Connecticut Valley Section, Cromwell, CT
- March 2007 DHMC Pertussis “Outbreak”: The Postmortem, Department of Pathology, Anatomic Pathology Conference, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- March 2007 Is it or isn’t it: The ultimate in Pathology quality assurance. American Association of Professional Coders, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- March 2007 Molecular oncology: Quantification of the bcr-abl transcript. Northeast Regional Genetics Group annual meeting, Holyoke, MA
- June 2007 An update on molecular pathology and clinical applications. Central Vermont Medical Center, Barre, VT
- July 2007 STAT molecular testing: from infectious diseases to oncology. New England On Demand Molecular Diagnostics Symposium, Framingham, MA
- October 2007 New molecular tests in pancreatic cancer. 7th Annual Dartmouth Conference on Liver, Pancreas and Biliary Disease, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- October 2007 Applications of molecular techniques in the diagnosis of human cancers. Diagnostic Genetic Sciences Program, University of Connecticut, Storrs, CT
- October 2007 Personalized medicine, pharmacogenomics, and the pathologist. Department of Pathology, Clinical Pathology Conference, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- October 2007 When a cough is more than just a cough. Northeast Laboratory Conference, Portland, ME
- November 2007 A Molecular Pathology Update, DHMC Alliance Managers Group, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- November 2007 The promises and challenges of the use of physiogenomics in the practice of preventative medicine. American College of Sports Medicine, Providence, RI
- March 2008 Tumor markers. Department of Pathology Residents, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- March 2008 miRNA profiling in pancreatic cancer. Gastrointestinal Tumor Board, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- March 2008 Trends in molecular diagnostics. S. G. Cowen & Company 28th Annual Health Care Conference, Boston, MA
- April 2008 miRNAs as novel biomarkers in human cancers. Department of Pathology, Clinical Pathology Seminar, Dartmouth-Hitchcock Medical Center, Lebanon, NH

April 2008 Chimerism analysis in the bone marrow transplant patient. Bone Marrow Transplant Program Seminar, Dartmouth-Hitchcock Medical Center, Lebanon, NH

May 2008 Automated molecular platforms and the hospital laboratory. G-2 Reports: Business and Financial Strategies for Molecular Diagnostics, Cambridge, MA

October 2008 The polymerase chain reaction: then and now. Department of Pathology, Residents' Seminar, Baystate Medical Center, Springfield, MA

October 2008 Targeted therapies and the impact on the clinical laboratory. Department of Pathology, Baystate Medical Center, Springfield, MA

October 2008 Molecular pathology: Applications of qualitative testing. Department of Pathology, Clinical Pathology Seminar, Dartmouth-Hitchcock Medical Center, Lebanon, NH

October 2008 The BCR-ABL paradigm. Northern New England Clinical Oncology Society annual meeting, Whitefield, NH

November 2008 Oncology: A laboratory guided tour. NH/VT Clinical Laboratory Management Association meeting, Concord, NH

November 2008 Molecular therapeutics: where are we? Department of Allied Health, University of Connecticut, Storrs, CT

March 2009 Microarrays in clinical practice. Medical Genetics Seminar Series, Dartmouth-Hitchcock Medical Center, Lebanon, NH

June 2009 Gene Rearrangements, Department of Pathology, Baystate Health Center, Springfield, MA

November 2009 The Clinical Laboratory of the Future. NH/VT Clinical Laboratory Management Association meeting, Concord, NH

January 2010 The human genome, clinical practice and the iPhone. Pathology Research and Review Seminar, Dartmouth-Hitchcock Medical Center, Lebanon, NH

January 2010 QC practices in molecular pathology. Interleukin Genetics, Waltham, MA

January 2010 Targeted therapy: Revitalizing clinical laboratory services. Department of Pathology, Clinical Pathology Conference, Brigham and Women's Hospital, Boston, MA

February 2010 Hereditary Cancer Syndromes, Department of Pathology, Baystate Health Center, Springfield, MA

March 2010 Market trends in molecular diagnostics. S.G. Cowen & Company 30th Annual Healthcare Conference, Boston, MA

April 2010 Pharmacogenomics: Where are we going from here? Annual Cancer Symposium, Berkshire Medical Center, Pittsfield, MA

May 2010 The clinical utility of molecular diagnostic testing. Department of Pathology Grand Rounds, University of Vermont College of Medicine, Burlington, VT

June 2010 Molecular Pathology and the Human Genome: More Apps than the iPhone. Department of Pathology Grand Rounds, Montefiore Medical Center, New York, NY

September 2010 Transitioning from the research lab to the clinical lab: Our role in personalized health. Molecular Therapeutics Program, Norris Cotton Cancer Center, Lebanon, NH

September 2010 Molecular Pathology: An avenue to translational research and better patient management. Hematology-Oncology Core Research Lecture, Dartmouth-Hitchcock Medical Center, Lebanon, NH

October 2010 Genomic Medicine: 22 and You. Rheumatology Interdisciplinary Research Program, Dartmouth-Hitchcock Medical Center, Lebanon, NH

October 2010 Molecular Pathology: Making the transition. NCCC Symposium to promote Clinical Research, Dartmouth-Hitchcock Medical Center, Lebanon, NH

November 2010 Ethics and the agonies of clinical lab testing. Department of Genetics, Molecular and Cellular Biology, University of Connecticut, Storrs, CT

November 2010 What if your DNA could Talk? NH/VT CLMA Annual Meeting, Concord, NH
November 2010 Cancer Genes. Anatomic Pathology Seminar, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

February 2011 From bench to bedside...really? Norris Cotton Cancer Center Grand Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

February 2011 Using translational technologies. SYNERGY Research Training Introductory Program, Dartmouth-Hitchcock Medical Center, Lebanon, NH

March 2011 Introducing microarray technologies into the clinical laboratory. Department of Pathology, Baystate Health System, Springfield, MA

March 2011 Personalized medicine for the cancer patient. American Association for Professional Coders, Dartmouth-Hitchcock Medical Center, Lebanon, NH

April 2011 Selecting the best molecular platform for your laboratory. G2 Conference on Molecular Diagnostics, Boston, MA

April 2011 Personalized medicine for the cancer patient. Pathologist's Assistants of New England regional meeting, Northampton, MA

May 2011 Molecular pathology and translational research programs at DHMC. Molecular Epidemiology Seminar Series, Dartmouth-Hitchcock Medical Center, Lebanon, NH

June 2011 Human Papillomavirus. Department of Pathology, Baystate Health System, Springfield, MA

October 2011 Basic principles of molecular pathology. Clinical Pathology Seminar Series, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

November 2011 Tissue, tissue everywhere. Integrative Biomedical Sciences Course, Quantitative Biomedical Sciences Program, Dartmouth-Hitchcock Medical Center, Lebanon, NH

November 2011 HER2 FISH Analysis. Breast Cancer Oncology Group Tumor Board, Dartmouth-Hitchcock Medical Center, Lebanon, NH

March 2012 Navigating the mid- to high throughput molecular diagnostics market. Cowen and Company 32nd Annual Healthcare Conference, Boston, MA

March 2012 22 and you: How personal are the base-ics. Dartmouth Community Medicine Series, Hanover, NH

March 2012 Chimerism analysis. Topics in Molecular Pathology Lecture Series, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

April 2012 Pathology Translational Research Program: The tissue is the issue. Introduction to Clinical Research Course, Dartmouth-Hitchcock Medical Center, Lebanon, NH

April 2012 Molecular Pathology: Qualitative analysis. Clinical Pathology Seminar Series, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

April 2012 Genes R Us, Aren't they? Science Café, Dartmouth College, Hanover, NH

June 2012 Clinical Pathology/Translational Research Laboratory Shared Resources, SYNERGY: The Dartmouth Center for Clinical and Translational Science, Dartmouth-Hitchcock Medical Center, Lebanon, NH

October 2012 Next generation molecular texting: What happened to the first generation. NH/VT CLMA conference, Dartmouth-Hitchcock Medical Center, Lebanon, NH

December 2012 Key reimbursement trends in diagnostics. Cowen Medtools Unlocked Conference, Boston, MA

December 2012 Evaluating new platforms and competition in in vitro diagnostics. Cowen Medtools Unlocked Conference, Boston, MA

January 2013 Molecular diagnostics and targeted therapies. Anatomic Pathology Seminar Series, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

January 2013 Molecular Pathology: Qualitative infectious disease testing. Clinical Pathology Seminar Series, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

April 2013 The Digital Human: How Genomics Is Impacting You. The 8th Annual John and Valerie Rowe Lectureship, University of Connecticut, Storrs, CT

April 2013 The Digital Human and Next Generation Molecular Testing. Concord Hospital, Concord, NH

May 2013 Bringing science to local teachers. Dartmouth Science Café, Newport, NH.

October 2013 Hereditary Cancers, Anatomic Pathology seminar series, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

November 2013 Cancer; identifying and using the pieces of the puzzle. Prouty Board of Directors, Norris Cotton Cancer Center, Lebanon, NH

November 2013 Diagnostics in the developing world. New England Alliance for Health meeting, Dartmouth Hitchcock Medical Center, Lebanon, NH

January 2014 So what's in a genome, Norris Cotton Cancer Center Grand Rounds, Lebanon, NH

February 2014 The Digital Human: What genomics means for your cancer. ILEAD Course: Cancer Genomics Revealed: The Promise of Revolutionizing Treatment, Hanover, NH

March 2014 Somatic mutations: A resurgence in clinical molecular oncology, Van Slyke Award Lectureship, AACC New York Metropolitan Section, Tarrytown, NY

March 2014 Somatic mutations: The good, the bad and the ugly. Department of Pathology Research and Review Seminar, Lebanon, NH

May 2014 Molecular cytology: What you can't see under the microscope, 32nd Annual Cytopathology Symposium, Northampton, MA

June 2014 Health Promotion: Lessons from the Developing World, Department of Allied Health, University of Connecticut, Storrs, CT

September 2014 Integrating molecular profiling into the practice of neuro-oncology, New England Neuro-Oncology Symposium, Boston, MA

October 2014 Studying your blood to treat your tumor, Friends of Norris Cotton Cancer Center, Lebanon, NH

October 2014 Diagnostics in the developing world: An update, NH/VT CLMA Technical Conference, Lebanon, NH

October 2014 The continuing evolution of molecular diagnostics, TriMark Molecular Diagnostic and Personalized Medicine Conference, New York, NY

April 2015 So what's in your genome? Elliott Hospital, Manchester, NH

July 2015 Precision Medicine- It's all about the tissue! National Society for Histotechnology Region 1, Manchester, NH

July 2015 Precision Medicine Part II: Doctors and Diagnostics, MassBio Forum of the Drug Discovery Working Group, Cambridge, MA

September 2015 1,000 Patient Tumor Sequencing Project, New Hampshire Society of Pathologists, Lebanon, NH

October 2015 Precision Medicine: The pros and cons of somatic mutation testing. Department of Pathology, Hartford Hospital, Hartford, CT

October 2015 Is the secret to your wellness hiding in your bladder? Friends of Norris Cotton Cancer Center, Lebanon, NH

February 2016 Laboratory testing in the developing world, Thayer School of Engineering (Engs 16), Hanover, NH

March 2016 Unraveling the complex world of somatic mutation testing, Department of Pathology, UMASS Memorial Health System, Worcester, MA

September 2016	Somatic mutation analysis in human cancer: Tip of the iceberg or end of the story? Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
October 2016	Clinical genomics and advanced technology at DHMC, Smart Data Forum- US and German Delegation at DHMC, Lebanon, NH
October 2016	Precision medicine for the community healthcare provider, Maine Primary Care Association, Bar Harbor, ME
October 2016	Cervical cancer in Honduras: Stepping up to improve early detection, NCCC Grand Rounds, Lebanon, NH
November 2016	Bringing somatic mutation analysis into the laboratory, KEW, Cambridge, MA
December 2016	Somatic Mutation Analysis, DHMC Anatomic Pathology Seminar series, Lebanon, NH
February 2017	Biomarker Discovery: The CLL Story, Professional Science Masters in Applied Genomics, University of Connecticut, Storrs, CT
February 2017	Genetic Disease Testing, DHMC DPLM Post-doctoral fellows lecture series, Lebanon, NH
March 2017	Precision Medicine: The role of clinical genomics, Department of Pathobiology, University of Connecticut, Storrs, CT
March 2017	Clinical genomics and human disease, OSHER Lecture Series, Hanover Senior Center, Hanover, NH
October 2017	The CGAT Global Initiative: An update on our war against cancer south of the border, CLMA Annual meeting, Lebanon, NH
June 2018	Somatic mutation analysis: Beyond NGS. World Congress on Biomarkers and Immuno-Oncology, Boston, MA
August 2018	Amplification Technologies. Clinical Pathology Seminar Series, Dartmouth Hitchcock Medical Center, Lebanon, NH
September 2018	HPV and cervical cancer: The journey from New Hampshire to Honduras, The 35 th Annual Cytopathology Symposium, Hadley, MA
October 2018	The impact of clinical genomics on cancer patient management. Laboratory Medicine Conference, Department of Pathology, UMASS Medical School and Quest Diagnostics, Marlborough, MA
November 2018	Product service and support in clinical uses. Analytical, Life Science & Diagnostics Association Annual Meeting for Service & Support Executives, Cambridge, MA
February 2019	When precision medicine is as easy as 1, 2, 3. Friends of the Norris Cotton Cancer Center, Lebanon, NH
February 2019	Liquid biopsy: current utility and future potentials. Pathology Grand Rounds, Department of Pathology, Brigham and Womens Hospital, Boston, MA

XVIII. BIBLIOGRAPHY:

A. Peer-reviewed publications in print or other media

Original articles:

1. **Tsongalis GJ**, Lambert WC, Lambert MW. Electroporation of normal human endonucleases into xeroderma pigmentosum cells corrects their DNA repair defect. *Carcinogenesis*, 11:499-503, 1990.
2. **Tsongalis GJ**, Lambert WC, Lambert MW. Correction of the ultraviolet induced DNA repair defect in xeroderma pigmentosum cells by electroporation. *Mutation Research*, 244:257-263, 1990.

3. Lambert MW, **Tsongalis GJ**, Lambert WC, Huang B, Parrish DD. Defective DNA endonucleases in Fanconi's anemia cells, complementation groups A and B. *Mutation Research*, 273:57-71, 1991.
4. **Tsongalis GJ**, Coleman WB, Smith GJ, Kaufman DG. Partial characterization of nuclear matrix attachment regions from human fibroblast DNA using *Alu* polymerase chain reaction. *Cancer Research*, 52:3807-3810, 1992.
5. **Tsongalis GJ**, Coleman WB, Esch GL, Smith GJ, Kaufman DG. Identification of human DNA in complex biological samples using the *Alu* polymerase chain reaction. *Journal of Forensic Sciences*, 38(4):961-967, 1993.
6. Brylawski BP, **Tsongalis GJ**, Cordeiro-Stone M, May WT, Comeau LD, Kaufman DG. Putative association of origins of replication with the nuclear matrix in normal human fibroblasts. *Cancer Research* 53:3865-3868, 1993.
7. **Tsongalis GJ**, Silverman LM. 1993. Molecular Pathology of the Fragile X Syndrome. *Arch. Pathol. Lab. Med.* 117:1121-1125, 1993.
8. **Tsongalis GJ**, Kaufmann WK, Wilson SJ, Friedman KJ, Silverman LM. Rapid screening for p53 mutations using a sensitive heteroduplex detection technique. *Clinical Chemistry*, 40:485-486, 1994.
9. **Tsongalis GJ**, McPhail A, Lodge-Rigal D, Silverman LM, Chapman JF. Localized in situ amplification (LISA): A novel approach to in situ PCR. *Clinical Chemistry*, 40:381-384, 1994.
10. **Tsongalis GJ**, Silverman LM. In situ amplification: Detection of target sequences in whole tissues. *Annals Clin Lab Sci.* 24:436-440, 1994.
11. **Tsongalis GJ**, Faber G, Daldorf FG, Friedman KJ, Silverman LM, Yankaskas JR. Association of pancreatic adenocarcinoma, mild lung disease, and delta F508 mutation in a cystic fibrosis patient. *Clin. Chem.* 40:1972-1974, 1994.
12. **Tsongalis GJ**, Silverman LM. DNA repair: Understanding mechanisms involved in neoplastic disease. *Clin. Lab. News.* 20:8, 22, 1994.
13. Coleman WB, **Tsongalis GJ**. Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. *Clin. Chem.* 41(5):644-657, 1995.
14. Johnson RC, Pedersen CA, Cartun RW, Moore RE, Ricci A Jr, **Tsongalis GJ**. Characterization of an immunohistochemically localized truncated p53 protein by molecular analysis. *Cell Vision.* 2(5):338-342, 1995.
15. Albright CD, **Tsongalis GJ**, Resau JH, Kaufman DG. Human endometrial carcinoma cells release factors which inhibit the growth of normal epithelial cells. *Cell Biol.Toxicol.* 11:251-261, 1995.
16. Contois J, Anamani DE, **Tsongalis GJ**. The underlying molecular mechanism of apolipoprotein E polymorphism: Relationships to cardiovascular and Alzheimer's disease. *Clinics in Laboratory Medicine.* 16:105-123, 1996.

17. Hodges KA, Kosciol CM, Rezuke WN, Abernathy EC, Pastuszak WT, **Tsongalis GJ**. Enhanced chemiluminescent detection of gene rearrangements in hematologic malignancy. *Annals Clin Lab Sci.*, 26:114-118, 1996.
18. **Tsongalis GJ**, Anamani DE, Wu AHB. DNA fingerprinting of urine specimen donors by polymerase chain reaction amplification typing of the HLA DQ α locus. *J Forensic Sci*, 41(6):1031-1034, 1996.
19. Lambert MW, **Tsongalis GJ**, Lambert WC, Parrish DD. Correction of the DNA repair defect in Fanconi anemia complementation groups A and D cells. *Biochem Biophys Res Commun*, 230(3):587-591, 1997.
20. Mandavilli S, Cartun RW, Ricci A Jr, **Tsongalis GJ**. Immunohistochemical evaluation of genetic and epigenetic factors in primary breast cancers. *J Histotechnol*, 20:27-30, 1997.
21. **Tsongalis GJ**, Berman MM. Application of forensic identity testing in a clinical setting. *Diagn Mol Pathol*, 6(2):111-114, 1997.
22. **Tsongalis GJ**, Mandavilli S, Johnson RC, Cartun RW, Ricci A Jr, Esch GL, Smith GA, Coleman WB. bcl-2 expression in a subset of p53 mutant primary breast cancers. *Cell Vision*, 4(1):32-37, 1997.
23. Saif MW, Volpe BT, Dailey M, **Tsongalis GJ**. Life threatening pulmonary embolus in a Factor V Leiden carrier on oral contraceptives: A case report. *Connecticut Medicine*, 61(6):333-337, 1997.
24. Joshi VV, **Tsongalis GJ**. Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma. *Challenges and Opportunities in Pediatric Oncology*, *Annals N.Y. Acad. Sci.*, 824:71-83, 1997.
25. Rezuke WN, Abernathy E, **Tsongalis GJ**. Molecular Diagnosis of B and T Cell Lymphomas: Fundamental Principles and Clinical Applications. *Clin. Chem.*, 43(10):1814-1823, 1997.
26. Chen C, Ma L, Linfert DR, Lai T, Fallon JT, Gillam LD, Waters DD, **Tsongalis GJ**. Myocardial cell death and apoptosis in hibernating myocardium. *J. Am. Col. Cardiol.*, 30(5):1407-1412, 1997.
27. Linfert DR, Chen C, Ma L, Lai T, **Tsongalis GJ**. Internucleosomal DNA fragmentation in apoptotic myocytes from a pig model. *Clin. Chem.*, 43(12):2431-2434, 1997.
28. Wu A, Linfert DR, **Tsongalis GJ**, McKay C. DNA typing of urine: A case report. *MRO Update*, 1998.
29. **Tsongalis GJ**, Ricci A Jr. Diagnostic capabilities for molecular oncology. *Advance for Administrators of the Laboratory*, 7(5):85-86, 1998.
30. **Tsongalis GJ**, Linfert DR, Johnson RC, Ackroyd R, Berman MM, Ricci A Jr. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. *Archives Pathol Lab Med*, 122:548-550, 1998.
31. Linfert DR, Wu AHB, **Tsongalis GJ**. The effect of pathologic substances and adulterants on the DNA typing of urine by the PM+DQA1 assay kit. *J Forensic Sci* 43(5):1041-1045, 1998.

32. Linfert DR, Rezuze WN, **Tsongalis GJ**. Rapid multiplex analysis for the Factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia. *Connecticut Med* 62(9):519-525, 1998.
33. **Tsongalis GJ**, Coleman WB. Molecular Oncology: Diagnostic and prognostic assessment of human cancers in the clinical laboratory. *Cancer Invest* 16(7):485-502, 1998.
34. Johnson RC, Ricci A Jr, Cartun RW, **Tsongalis GJ**. Clinical laboratory evaluation of erbB-2 oncogene amplification in primary human breast cancers. *Europ J Laborat Med* 6(3):156-160, 1998.
35. **Tsongalis GJ**, Stevenson AJ, Hodges KA, Rezuze WN. Clonal analysis of B-cell lymphoproliferative disorders. *Europ J Laborat Med* 6(3):142-145, 1998.
36. Linfert DR, **Tsongalis GJ**. Confirmation of known gene mutations using a reverse dot blot assay. *Europ J Laborat Med* 6(3):146-149, 1998.
37. Fiel-Gan MD, Almeida LM, Rose DC, Takano A, Rezuze WN, Cartun RW, Coleman WB, Garcia N, **Tsongalis GJ**. Proliferative fraction, bcl-1 gene translocation, and p53 mutation status are independent prognostic indicators in mantle cell lymphoma. *Intl J Molec Med* 3:373-379, 1999.
38. Frasca Jr. S, Linfert DR, **Tsongalis GJ**, Gorton TS, Garmendia AE, Hedrick RP, West AB, Van Kruiningen HJ. Molecular characterization of the Myxosporean associated with parasitic encephalitis of farmed Atlantic salmon *Salmo salar* in Ireland. *Diseases of Aquatic Organisms* 35:221-233, 1999.
39. **Tsongalis GJ**, Wu AHB, Silver H, Ricci A Jr. Applications of forensic identity testing in the clinical laboratory. *Am J Clin Pathol* 112:S93-S104, 1999.
40. Vadlamudi G, Rezuze WN, Ross JW, Cartun RW, Ackroyd R, Knibbs DR, **Tsongalis GJ**. The use of monoclonal antibody R92F6 and polymerase chain reaction to confirm the presence of parvovirus B19 in bone marrow specimens of patients with acquired immunodeficiency syndrome. *Arch Pathol Lab Med*. 123(9):768-773, 1999.
41. Coleman WB, **Tsongalis GJ**. The role of genomic instability in human carcinogenesis. *Anticancer Research* 19:1-20, 1999.
42. Marshall DS, Linfert DR, **Tsongalis GJ**. Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. *Intl J Molec Med* 4:389-393, 1999.
43. Wu AHB, Holtman V, **Tsongalis GJ**, Macer J. Homocysteine screening of a female Hispanic population. *Intl J Molec Med, Int J Mol Med*. 4(3):295-297, 1999.
44. Fiel-Gan M, Villamil CF, Mandavilli SR, Ludwig M, **Tsongalis GJ**. Rapid detection and typing of HSV from cytology specimens collected into thinprep fixative. *Acta Cytologica* 43:1034-8, 1999.
45. Feng YJ, Linfert DR, Wu AHB, **Tsongalis GJ**. Polymorphisms in the genes for coagulation factors II, V, and VII in Patients with Ischemic Heart Disease. *Arch Pathol Lab Med*. 1999;123:1230-1235, 1999.

46. Makowski GS, Hopfer SM, **Tsongalis GJ**, Wu AH. Changes in Academic Productivity: Implications for Clinical Laboratory Research and Development. *Clin Chem Feb*;46(2):303-305, 2000.
47. Joshi VV, Balarezo F, Hicks MJ, Mierau GW, **Tsongalis GJ**. Approach to small round cell tumors of childhood. *Pathol Case Reviews* 5:26-41, 2000.
48. Johnson RC, Ricci A Jr, Cartun RW, Ackroyd R, **Tsongalis GJ**. Detection of p185HER2 overexpression in breast cancer using a molecular and immunohistochemical approach. *Cancer Investigation* 18(4):336-342, 2000.
49. Mandavilli B, Shoup RM, DiGiuseppe JA, Rezuke WN, **Tsongalis GJ**. Concurrent Factor V Leiden and prothrombin G20210A gene mutations in a patient with a history of recurrent thrombosis. *Conn Med* 64:259-261, 2000.
50. de Medeiros BC, Rezuke WN, Ricci A Jr, **Tsongalis G**, Shen PU, Bona RD, Feingold JM, Edwards RL, Tutschka PJ, Bilgrami S. Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. *Acta Haematol.* 104(2-3):115-118, 2000.
51. **Tsongalis GJ**, Cartun RW, Ricci A Jr. Gene amplification as a means for determining therapeutic strategies in human cancers. *Clin Chem Lab Med*, 38(9):837-839, 2000.
52. Felice KJ, Lira MG, Natowicz M, Grunnett ML, **Tsongalis GJ**, Sima AAF, Kaplan RF. Adult onset MLD: A gene mutation with isolated polyneuropathy. *Neurology* 55:1036-1039, 2000.
53. Marshall DS, Linfert DR, Draghi A, McCarter YS, **Tsongalis GJ**. Identification of herpes simplex virus genital infection: Comparison of a multiplex PCR assay and traditional viral isolation techniques. *Mod Pathol*, 14(3):152-156, 2001.
54. Rhodes RB, Lewis K, Shultz J, Huber S, Voelkerding KV, Leonard DGB, **Tsongalis GJ**, Kephart DD. Automated analysis of the Factor V Leiden mutation using a novel luciferase-based molecular analysis tool. *Molec Diagn*, 6(1):55-61, 2001.
55. **Tsongalis GJ**, Ricci Jr A. HER2: The Neu prognostic marker for breast cancer. *Crit Rev Lab Med* 38(2):167-182, 2001.
56. Linfert DR, **Tsongalis GJ**. Coexistence of the methylenetetrahydrofolatereductase (MTHFR) single nucleotide polymorphism (C677T) in patients with the Factor V Leiden or prothrombin G20210A polymorphisms. *Diagn Molec Pathol* 10(2):111-115, 2001.
57. Wu AH, **Tsongalis GJ**. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. *Am J Cardiol* 87(12):1361-1366, 2001.
58. Wiecek SJ, **Tsongalis GJ**. Pharmacogenomics: Will it change the field of medicine? *Clin Chim Acta* 308:1-8, 2001.
59. **Tsongalis GJ**, Rainey BJ, Hodges KA. READIT: A novel technology used in the interrogation of nucleic acid sequences for single nucleotide polymorphisms (SNPs). *Exper Molec Pathol* 71:222-225, 2001.

60. Peng F, LaBelle LA, Rainey BJ, **Tsongalis GJ**. Single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene are common in U.S. and Hispanic American populations. *Int J Mol Med*. 8(5):509-511, 2001.
61. Bowenkamp BE, Frasca S Jr, Draghi A, **Tsongalis GJ**, Koerting C, Hinckley L, DeGuise S, Montali RJ, Goertz CEC, St. Aubin DJ, Dunn JL. Mycobacterium marinum dermatitis and panniculitis with chronic pleuritis in a captive white whale (*Delphinapterus leucas*) with aortic rupture. *J Vet Diagn Invest* 13:524-530, 2001.
62. Blechner MD, Mandavilli SR, **Tsongalis GJ**. Measuring telomerase activity for the early detection of cancer. *Conn Med* 65 (11):643-648, 2001.
63. Marshall-Taylor C, Rezuke WN, **Tsongalis GJ**. The Clinical and Hematologic Sequelae of Parvovirus B19. *J Clin Ligand Assay* 24:108-111, 2001.
64. Bean P, Ryan A, Tsongalis GJ. Point mutation detection technology for the new-century laboratory. *Am Clin Lab* 20(3):13-16, 2001.
65. Hurford MT, Marshall-Taylor C, Vicki S, Zhou JZ, Silverman LM, Rezuke WN, Altman A, **Tsongalis GJ**. A novel mutation in exon 5 of the ALAS2 gene results in X-linked sideroblastic anemia. *Clin Chim Acta* 321:49-53, 2002.
66. Killeen AA, Leung WC, Payne D, Sabath DE, Snow K, **Tsongalis GJ**, Van Deerlin V, Weck K. Certification in molecular pathology in the United States. *J Mol Diagn* 4:181-184, 2002. PMID: PMC1907356
67. **Tsongalis GJ**, Ricci A Jr. Breast Cancer as a Model of realistic Challenges in Pharmacogenomics. *Clin Biochemn* 36:89-94, 2003.
68. Furmaga WB, Ryan JL, Coleman WB, Cole SR, **Tsongalis GJ**. Alu-profiling of primary and metastatic non-small cell lung cancer. *Exp Molec Pathol* 74(3):224-229, 2003.
69. **Tsongalis GJ**. A reality check for molecular diagnostics in clinical practice. *Pharmacogenomics* 4(5):667-668, 2003.
70. Furmaga WB, Colon SR, **Tsongalis GJ**. The use of Alu-PCR to distinguish between typical pulmonary carcinoids versus classical midgut carcinoids. *Intl J Oncol* 24(1):223-226, 2003.
71. Lewis MJ, Lewis EH, Amos JA, **Tsongalis GJ**. Cystic Fibrosis. *Am J Clin Pathol* 120(Suppl 1):S3-S13, 2003.
72. Thompson PD, **Tsongalis GJ**, Seip R, Meckes C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos T, Pescatello L, Bausserman L, Niall M. Apolipoprotein E Genotype and Changes in Serum Lipids and Maximal Oxygen Uptake With Exercise Training. *Metabolism* 53(2):193-202, 2004.
73. Poulin M, Pescatello LS, D'Agostino D, Wolf S, **Tsongalis GJ**. The Glu298Asp single nucleotide polymorphisms in the endothelial nitric oxide synthase gene is common in the Puerto Rican Hispanic patients. *Preclinica* 2(2):147-150, 2004.

74. Angeline T, Jeyaraj N, Granito S, **Tsongalis GJ**. Prevalence of MTHFR gene polymorphisms (C677T and A1298C) among Tamilians. *Exper Molec Pathol* 77(2):85-88, 2004.
75. **Tsongalis GJ**, Belloni DR, Grody WW. Cystic fibrosis mutation analysis: How many is enough? *Genet Med* 6(5):456-457, 2004.
76. Draghi A 2nd, Popov VL, Kahl MM, Stanton JB, Brown CC, **Tsongalis GJ**, West AB, Frasca S Jr. Characterization of "*Candidatus* Piscichlamydia salmonis" (Order *Chlamydiales*), a Chlamydia-like bacterium associated with epitheliocystis in farmed Atlantic salmon (*Salmo salar*). *J Clin Microbiol* 42(11):5286-5297, 2004. PMID: PMC525185
77. **Tsongalis GJ**. DNA STAT: The ability to perform clinical analysis in real time. *Expert Rev Mol Diagn* 5:627-628, 2005.
78. Bentley HA, Belloni DR, **Tsongalis GJ**. Parameters involved in the conversion of real time PCR assays from the ABI Prism 7700 to the Cepheid Smartcycler II. *Clin Biochem* 38:183-186, 2005.
79. Ligato S, Furmaga W, Cartun RW, Hull D, **Tsongalis GJ**. Primary carcinoid tumor of the common hepatic duct: A rare case with immunohistochemical and molecular findings. *Oncol Rep* 13(3):543-546, 2005.
80. Angeline T, Bentley HA, Hawk AB, Manners RJ, Mokashi HA, Jeyaraj N, **Tsongalis GJ**. Prevalence of the factor V G1691A and the factor II/prothrombin G20210A gene polymorphisms among Tamilians. *Exp Molec Pathol* 79:9-13, 2005.
81. Adeyi OA, Belloni DR, Dufresne SD, Schned AR, **Tsongalis GJ**. Real-time polymerase chain reaction and laser capture microdissection techniques in the diagnosis of BK virus infection of renal allografts. *Am J Clin Pathol* 124(4):537-542, 2005.
82. **Tsongalis GJ**, Gleeson T, Rodina M, Anamani D, Ross J, Joannisse I, Tanimoto L, Ziermann R. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. *J Clin Virol* 34:268-271, 2005.
83. Coleman WB, **Tsongalis GJ**. Molecular mechanisms of human carcinogenesis. *EXS*, 96:321-349, 2006.
84. **Tsongalis GJ**. Branched-DNA (bDNA) technology in molecular diagnostics. *Am J Clin Pathol* 126(3):448-453, 2006.
85. **Tsongalis GJ**, Coleman WB. Clinical genotyping: The need for interrogation of single nucleotide polymorphisms and mutations in the clinical laboratory. *Clin Chim Acta*, 363:127-137, 2006.
86. Thompson PD, **Tsongalis GJ**, Ordovas J, Seip RL, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N. Angiotensin converting enzyme genotype and adherence to aerobic exercise training. *Preventative Cardiology*, 9(1):21-24, 2006.
87. Dufresne SD, Belloni DR, Wells WA, **Tsongalis GJ**. BRCA1 and BRCA2 mutation screening using high resolution melt curve analysis. *Arch Pathol Lab Med* 130(2):185-187, 2006.

88. Schned AR, Ornvold K, **Tsongalis GJ**, Chobanian MC. Fatal relapse of ANCA-associated glomerulonephritis triggered by successive Epstein-Barr and varicella zoster virus infections. *Am J Kidney Dis.* 47(5):915-922, 2006.
89. Blanchard BE, **Tsongalis GJ**, Guidry MA, LaBelle LA, Poulin M, Taylor AL, Maresh CM, Devaney J, Thompson PD, Pescatello LS. RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension. *Eur J Appl Physiol* 97:26-33, 2006.
90. Caliendo AM, Valsamakis A, Zhou Y, Yen-Lieberman B, Andersen J, Young S, Ferreira-Gonzalez A, **Tsongalis GJ**, Pyles R, Bremer JW, Lurain NS. Multilaboratory comparison of hepatitis C viral load assays. *J Clin Microbiol* 44(5):1726-1732, 2006. PMID: PMC1479213
91. **Tsongalis GJ**, Silverman LM. Molecular diagnostics: A historical perspective. *Clin Chim Acta* 369:188-192, 2006.
92. Lee HK, Lewis LD, **Tsongalis GJ**, McMullin M, Schur BC, Wong SH, Yeo KTJ. Negative Urine Opioid Screening Caused By Rifampin Mediated Induction of Oxycodone Hepatic Metabolism *Clin Chim Acta* 367(1-2):196-200, 2006.
93. Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, Roth RM, Mamourian AC, **Tsongalis GJ**, Rhodes CH. Regional brain atrophy in cognitively intact adults with a single APOE e4 allele. *Neurology* 67(7):1221-1224, 2006.
94. Ruano G, Seip RL, Windemuth A, Zollner S, **Tsongalis GJ**, Ordovas J, Otvos J, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson PD. Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. *Atherosclerosis* 185(1):65-69, 2006.
95. Seip RL, Otvos J, Bilbie C, **Tsongalis GJ**, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson PD. The effect of apolipoprotein E genotype on serum lipoprotein particle response to exercise. *Atherosclerosis* 188(1):126-133, 2006.
96. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, **Tsongalis GJ**, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. *Proc Natl Acad Sci USA* 6;104(10):4089-4094, 2007. PMID: PMC1820713
97. Lee HK, Lewis LD, **Tsongalis GJ**, Schur BC, Jannetto PJ, Wong SH, Yeo KTJ. Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation. *Clin Chem* 53(5):823-828, 2007.
98. Pescatello LS, Turner D, Rodriguez N, Blanchard BE, **Tsongalis GJ**, Maresh CM, Duffy V, Thompson PD. Dietary calcium intake and renin angiotensin system polymorphisms alter the blood pressure response to aerobic exercise: A randomized control design. *Nutrition Metab* 4:1, 2007. PMID: PMC1779272
99. Tafe LJ, Belloni DR, **Tsongalis GJ**. Detection of the C282Y and H63D polymorphisms associated with hereditary hemochromatosis using the ABI 7500 FAST real time PCR platform. *Diagn Mol Pathol* 16(2):112-115, 2007.

100. Blanchard BE, **Tsongalis GJ**, Maresh CM, Van Heest JL, Thompson PD, Pescatello LS. The effect of hemostatic biomarkers on postexercise hypotension. *Med Sci Sports Exerc* 39(5 Suppl):S92-93, 2007.
101. Angeline T, Jeyaraj N, **Tsongalis GJ**. MTHFR gene polymorphisms, B-vitamins, and hyperhomocystinemia in young and middle aged acute myocardial infarction patients. *Exp Mol Pathol* 82:227-233, 2007.
102. Dufresne SD, Belloni DR, Levy NB, **Tsongalis GJ**. Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL monitor assay. *Arch Pathol Lab Med* 131:947-950, 2007.
103. Lefferts J, Bartels C, **Tsongalis GJ**. Pharmacogenetics: where are we with respect to personalized medicine? *Expert Opin Med Diagn* 1:117-128, 2007.
104. Van Kruiningen HJ, Poulin M, Garmendia AE, Desreumaux P, Colombel JF, DE Hertogh G, Geboes K, Vermeire S, **Tsongalis GJ**. Search for evidence of recurring or persistent viruses in Crohn's disease. *APMIS* 115:962-968, 2007.
105. Winn-Deen ES, Helton B, Van Atta R, Wong W, Peralta J, Wang J, **Tsongalis GJ**, Belloni D, Chan D, Eschleman JR, Gocke CD, Jobbagy Z, Beppu J, Radich JP. Development of an integrated assay for detection of BCR-ABL RNA. *Clin Chem* 53:1593-1600, 2007.
106. Pescatello LS, Blanchard BE, **Tsongalis GJ**, Maresh CM, O'Connell A, Thompson PD. The α -adducin Gly460Trp polymorphism and the antihypertensive effects of exercise among men with high blood pressure. *Clin Sci* 113(5):251-258, 2007.
107. Lefferts JA, Bartels CL, **Tsongalis GJ**. Molecular Oncology: Current trends in diagnostics. *Future Oncol* 4:61-70, 2008.
108. Gonzalez JL, Balestra S, Schned AR, Gutmann EJ, **Tsongalis GJ**. Polyomavirus infection of the urinary tract presenting as hemorrhagic cystitis in an immunocompetent five-year-old boy. *Diagn Cytopathol* 36(6):375-378, 2008.
109. Zlotnick DM, Merrens EJ, Petras ML, **Tsongalis GJ**, Bentley H, Fingar EL, Levy NB. Intravascular lymphoma as a recurrence of testicular Non-Hodgkin's lymphoma confirmed by polymerase chain reaction. *Am J Hematol* 83(8):681-682, 2008.
110. McAllister TW, Flashman LA, Rhodes CH, Tyler AL, Moore JH, Saykin AJ, McDonald BC, Tosteson TD, **Tsongalis GJ**. Single nucleotide polymorphisms in ANKK1 and the dopamine D2 receptor gene affect cognitive outcome shortly after traumatic brain injury: a replication and extension study. *Brain Inj.* 22(9):705-714, 2008. PMID: PMC3169811
111. Pescatello LS, Blanchard BE, **Tsongalis GJ**, O'Connell AA, Gordish-Dressman H, Maresh CM, Thompson PD. A comparison of the genetic and clinical profile of men that respond and do not respond to the immediate antihypertensive effects of aerobic exercise. *Appl Clin Genet* ([ACG_3813_Pescatello_091208.pdf](#)) 1:7-17, 2008. PMID: PMC3681122
112. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Mundingv JB, Barth Jr RJ, Gutmann EJ, Suriawinata AA, Pipas JM, Tannapfel A, Korc M, Hahn SA, Labourier E, **Tsongalis**

GJ. Analysis of microRNAs in Pancreatic Fine Needle Aspirates Can Classify Benign and Malignant Tissues, *Clin Chem* 54(10):1716-1724, 2008.

113. Mercer RR, Lucas NC, Zander DS, **Tsongalis GJ**, Funkhouser WK, Coleman WB. Molecular discrimination of multiple primary versus metastatic squamous cell cancers of the head/neck and lung. *Exp Molec Pathol* 86(1):1-9, 2009.
114. Bartels CL, **Tsongalis GJ**. MiRNAs: novel biomarkers for human cancer. *Clin Chem*. 55(4):623-631, 2009.
115. Augeri AL, **Tsongalis GJ**, Van Heest JL, Maresh CM, Thompson PD, Pescatello LS. The endothelial nitric oxide synthase -786 T>C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure. *Atherosclerosis* 204(2):e28-34, 2009.
116. Lefferts JA, Jannetto PJ, **Tsongalis GJ**. Evaluation of the Verigene system and the Verigene F5/F2/MTHFR nucleic acid tests. *Exp Molec Pathol* 87(2):105-108, 2009.
117. Bartels CL, Marchetti AL, Highsmith WE, **Tsongalis GJ**. Real time PCR detection of the PI*Z and PI*S mutations associated with alpha-1 antitrypsin deficiency. *Am J Transl Res* 1(4):406-411, 2009. PMID: PMC2780033 (http://www.ajtr.org/V1_No4.html).
118. Tafe LJ, Schwab MC, Lefferts JA, Wells WA, **Tsongalis GJ**. A Validation Study of a New Molecular Diagnostic Assay: The Dartmouth-Hitchcock Medical Center Experience with the GeneSearchT BLN Assay in Breast Sentinel Lymph Nodes. *Exp Molec Pathol* 88(1):1-6, 2010.
119. Staples CG, Henderson D, **Tsongalis GJ**, Fernandez M, Krejci-Manwaring J. Condylomata of the pannus in three obese patients: a new location for a common disease. *Arch Dermatol*. 146(5):572-574, 2010.
120. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, **Tsongalis GJ**, Suriawinata AA, Carrère N, Buscail L, Cordelier P. MicroRNA miR-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. *Clin Chem* 56(4):603-612, 2010.
121. Sloan CD, Shen L, West JD, Wishart HA, Flashman LA, Rabin LA, Santulli RB, Guerin SJ, Rhodes CH, **Tsongalis GJ**, McAllister TW, Ahles TA, Lee SL, Moore JH, Saykin AJ. Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnesic mild cognitive impairment using clinical and neuroimaging phenotypes. *Am J Med Genet B Neuropsychiatr Genet* 153B(5):1060-9, 2010. PMID: PMC3021757
122. Hanoun N, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J, **Tsongalis GJ**, Dufresne M, Buscail L, Cordelier P, Torrisani J. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. *Clin Chem* 56(7):1107-1118, 2010.
123. Lefferts JA, Hicks ND, **Tsongalis GJ**. Evaluation of a BK virus real-time PCR assay designed using novel bioinformatics technology. *Exp Molec Pathol* 89(2):99-102, 2010.
124. Lefferts JA, Schwab MC, Dandamudi UB, Lee HK, Lewis LD, **Tsongalis GJ**. Warfarin genotyping using three different platforms. *Am J Transl Res* 2(4):441-446, 2010. PMID: PMC2923866

125. Eicher JD, Maresh CM, **Tsongalis GJ**, Thompson PD, Pescatello LS. The additive blood pressure lowering effects of exercise intensity on post-exercise hypotension. *Am Heart J* 160(3):513-20, 2010.
126. Angeline T, Isabel W, **Tsongalis GJ**. Endothelial Nitric Oxide Gene Polymorphisms, Nitric Oxide Production And Coronary Artery Disease Risk In A South Indian Population. *Exp Molec Pathol*, 89(3):205-208, 2010.
127. Black CC, Bentley HA, Davis TH, **Tsongalis GJ**. Use of a linear array for the detection of human papillomavirus genotypes in head and neck cancer. *Arch Pathol Lab Med*, Dec 134(12):1813-1817, 2010.
128. Bartels CL, **Tsongalis GJ**. [MicroRNAs: Novel biomarkers for human cancer.] *Ann Biol Clin (Paris)*. 68(3):263-72, 2010. (French)
129. Wishart HA, Roth RM, Saykin AJ, Rhodes CH, **Tsongalis GJ**, Pattin KA, Moore JH, McAllister TW. COMT Val158Met Genotype and Individual Differences in Executive Function in Healthy Adults. *J Int Neuropsychol Soc*. Jan; 17(1):174-80, 2011. PMID: PMC3114452
130. Seip RL, Zoeller RF, Angelopoulos TJ, Salonia J, Bilbie C, Moyna NM, Miles MP, Visich PS, Pescatello LS, Gordon PM, **Tsongalis GJ**, Bausserman L, Thompson PD. Interactive effects of APOE haplotype, sex, and exercise on postheparin plasma lipase activities. *J Appl Physiol*, Apr; 110(4):1021-1028, 2011. PMID: PMC3075133
131. Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, **Tsongalis GJ**, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle S, Kurie JM, Waxman S, Dmitrovsky E. Bexarotene Plus Erlotinib Suppresses Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models. *Cancer Prev Res*, Jun; 4(6):818-828, 2011. PMID: PMC3108499
132. Fuld AD, Speck ME, Harris BT, Simmons NE, Corless CL, **Tsongalis GJ**, Pastel DA, Hartford AC, Ernstoff MS. Primary Melanoma of the Spinal Cord: A case report, molecular footprint and review of the literature. *J Clin Oncol*. Jun 10;29(17):e499-502, 2011.
133. Chen H, Lefferts JA, Schwab MC, Suriawinata AA, **Tsongalis GJ**. Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation. *Cancer Genet*, Apr 204:245-251, 2011.
134. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, **Tsongalis GJ**, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. CALGB Pathology Committee Guidelines for tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues. *J Clin Oncol*, Jun; 29(16):2282-2290, 2011. PMID: PMC3107745
135. Tafe LJ, **Tsongalis GJ**. The human epidermal growth factor receptor 2 (HER2). *Clin Chem Lab Med*. Sep; 50(1):23-30, 2011.
136. Caliendo AM, Valsamakis A, Bremer JW, Ferreira-Gonzalez A, Granger S, Sabatini L, **Tsongalis GJ**, Wang YF, Yen-Lieberman B, Young S, Lurain NS. Multilaboratory Evaluation of Real-Time PCR Tests for Hepatitis B Virus DNA Quantification. *J Clin Microbiol*, Aug; 49(8):2854-2858, 2011. PMID: PMC3147738

137. Petras ML, Lefferts JA, Suriawinata AA, **Tsongalis GJ**. KRAS Detection in Colonic Tumors Via DNA Extraction from FTA Paper: The Molecular Touch-Prep. *Diagn Molec Pathol*, Dec 20(4): 189–193, 2011.
138. Ward BP, **Tsongalis GJ**, Kaur P. MicroRNAs in chronic lymphocytic leukemia. *Exp Mol Pathol* Apr; 90(2):173-178, 2011.
139. McAllister TW, Tyler AL, Flashman LA, Rhodes CH, McDonald BC, Saykin AJ, Tosteson TD, **Tsongalis GJ**, Moore JH. Polymorphisms in the Brain-Derived Neurotrophic Factor Gene Influence Memory and Processing Speed One Month After Brain Injury. *J Neurotrauma*. Apr; 29(6):1111-1118, 2012. PMID: PMC3325555
140. Olson KM, Augeri AL, Seip RL, **Tsongalis GJ**, Thompson PD, Pescatello LS. Correlates of endothelial function and the peak systolic blood pressure response to a graded maximal exercise test. *Atherosclerosis*, May 222(1):202-207, 2012.
141. Hlousek L, Voronov S, Diankov V, Leblang AB, Wells PJ, Ford DM, Nolling J, Hart KW, Espinoza PA, Bristol MR, **Tsongalis GJ**, Yen-Lieberman B, Slepnev VI, Kong LI, Lee MC. Automated high multiplex PCR platform for simultaneous detection and quantification of multiple nucleic acid targets. *Biotechniques*, May 52(5):316-324, 2012.
142. Abou Tayoun AN, Ward BP, Maltezos G, Scherer A, **Tsongalis GJ**. Evaluating the thermostability of commercial fast real-time PCR master mixes. *Exp Molec Pathol* May 93:261-263, 2012.
143. Miravalle L, Lefferts JA, Al-Haddad M, **Tsongalis GJ**, Cheng L. Performance evaluation of a new KRAS mutation detection assay. *Cancer Genomics Proteomics*, Sept 9:337-342, 2012.
144. Martin IW, Steinmetz HB, Lefferts CL, Dumont LJ, Tafe LJ, **Tsongalis GJ**. Evaluation of the Cobas 4800 HPV tests for detecting high-risk human papilloma-virus. *Pathogens*, Sept 1:30-36; 2012.
145. Pipas JM, Zaki BI, McGowan MM, Tsapakos MJ, Ripple GH, Suriawinata AA, **Tsongalis GJ**, Colacchio TA, Gordon SR, Sutton JE, Srivastava A, Smith KD, Gardner TB, Korc M, Davis TH, Preis M, Tarczewski SM, MacKenzie TA, Barth Jr RJ. Neoadjuvant Cetuximab, twice-weekly Gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. *Annals Oncol* Nov 23(11):2820-7 2012.
146. Rauwerdink CA, **Tsongalis GJ**, Tosteson TD, Hill JM, Meehan KR. The practical application of chimerism analyses in allogeneic stem cell transplant recipients: Blood chimerism is equivalent to marrow chimerism. *Exp Molec Pathol* Dec 93:339-344, 2012 (Jul 28. [Epub ahead of print]).
147. Sam S, Lebel KA, Bissaillon CL, Tafe LJ, **Tsongalis GJ**, Lefferts JA. Automation of genomic DNA isolation from formalin-fixed, paraffin-embedded tissues. *Pathol Res Pract*. Dec 208(12):705-707, 2012.
148. Marotti JD, Schwab MC, McNulty NJ, Rigas JR, DeLong PA, Memoli VA, **Tsongalis GJ**, Padmanabhan V. Cytomorphologic Features of Advanced Lung Adenocarcinomas Tested for EGFR and KRAS Mutations: A Retrospective Review of 50 Cases. *Diagn Cytopathol J*, Jan 41(1):15-21, 2013 (Jun 16, 2011. 10.1002/dc.21749. Epub ahead of print).

149. Sidor IF, Dunn JL, **Tsongalis GJ**, Frasca Jr S. A multiplex real-time PCR assay with two internal controls for the detection of *Brucella* spp. in tissues, blood and feces from marine mammals. J Vet Diagn Invest. Jan 25(1):72-81, 2013.
150. Cervinski MA, Schwab MC, Lefferts JA, Lewis LD, Lebel KA, Tyropolis AM, Pflueger SMV, **Tsongalis GJ**. Establishment of a CYP2C19 genotyping assay for clinical use. Am J Clin Pathol, Feb 139(2):202-207, 2013.
151. Gardner TB, Glass LM, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Tsapakos MJ, Suriawinata AA, **Tsongalis GJ**, Pipas JM, Gordon SR. Pancreatic Cyst Prevalence and the Risk of Mucin-Producing Adenocarcinoma in US Adults. Am J Gastroentero, Oct;108(10):1546-50, 2013.
152. Burchard PR, Malhotra S, Kaur P, **Tsongalis GJ**. Detection of the FCGR3A Polymorphism Using a Real Time Polymerase Chain Reaction Assay. Cancer Genet, Apr 2013, 206:130-134.
153. Sam SS, Steinmetz HB, **Tsongalis GJ**, Tafe LJ, Lefferts JA. Validation of a Solid-Phase Electrochemical Array for Genotyping Hepatitis C Virus. Exp Molec Pathol, Apr 2013, 95:18-22.
154. Pipas JM, Lewis LD, Ernstoff MS, **Tsongalis GJ**. Personalized Medicine: Some Things to Consider. Oncol Hematol Rev, May 2013, 9:75-80.
155. Abou Tayoun AN, de Abreu F, Lefferts JA, **Tsongalis GJ**. A Clinical PCR Fragment Analysis Assay for TA Repeat Sizing in the UGT1A1 Promoter Region. Clinica Chimica Acta, June 2013, 422:1-4.
156. Srivastava S, **Tsongalis GJ**, Kaur P. Recent Advances in MicroRNA-Mediated Gene Regulation in Chronic Lymphocytic Leukemia. Clin Biochem, Jul 2013, 46:901-908.
157. **Tsongalis GJ**, Lockwood CM. Clinical utility of miRNAs in diagnosis and prognosis. Clin Biochem. 2013 Jul;46(10-11):839. PMID:23726293
158. Hourdequin KC, Lefferts JA, Brennick JB, Ernstoff MS, **Tsongalis GJ**, Pipas JM. The Merkel Cell Polyomavirus and Extrapulmonary Small Cell Carcinoma. Oncol Letters, 2013 Oct;6(4):1049-1052.
159. Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth Jr RJ, Suriawinata AA, **Tsongalis GJ**. MicroRNAs as Diagnostic Markers for Pancreatic Ductal Adenocarcinoma and Its Precursor, Pancreatic Intraepithelial Neoplasm. Cancer Genetics, 2013 Jun; 206(6):217-21. PMID:23933230
160. Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyenetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, **Tsongalis GJ**, Kurie JM, Li H, Drenzo J, Guo Y, Freemantle SJ, Dagnev KH, Dmitrovsky E. Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Lung Cancer Patients. Mol Cancer Ther. Aug 2013;12(8):1545-1555.
161. Abou Tayoun AN, Tunkey CD, Pugh TJ, Ross T, Shah M, Lee CC, Harkins TT, Wells WA, Tafe LJ, Amos CI, **Tsongalis GJ**. A Comprehensive Assay for CFTR Mutational Analysis Using Next-Generation Sequencing. Clin Chem. Oct 2013; 59(10):1481-1488.

162. Roengvoraphoj M, **Tsongalis GJ**, Dragnev KH, Rigas JR. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. *Cancer Treat Rev*, 2013 Dec, 39(8):839-850.
163. De Abreu FB, Wells WA, **Tsongalis GJ**. The Emerging Role of the Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine. *Am J Pathol*. 2013 Oct;183(4):1075-83. PMID:23920325.
164. Gowarty MA, Zaki BI, Tsapakos MJ, Gordon SR, Suriawinata AA, **Tsongalis GJ**, Sutton JE, Pipas JM. Successful retreatment with chemoradiotherapy for local recurrence of pancreatic adenocarcinoma after neoadjuvant therapy and pancreaticoduodenectomy. *Gastrointestinal Cancer Res* 2013 July/August 6 (4):118-119.
165. Koestler DC, Li J, Baron JA, **Tsongalis GJ**, Butterly LF, Goodrich M, Lesseur C, Karagas MR, Marsit CJ, Moore JH, Andrew AS, Srivastava A. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. *Mod Pathol*. 2014 Jan;27(1):145-55. PMID: 23868178.
166. **Tsongalis GJ**, Peterson JD, de Abreu F, Tunkey CD, Gallagher TL, Strausbaugh LD, Wells WA, Amos CI. Routine Use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for Identification of Clinically Actionable Somatic Mutations. *Clin Chem Lab Med* 2014 May;52(5):707-714. PMID:24334431.
167. Cervinski MA, Sam S, Steinmetz HB, Wood B, **Tsongalis GJ**. Validation of an Interleukin 28B Genotyping Assay for Clinical Use. *Clin Biochem* 2014 Apr; 47(6):478-480. PMID:24462832
168. Putra J, Kim J, Peterson JD, De Abreu FB, Muller KE, **Tsongalis GJ**, Liu X. Metastatic Alveolar Rhabdomyosarcoma to the Breast: Case Report and Literature Review. *J Pediatric Oncol* 2013 June; 1(2):67-71.
169. Abou Tayoun AN, Burchard PR, Malik I, Scherer A, **Tsongalis GJ**. Democratizing molecular diagnostics for the developing world. *Am J Clin Pathol*. 2014 Jan;141(1):17-24. PMID: 24343733.
170. Liu X, Mody K, de Abreu FB, Pipas JM, Peterson JD, Gallagher TL, Suriawinata AA, Ripple GH, Hourdequin KC, Smith KD, Barth Jr. RJ, Colacchio TA, Tsapakos MJ, Zaki BI, Gardner TB, Gordon SR, Amos CI, Wells WA, **Tsongalis GJ**. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. *Clin Chem* 2014, Jul;60(7):1004-11. PMID:24821835.
171. De Abreu FB, Gallagher TL, Liu EZ, Tsongalis GJ. Determining methylation status of methylguanine DNA methyl transferase (MGMT) from formalin-fixed, paraffin embedded tumor tissue. *Methods X* 2014, July, 1:42-48.
172. Tafe LJ, Cao J, Sabbath-Solitare M, Redondo TC, Lara J, **Tsongalis GJ**. HER2 testing in gastroesophageal cancer paired biopsy and resection specimens – A multi-institutional immunohistochemistry and fluorescence in-situ hybridization correlation study. *J Clin Exp Oncol* 2014, 3:2.

173. Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, **Tsongalis GJ**, Moore JH, Saykin AJ. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. *Psycho-Oncology*, 2014 (online). PMID: 24789331.
174. De Abreu FB, Schwartz GN, Wells WA, **Tsongalis GJ**. Personalized therapy for breast cancer. *Clinical Genetics* 2014, Jul;86(1):62-67.
175. Tafe LJ, Allen SF, Steinmetz HB, Dokus BA, Cook LJ, Marotti JD, **Tsongalis GJ**. Automated Processing of Fluorescence In-Situ Hybridization Slides for *HER2* Testing in Breast and Gastroesophageal Carcinomas. *Exp Molec Pathol* 2014 (Aug) 97:116-119. PMID:24927872.
176. Burchard PR, Abou Tayoun AN, Scherer A, **Tsongalis GJ**. A rapid RT-PCR assay for the detection of HIV-1 in human plasma specimens. *Exp Molec Pathol* 2014 Oct; 97(1):111-5. PMID: 24945443.
177. Schink JC, Trosman JR, Weldon CB, Siziopikou KP, **Tsongalis GJ**, Rademaker AW, Patel JD, Benson III AB, Perez EA, Gradishar WJ. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. *JNCI* 2014 Sept 12;106:10. PMID:25217578
178. Gardner TB, Hessami N, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Zaki B, Tsapakos MJ, Suriawinata AA, Putra J, **Tsongalis GJ**, Mody K, Gordon SR, Pipas JM. The effect of neoadjuvant chemoradiation on pancreatic cancer associated diabetes mellitus. *Pancreas*, Oct;43(7):1018-21, 2014. PMID:25000339
179. Brand RE, Adai AT, Centeno BA, , Lee LS, Rateb G, Vignesh S, Menard C, Wiechowska-Kozłowska A, Boldys H, Hartleb M, Sanders MK, Munding JB, Tannapfel A, Hahn SA, Stefanczyk L, **Tsongalis GJ**, Whitcomb DC, Conwell DL, Morisset, GardnerTB, Gordon SR, Suriawinata AA, Lloyd MB, Wylie D, Labourier E, Andruss BF, Szafranska-Schwarzbach AE. A MicroRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. *Clin Gastroenterol Hepatol*, Oct;12(10):1717-23, 2014. PMID: 24662333.
181. Korf BR, Berry AB, Limson M, Marian AJ, Murray MF, O'Rourke PP, Passamani ER, Relling MV, Tooker J, **Tsongalis GJ**, Rodriguez LL. Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics. *Genet Med*. 2014 Nov;16(11):804-9. PMID: 24763287
182. Kapp JR, Diss T, Spicer J, Gandy M, Schrijver I, Jennings LJ, Li MM, **Tsongalis GJ**, Gonzalez de Castro D, Bridge JA, Wallace A, Deignan JL, Hing S, Butler R, Verghese E, Latham GJ, Hamoudi RA. Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial. *J Clin Pathol* 2015 Feb;68(2):111-8. PMID:25430497.
183. Abou Tayoun AN, Burchard PR, Caliendo AM, Scherer A, **Tsongalis GJ**. A Multiplex PCR Assay for the Simultaneous Detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis*. *Exp Mol Pathol*. 2015 Apr; 98(2):214-218. PMID:25595915
184. Thomas AA, Fisher JL, Rahme GJ, Hampton TH, Baron U, Olek S, Schwachula T, Rhodes CH, Gui J, Tafe LJ, **Tsongalis GJ**, Lefferts JA, Wishart H, Kleen J, Miller M, Whipple CA, de Abreu FB,

Ernstoff MS, Fadul CE. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol. 2015 Jun; 17(6):801-809. PMID: 25618892.

185. Tafe LJ, Steinmetz HB, Allen SF, Dokus BJ, **Tsongalis GJ**. Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer. *J Clin Pathol*. 2015 Apr; 68(4):306-308. PMID: 25576545
186. Tafe LJ, **Tsongalis GJ**. A 78-year old women with brain metastases. *Clin Chem* 2015 Apr 61(4):584-586.
187. Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, **Tsongalis GJ**, Miller TW, Chamberlin MD. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. *Oncologist*. 2015 Sep;20(9):1011-8. PMID:26205736
188. Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, **Tsongalis GJ**, Suriawinata AA. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. *Exp Molec Pathol* 2015; 99:240-244. PMID:26189129
189. Miraflor AP, Ghajar LD, Subramaniam S, de Abreu FB, Castanedo-Tardan MP, Samie FH, Mann JA, Holmes AV, **Tsongalis GJ**, Yan S. Rat-bite fever: An uncommon cause of fever and rash in a 9-year-old patient. *J Am Acad Dermatol Case Reports* 2015 (Oct), 1:371-374.
190. Turner SA, Dinulos MBP, Vallee SE, Kennedy L, Mason P, Seibert D, Martinez MT, Steinmetz HB, **Tsongalis GJ**, Lefferts JA. Discovery of a novel cystathionine-beta-synthase mutation and diagnosis of homocystinuria by whole exome sequencing in a family from rural Honduras. Case report *Clin Pathol* 2015 Sept;2(3):59-65.
191. Mockus SM, Patterson SE, Statz C, Bult CJ, **Tsongalis GJ**. Clinical trials in precision oncology. *Clin Chem* 2016 March; 62(3):442-448. PMID:26607725.
192. Tafe LJ, Muller KE, Ananda G, Mitchell T, Spotlow V, Patterson SE, **Tsongalis GJ**, Mockus SM. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification. *Am J Pathol*. 2016 Jan 18. PMID:26797085.
193. Pierce KJ, Currens HS, Tafe LJ, **Tsongalis GJ**, Padmanabhan V. An Analysis of Human Papillomavirus (HPV) Testing and Endocervical Component on Pap Tests: A Pilot Study Using the Roche Cobas® Assay. *Diagnostic Cytopathology* 2016, Jan 23. doi: 10.1002/dc.23436. [Epub ahead of print] PMID: 26801205
194. Allaway RJ, Fischer DA, de Abreu FB, Gardner TB, Gordon SR, Barth RJ, Colacchio TA, Wood M, Kacsoh BZ, Bouley S, Cui J, Hamilton J, Choi JA, Lange J, Peterson JD, Padmanabhan V, Tomlinson CR, **Tsongalis GJ**, Suriawinata AA, Greene CS, Sanchez Y, Smith KD. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. *Oncotarget*, 2016 Mar 29;7(13):17087-102. PMID:26934555
195. Vankruiningen HJ, Hayes AW, Garmendia A, Cui J, de Abreu FB, **Tsongalis GJ**, Colombel JF. Evidence for chlamydia in Crohn's disease. *iMedPub-Intl J Digest Dis* 2016; 2(1):15.

196. De Abreu FB, Peterson JD, Amos CI, Wells WA, **Tsongalis GJ**. Effective quality management practices in routine clinical next generation sequencing. *Clin Chem Lab Med* 2016 (April);54(5):761-71. PMID:26872315.
197. Whipple CA, Boni A, Fisher JL, Hampton TH, **Tsongalis GJ**, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. *Melanoma Res*. 2016 Jun;26(3):223-35. PMID:26974965
198. Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, **Tsongalis GJ**, Tafe LJ. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers. *Exp Mol Pathol*. 2016 Jun;100(3):421-5. PMID: 27095739
199. Biernacka A, Tsongalis PD, Peterson JD, de Abreu FB, Black CC, Gutmann EJ, Liu X, Tafe LJ, Amos CI, **Tsongalis GJ**. The Need to Re-review Results of Somatic Mutation Testing: KRAS Status in Lung Adenocarcinoma. *Cancer Genet* 2016 May;209(5):195-8. PMID: 27068338
200. Turner SA, Peterson JD, Pettus JR, de Abreu FB, Amos CI, Dragnev KH, **Tsongalis GJ**. The pitfalls of companion diagnostics: evaluation of discordant EGFR mutation results from a clinical laboratory and a central laboratory. *J Molec Diagn* 2016 May;18(3):331-5. PMID: 26923179
201. Padmanabhan V, Steinmetz HB, Rizzo EJ, Erskine AJ, Fairbanks TL, de Abreu FB, **Tsongalis GJ**, Tafe LJ. Improving Adequacy of Small Biopsy and Fine Needle Aspiration Specimens collected by Rapid On-Site Evaluation for Molecular Testing by Next Generation Sequencing in Patients with Lung Cancer: A Quality Improvement Study". *Archives Pathol Lab Med* 2017 Mar;141:402-409. PMID:27763790
202. Gardner JA, Peterson JD, Turner SA, Soares BL, Lancor CR, dos Santos LL, Kaur P, Ornstein DL, **Tsongalis GJ**, de Abreu FB. Detection of CALR mutation in clonal and non-clonal hematologic diseases using fragment analysis and next generation sequencing. *Am J Clin Pathol*, 2016 Oct; 146 (4): 448-455.
203. Dillon J, Mockus S, Patterson S, Ananda G, Spotlow V, Palisoul S, Wells WA, **Tsongalis GJ**, Marotti JD. Somatic Gene Mutation Analysis of Triple Negative Breast Cancers. *Breast J*, 2016 Oct;29:202-7. PMID: 27397723
204. Tafe LJ, Pierce KJ, Peterson JD, de Abreu F, Memoli VA, Black CC, Pettus JR, Marotti JD, Gutmann EJ, Liu X, Shirai K, Dragnev KH, Amos CI, **Tsongalis GJ**. Clinical Genotyping of Non-Small Cell Lung Cancers using Targeted Next Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes. *Neoplasia*, 2016 September, 18(9):577-583. PMID: 27659017
205. Pierce KJ, de Abreu FB, Peterson JD, Suriawinata AA, **Tsongalis GJ**, Liu X. The Genomic Profile of Pancreatic Adenocarcinoma and Its Relationship to Metastatic Disease. *Exp Mol Pathol*. 2016 Aug;101(2):172-175. PMID: 27498048
206. Shee K, Lucas A, Flashman LA, Nho K, **Tsongalis GJ**, McDonald BC, Saykin AJ, McAllister TW, Rhodes CH. Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury. *Neurosci Lett*. 2016 Sep;630:241-6. PMID: 27478013

207. Srivastava S, **Tsongalis GJ**, Kaur P. Role of microRNAs in regulation of the TNF/TNFR gene superfamily in chronic lymphocytic leukemia. *Clin Biochem*. 2016 Aug PMID: 27544753
208. Tafe LJ, de Abreu FB, Peterson JD, **Tsongalis GJ**. MET exon 14 skipping mutation in non-small cell lung cancer identified by anchored multiplex PCR and next-generation sequencing. *J Cancer Epidemiol Prev* 2016;1:1-3.
209. Jung HS, Lefferts JA, **Tsongalis GJ**. Utilization of the OncoScan Microarray Assay in Cancer Diagnostics. *Appl Cancr Res*, 2017; 37:1-8.
210. Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher TL, **Tsongalis GJ**, Plimack ER, Greenberg RE, Geynisman DM. A Phase II Trial of Dovitinib in BCG-Unreponsive Urothelial Carcinoma with FGFR3 Mutations or Over-expression: Hoosier Cancer Research Network Trial HCRN 12-157. *Clin Cancer Res* 2017, Jun 15;23(12):3003-3011. PMID:27932416
211. Thomas AA, Fisher JL, Hampton TH, Christensen BC, **Tsongalis GJ**, Rahme GJ, Whipple CA, Steel SE, Davis MC, Lewis LD, Ernstoff MS, Fadul CE. Immune Modulation Associated with Vascular Endothelial Growth Factor (VEGF) Blockade in Patients with Glioblastoma. *Cancer Immunol Immunother* 2017 Mar;66:379-389. PMID:27942839
212. Andrew AS, Baron JA, Butterly LF, Suriawinata AA, **Tsongalis GJ**, Robinson CM, Amos CI. Hyper-methylated loci persisting from sessile serrated polyps to serrated cancers. *Intl J Molec Sci* 2017, PMID:28257124
213. Hampel KJ, de Abreu FB, Sidiropoulos N, Peterson JD, **Tsongalis GJ**. Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments. *Exp Molec Pathol* 2017; 102:215-218.
214. Smits NC, Kobayashi T, Srivastava PK, Skopelja S, Ivy JA, Elwood DJ, Stan RV, **Tsongalis GJ**, Sellke FW, Gross PL, Cole MD, DeVries JT, Kaplan AV, Robb JF, Williams SM, Shworak NW. HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. *Matrix Biol*. 2017 Jan 23. [Epub ahead of print] PMID: 28126521.
215. **Tsongalis GJ**, Coleman WB. Somatic mutation analysis of human cancers: Challenges in clinical practice. *J Clin Pharmacol*, 2017 Oct;57 Suppl 10:S60-S66.
216. de Abreu FB, Liu X, **Tsongalis GJ**. MiRNA Analysis in Pancreatic Cancer: The Dartmouth Experience. *Clin Chem Lab Med*, 2017 (May);55(5):755-762. PMID: 28343174.
217. Marotti JD, de Abreu FB, Wells WA, **Tsongalis GJ**. Triple Negative Breast Cancer: Next Generation Sequencing for Target Identification. *Am J Pathol* 2017, PMID: 28734944.
218. Kaul KL, Sabatini LM, **Tsongalis GJ**, Caliendo Am, Olsen RJ, Ashwood ER, Bale S, Benirschke R, Carlow D, Funke BH, Grody WW, Hayden RT, Hegde M, Lyon E, Murata K, Pessin M, Press RD, Thomson RB. The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. *Academic Pathol*, 2017 (July); 4:1-21.
219. Turner SA, Deharvengt SJ, Lyons KD, Plata Espinal JA, LaRochelle EPM, Bejarano S, Kennedy L,

- Tsongalis GJ.** Implementation of Multi-color Melt Curve Analysis for hrHPV Detection in LMICs: A Pilot Study for Expanded Cervical Cancer Screening in Honduras. *J Global Oncol*, 2018 (Sept);4:1-8, PMID:30241169.
220. De Abreu FB, Peterson JD, Deharvengt SJ, Daber R, Sarsani VK, Spotlow V, Harrington RD, Lih CJ, Williams PM, Bouk CH, Konigshofer Y, Huang C, Anekella B, Davis L, Garlick RK, Ferreira-Gonzalez A, Dumur CI, Fernandes H, Haralampu S, **Tsongalis GJ.** Use of biosynthetic controls as performance standards for next-generation sequencing assays of somatic tumors: A multilaboratory study. *J Appl Lab Med* 2018 (Sept); 2(2):138-149.
221. Miraflor AP, de Abreu FB, Peterson JD, Turner SA, Amos CI, **Tsongalis GJ,** Yan S. Somatic mutation analysis in melanoma using targeted next generation sequencing. *Exp Mol Pathol* 2017 Oct;103:172-177. PMID:28822769
222. Jung HS, **Tsongalis GJ,** Lefferts JA. Development of HLA-B*57:01 Genotyping Real-Time PCR with Optimized Hydrolysis Probe Design. *J Mol Diagn.* 2017 Sep;19(5):742-754. PMID:28732216.
223. Shajani-Yi Z, de Abreu FB, Peterson JD, **Tsongalis GJ.** Frequency of somatic TP53 mutations in combination with known pathogenic mutations in colon adenocarcinoma, non-small cell lung carcinoma and gliomas as Identified by next-generation sequencing. *Neoplasia*, 2018 Feb, 20(3):256-262. PMID: 29454261
224. Nerenz RD, **Tsongalis GJ.** Pharmacogenetics of opioid use and implications for pain management. *J Appl Lab Med* 2018 (Jan);1:622-632.
225. Al-Turkmani MR, Schutz S, **Tsongalis GJ.** The potential of STAT somatic mutation testing at resection. *Clin Chem* 2018, May;64(5):865-866. PMID: 29483108
226. Atkinson A, Studwell C, Bejarano S, Castellón AMZ, Espinal JAP, Deharvengt S, LaRochelle EPM, Kennedy LS, **Tsongalis GJ.** Rural distribution of human papilloma virus in low- and middle-income countries. *Exp Mol Pathol.* 2018 Apr,104(2):146-150. PMID: 29551573
227. Kumar N, Tafe LJ, Higgins J, Peterson JD, de Abreu FB, Deharvengt S, **Tsongalis GJ,** Amos CI, Hassanpour S. Identifying Associations between Somatic Mutations and Clinicopathologic Findings in Lung Cancer Pathology Reports. *Methods Inform Med* 2018 (Feb),57(1):63-73. PMID:29621832
228. Al-Turkmani MR, Godwin KN, Peterson JD, **Tsongalis GJ.** Rapid somatic mutation testing in colorectal cancer by use of a fully automated system and single-use cartridge: A comparison with next generation sequencing. *J Appl Lab Med* 2018 (Sept);3:178-184.
229. Jung HS, Vallee SE, Dinulos MB, **Tsongalis GJ,** Lefferts JA. Maternally inherited 133 kb deletion of 14q32 causing Kagami-Ogata Syndrome. *J Hum Genet* 2018 (Sept), PMID:30232357.
230. Facciponte DN, Bough MW, Seidler D, Carroll JL, Ashare A, Andrew AS, **Tsongalis GJ,** Vaickus LJ, Henegan PL, Butt TH, Stommel EW. Identifying aerosolized cyanobacteria in the human respiratory tract: A proposed mechanism for cyanotoxin-associated diseases. *Sci Total Environ.* 2018 (Dec), 15;645:1003-1013. PMID: 30248825

231. Shee K, Muller KE, Marotti J, Miller TW, Wells WA, **Tsongalis GJ**. Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. *Am J Pathol*. 2018 (Oct). PMID: 30385093
232. Rajagopal A, Yurk D, Shin C, Menge K, Jacky L, Fraser S, Tombrello TA, **Tsongalis GJ**. Significant Expansion of Real-Time PCR Multiplexing with Traditional Chemistries using Amplitude Modulation. *Sci Rep*. 2019 (Jan);9(1):1053. PMID: 30705333
233. Tadimety A, Zhang Y, Kready KM, Palinski TJ, **Tsongalis GJ**, Zhang JXJ. Design of peptide nucleic acid probes on plasmonic gold nanorods for detection of circulating tumor DNA point mutations. *Biosens Bioelectron*. 2019 (Jan);130:236-244. PMID: 30769288
234. Al-Turkmani MR, Gordon SR, Smith KD, **Tsongalis GJ**, Liu X. Pancreatic cyst fluid harboring a KRAS mutation. *Cold Spring Harb Mol Case Stud* 2019 (Apr);5:1-6. PMID: 30936197
235. Atkinson AE, Mandujano CAM, Bejarano S, Kennedy LS, **Tsongalis GJ**. Screening for Human Papillomavirus in a Low- and Middle-Income Country. *J Glob Oncol*. 2019 (May);5:JGO1800233. doi: 10.1200/JGO.18.00233. PMID: 31050922
236. Bonneau E, Neveu B, Kostantin E, **Tsongalis GJ**, De Guire V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. *EJIFCC*. 2019 (Jun) 24;30(2):114-127. PMID:31263388

Books:

1. Coleman, WB and **Tsongalis GJ** (eds.) *Molecular Diagnostics for the Clinical Laboratorian*, The Humana Press Inc., Totowa, NJ, 1997, 390 pp.
2. Wu AHB, Moore RE, Burnett RW, **Tsongalis GJ** (eds.) *Clinical Chemistry Self-Assessment*, Third Edition, AACC Press, Washington, DC, 2000, 336 pp.
3. Coleman WB and **Tsongalis GJ** (eds.) *Molecular Basis of Human Cancer*, The Humana Press Inc., Totowa, NJ, 2002, 600 pp.
4. **Tsongalis GJ** and Coleman WB (eds.) *Molecular Diagnostics: A Training and Study Guide*, AACC Press, 2002, 364 pp. (accompanying CD-version).
5. Coleman WB and **Tsongalis GJ** (eds.) *Molecular Diagnostics for the Clinical Laboratorian*, Second Edition. The Humana Press Inc., Totowa, NJ, 2006, 567 pp.
6. Coleman WB and **Tsongalis GJ** (eds.) *Molecular Pathology: The Molecular Basis of Human Diseases*, Elsevier Academic Press Inc., San Diego, CA, 2009, 636 pp.
7. Coleman WB and **Tsongalis GJ** (eds.) *Essential Concepts in Molecular Pathology*, Elsevier Academic Press Inc., San Diego, CA, 2010, 440 pp.
8. Coleman WB and **Tsongalis GJ** (eds.) *Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing*. Elsevier Academic Press Inc., San Diego, CA, 2017, 561 pp.

9. Coleman WB and **Tsongalis GJ** (eds.) *Molecular Basis of Human Cancer*, Second Edition, Springer, Ny, NY, 2017, 873 pp.
10. Coleman WB and **Tsongalis GJ** (eds.) *Molecular Pathology: The Molecular Basis of Human Diseases 2nd edition*, Elsevier Academic Press Inc., San Diego, CA, 2018, 786 pp.
11. Coleman WB and **Tsongalis GJ** (eds.) *Laboratory Exercises in Molecular Pathology*. Elsevier Academic Press Inc., San Diego, CA, 2019, in preparation.
12. Coleman WB and **Tsongalis GJ** (eds.) *Applied Molecular Pathology*. Elsevier Academic Press Inc., San Diego, CA, 2019, in preparation.

Book Chapters:

1. Lambert WC, Tanz WS, **Tsongalis GJ** and Okorodudu AO. Defective DNA synthesis and/or repair in amyotrophic lateral sclerosis. In: DNA Repair Mechanisms and Their Biological Implications in Mammalian Cells. M.W. Lambert and J. Laval (eds.) Plenum Press, pp. 501-521, 1989.
2. **Tsongalis GJ** and Silverman LM. Fragile X Syndrome: Molecular analysis of a genetically unstable trinucleotide repeat. Bulletin Lab Med, UNC Hospitals, Chapel Hill, NC. Vol. 132, pp. 1-5, 1994.
3. Silverman LM and **Tsongalis GJ**. Molecular Pathology. In: Clinical Guide to Laboratory Tests, Third Edition. N.W. Teitz (ed.), pp. 761-786, 1994.
4. **Tsongalis GJ**. Applications of Molecular Techniques to Anatomic Pathology. In: Molecular Pathology: Approaches to Diagnosing Human Disease in the Clinical Laboratory. L.M. Silverman and R. Heim (eds.) Carolina Academic Press, pp. 33-55, 1994.
5. Silverman LM and **Tsongalis GJ**. Isoenzymes. In: Encyclopedia of Analytical Science. Academic Press Limited, pp. 1197-1201, 1995.
6. Chapman JF and **Tsongalis GJ**. Pregnancy and Fetal Function. In: Clinical Chemistry. L.A. Kaplan and A.J. Pesce (eds.) TMIP Ltd, pp. 793-819, 1996.
7. **Tsongalis GJ**. Localized In Situ Amplification (LISA): PCR Amplification of Nucleic Acid Sequences in Tissue Sections. In: PRINS and In Situ PCR. J.R. Gosden (ed.), Humana Press, 71:133-139, 1996.
8. **Tsongalis, Gregory J**. An Overview of Molecular Genetics. In: Molecular Diagnostics for the Clinical Laboratorian. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 217-228, 1997.
9. Coleman WB and **Tsongalis GJ**. Molecular Mutations in Human Neoplastic Disease. In: Molecular Diagnostics for the Clinical Laboratorian. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 293-316, 1997.
10. **Tsongalis GJ**, Rezuze WN, Wu AHB. An epidemiological study to evaluate the incidence of activated protein C resistance in the general population using a PCR-mediated RFLP assay. In: Advances in Critical Care Testing. List WF, Muller MM, McQueen MJ (eds.), Springer Verlag, pp. 211-222, 1997.

11. **Tsongalis GJ**, Rezuke WN. Molecular genetics and Factor V Leiden mutation analysis. In: *Biotechnology International*. Fox F, Connor TH (eds.), Universal Medical Press, pp. 73-77, 1997.
12. Normandin M, and **Tsongalis GJ**. Detection methods for nucleic acid amplification products. In: *Laboratory Diagnosis of Viral Infections*, 3rd ed. Lennette EH and Smith TF (eds.), Marcel Dekker Inc., pp. 177-193, 1999.
13. **Tsongalis GJ**, Linfert DR, Almeida LM. Assessing chimerism after an allogeneic bone marrow transplant using polymorphic sequence analysis. In: *Biotechnology International II*. Connor TH, Weier HU, Fox F (eds.), Universal Medical Press, pp. 117-121, 1999.
14. Coleman WB and **Tsongalis GJ**. Cancer Epidemiology. In: *The molecular Basis of Human Cancer*. Coleman WB and Tsongalis GJ (eds.), Humana Press, pp. 3-22, 2002.
15. Coleman WB and **Tsongalis GJ**. The role of genomic instability in the development of human cancer. In: *The molecular Basis of Human Cancer*. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 115-142, 2002.
16. Coleman WB and **Tsongalis GJ**. The polymerase chain reaction. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp.47-55, 2006.
17. Weidenhammer E, **Tsongalis GJ**. An overview of molecular genetics. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 259-266, 2006.
18. Lewis E, Lewis M, Amos J, **Tsongalis GJ**. Cystic Fibrosis. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 321-327, 2006.
19. Coleman WB, **Tsongalis GJ**. Molecular pathogenesis of human cancer. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 349-374, 2006.
20. Rezuke WN, **Tsongalis GJ**. Molecular genetics and the diagnosis of hematological malignancies. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 393-413, 2006.
21. Voytek T, **Tsongalis GJ**. Human papillomavirus. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 447-451, 2006.
22. Ricci Jr. A, **Tsongalis GJ**. Molecular analysis for specimen identification. In: *Molecular Diagnostics for the Clinical Laboratorian*, 2nd edition. Coleman WB and Tsongalis GJ (eds.) Humana Press, pp. 517-522, 2006.
23. **Tsongalis GJ**, Presnell SC, Coleman WB. Introduction to Molecular Biology. In: *Pharmacogenomics and proteomics*. Wong, Linder, Valdes, eds. AACCC Press, pp.3-11, 2006.
24. **Tsongalis GJ**. Molecular diagnostics. *Clinical Guide to Laboratory Tests*, 4th edition. Wu AHB (ed.) W.B. Saunders, Philadelphia, PA, pp. 1201-1236, 2006.

25. **Tsongalis GJ** and Coleman WB. Nucleic Acid Probes Used in the Analysis of DNA. In: Contemporary Practice in Clinical Chemistry. Clarke and Dufour, (eds.), AACC Press, pp.127-133, 2006.
26. **Tsongalis GJ** and Coleman WB. The Polymerase Chain Reaction. In: Contemporary Practice in Clinical Chemistry. Clarke and Dufour, (eds.), AACC Press, pp.135-141, 2006.
27. Coleman WB, **Tsongalis GJ**. Molecular mechanisms of human cancer. In: Cancer: Cell Structures, Carcinogens, and Tumor Pathogenesis. LP Bignold, EXS Volume editor, 2006, in press.
28. **Tsongalis GJ** and Ricci A Jr. Specimen Identification Through DNA Analysis. In: Molecular Pathology in Clinical Practice. DGB Leonard (ed.), Springer-Verlag, NY, NY. 2007, pp.533-537.
29. Black C, Levy N, **Tsongalis GJ**. Pulmonary lymphoma. In: Molecular Pathology of Lung Diseases. Barrios, Cagle, Haque, Jagirdar, Popper, Zander, eds., Springer-Verlag, NY, NY., 2008.
30. Tafe LJ, Bartels CL, Lefferts JA, **Tsongalis GJ**. Molecular Diagnostics. In: Molecular Biology and Biotechnology 5th Edition. JM Walker and R Rapley, eds. RSC Publishing, Cambridge, UK. 2009, pp.51-75.
31. Lefferts JA, **Tsongalis GJ**. Molecular assessment of human disease in the clinical laboratory. In: *Molecular Pathology: The Molecular Basis of Human Diseases*, WB Coleman and GJ Tsongalis, eds., Elsevier Academic Press Inc., 2009, pp.605-612.
32. Lee HK, **Tsongalis GJ**. Pharmacogenomics and personalized medicine in the treatment of human diseases. In: *Molecular Pathology: The Molecular Basis of Human Diseases*, WB Coleman and GJ Tsongalis, eds., Elsevier Academic Press Inc., 2009, pp.613-622.
33. Lefferts JA, **Tsongalis GJ**. Molecular assessment of human disease in the clinical laboratory. In: *Essential Concepts in Molecular Pathology*, Elsevier Academic Press Inc., San Diego, CA, 2010, pp. 413-420.
34. Lee HK, **Tsongalis GJ**. Pharmacogenomics and personalized medicine in the treatment of human diseases. In: *Essential Concepts in Molecular Pathology*, Elsevier Academic Press Inc., San Diego, CA, 2010, pp. 421-428.
35. Suriawinata AA, Tsapakos M, **Tsongalis GJ**. Molecular Pathology of Liver Diseases. In: *Current and Future Methods for Diagnosis of Neoplastic Liver Disease*, Satdarshan (Paul) Singh Monga, ed.
36. Sam SS, **Tsongalis GJ**. Pharmacogenomics in Molecular Oncology. In: Molecular testing in Cancer, GM Yousef and S Jothy, eds. Springer, New York, 2014, pp. 405-421.
37. De Abreu, FB, **Tsongalis GJ**. Molecular Diagnostics. In: *Molecular Biology and Biotechnology*, 6th ed. R. Rapley and D. Whitehouse, eds. RSC Publishing, Cambridge, UK. 2015, pp.315-335.
38. Coleman WB, **Tsongalis GJ**. Basic Concepts in Molecular Pathology. In: *Diagnostic Molecular Pathology*. Coleman and Tsongalis (eds). Elsevier Academic Press Inc., San Diego, CA, 2017, pp. 3-14.

39. Coleman WB, **Tsongalis GJ**. Laboratory Approaches in Molecular Pathology –The Polymerase Chain Reaction. In: *Diagnostic Molecular Pathology*. Coleman and Tsongalis (eds). Elsevier Academic Press Inc., San Diego, CA, 2017, pp. 15-23.
40. Turner SA, **Tsongalis GJ**. Automation in the Molecular Diagnostics Laboratory. In: *Diagnostic Molecular Pathology*. Coleman and Tsongalis (eds). Elsevier Academic Press Inc., San Diego, CA, 2017, pp. 35-44.
41. Hedayat A, Yan S, **Tsongalis GJ**. Molecular Pathology and Testing in Melanocytic Tumors. In: *Diagnostic Molecular Pathology*. Coleman and Tsongalis (eds). Elsevier Academic Press Inc., San Diego, CA, 2017, pp. 321-332.
42. Deharvengt SJ, **Tsongalis GJ**. The Polymerase Chain Reaction. In: *Contemporary Practice in Clinical Chemistry*. Clarke and Dufour, (eds.), AACC Press, 2016, pp. 177-186.
43. Jung HS, **Tsongalis GJ**. Nucleic Acid Probes Used in the Analysis of DNA. In: *Contemporary Practice in Clinical Chemistry*. Clarke and Dufour, (eds.), AACC Press, 2016, pp.161-176.
44. Coleman WB, **Tsongalis GJ**. Cancer epidemiology: Incidence and etiology of human neoplasms. *Molecular Basis of Human Cancer*, Second Edition, Coleman WB and Tsongalis GJ (eds.) Springer, NY, NY, 2017, pp. 1-24.
45. Turner SA, **Tsongalis GJ**. Personalized medicine for the treatment of human cancer. *Molecular Basis of Human Cancer*, Second Edition, Coleman WB and Tsongalis GJ (eds.) Springer, NY, NY, 2017, pp. 843-856.
46. **Tsongalis GJ**. Integrative systems biology. *Molecular Pathology: The Molecular Basis of Human Diseases 2nd edition*, Coleman WB and Tsongalis GJ (eds.) Elsevier Academic Press Inc., San Diego, CA, 2018, pp. 205-216.
47. Coleman WB, **Tsongalis GJ**. Understanding molecular pathogenesis: The biological basais of human disease and implications for improved treatment of human disease. *Molecular Pathology: The Molecular Basis of Human Diseases 2nd edition*, Coleman WB and Tsongalis GJ (eds.) Elsevier Academic Press Inc., San Diego, CA, 2018, pp. 231-242.
48. Deharvengt SJ, **Tsongalis GJ**. Molecular assessment of human diseases in the clinical laboratory. *Molecular Pathology: The Molecular Basis of Human Diseases 2nd edition*, Coleman WB and Tsongalis GJ (eds.) Elsevier Academic Press Inc., San Diego, CA, 2018, pp. 709-730.
49. Kennedy LS, **Tsongalis GJ**. Case study: Introducing PCR testing for high-risk HPV in Honduras. *Cancer Screening in the Developing World*, ML Finkel (ed). Dartmouth College Press, Hanover, NY, 2018, pp. 103-121.
50. Al Turkmani MR, **Tsongalis GJ**. Molecular Diagnostics. *Genomics and Clinical Diagnostics*.R. Rapley and D. Whitehouse, eds. Royal Society of Chemistry, 2019, pp.226-248.
51. Deharvengt SJ, Petersen LM, Jung HS, **Tsongalis GJ**. Nucleic Acid Nucleic Acid Analysis in the Clinical Laboratory. In: *Contemporary Practice in Clinical Chemistry*. Clarke and Mackenzie, (eds.), AACC Press, 2019, in press.

B. Other Scholarly Work:

1. **Tsongalis GJ.** The past ten years in molecular diagnostics: A historical perspective. *IVD Technology* 11:62-67, 2005.
2. **Tsongalis GJ.** New applications of molecular diagnostics for the clinical lab. *Advance Admin Laboratory*. 83-88, 2006.
3. **Tsongalis GJ.** Genetic testing: current and future trends. *MLO Med Lab Obs* 38(10):42-44, 2006.
4. Lefferts JA, **Tsongalis GJ.** The MDx paradigm meets automation. *Advance Admin Laboratory* 17:40-42, 2008.
5. **Tsongalis GJ.** miRNAs in cardiac disease. Clin Chem podcast (<http://www.clinchem.com/podcasts/>), 2009.
6. Bartels CL, **Tsongalis GJ.** MDX market grows despite global economic slump. *Advance Admin Laboratory* 18(12):14-20, 2009.
7. Lefferts JA, **Tsongalis GJ**, Suriawinata AA, Funkhouser WK, Ladanyi M, Nowak JA, Pipas JM. KRAS mutation detection: a new look at an old gene. *Clin Chem*. 56(5):698-701, 2010.
8. Lefferts JA, **Tsongalis GJ.** Molecular Diagnostics: Parallels Between Infectious Disease and Emerging Oncology Testing. *Exp Opinion Molec Med*, 2010.
9. **Tsongalis GJ**, Calin G, Cordelier P, Croce C, Monzon F, Szafranska-Schwarzbach AE. MicroRNA Analysis: Is It Ready for Prime Time? *Clin Chem*. 59 (2):343-347, 2013.
10. **Tsongalis GJ**, Chao E, Hagenkord JM, Hambuch T, Moore JH. Bioinformatics: What the Clinical Laboratorian Needs to Know and Prepare For. *Clin Chem*. 2013 May 30. [Epub ahead of print]
11. Jenson EG, **Tsongalis GJ**, Tafe LJ. Importance of screening for Lynch Syndrome in patients with EC. *CAP Today*. 2013 (Aug);72-74.
13. **Tsongalis GJ.** The thrills and agonies of using next generation sequencing for somatic mutation detection in human cancers. *Future Medicine – Personalized Medicine* 2014;11(4):369-371.
14. Guire V, Fabbri M, **Tsongalis GJ.** Not all good things come in big packages. *Clin Chem Lab Med*. 2017 (May);55(5):605-607. PMID:28343175
15. Atkinson AE, Nerenz CE, Seger YR, **Tsongalis GJ.** CRISPR gets clinical. *Med Lab Manag* 2018;7(2):10-12.
16. Atkinson AE, Tafe LJ, Hughes EG, **Tsongalis GJ.** Developing technologies support proteogenomics. *Med Lab Manag* 2018;7(4):2-6.

C. Abstracts:

Presented at National Meetings:

1. Lambert WC, Tanz WS, Tsongalis GJ, and Okorodudu AO. Defective DNA repair as an etiology for neurodegenerative disease: Evidence in amyotrophic lateral sclerosis, NATO Advanced Research Workshop: DNA Repair Mechanisms and Their Biological Implications in Mammalian Cells, 1988.
2. Tanz WS, Tsongalis GJ, Lambert WC. Paradoxical impairment of down regulation of replicative DNA synthesis in ALS cells by methyl methane sulfonate. *Clinical Research*, 36(5):814A, 1988.
3. Lambert MW, Parrish DD, Tsongalis GJ, Lambert WC. Complementation at both the cellular and enzymatic level of a DNA repair defect in xeroderma pigmentosum cells with a human DNA endonuclease activity. *Journal of Investigative Dermatology*, 92(3):466, 1989.
4. Tanz WS, Tsongalis GJ, and Lambert WC. Bayesian analysis of carrier states in the co-recessive inheritance model for DNA repair deficient, cancer prone genetic diseases, *Proceedings of the American Association for Cancer Research*, 30:315, 1989.
5. Tsongalis GJ, Lambert WC, and Lambert MW. Complementation of a DNA repair defect in xeroderma pigmentosum cells with a human DNA endonuclease activity. *Proceedings of the American Association for Cancer Research*, 30:3, 1989.
6. Tsongalis GJ, Parrish DD, and Lambert MW. A defective chromosome-associated DNA endonuclease activity from Fanconi anemia cells on psoralen plus UVA light damaged DNA. *Photochemistry and Photobiology*, 49:98S, 1989.
7. Tanz WS, Tsongalis GJ, Sumner K, and Lambert WC. A new selective assay reveals a major abnormality in DNA metabolism in amyotrophic lateral sclerosis, *Neurology*, 40(4) Supplement 1:318(731P), 1990.
8. Tsongalis GJ, Lambert WC and Lambert MW. Electroporation of a normal human DNA endonuclease into xeroderma pigmentosum cells corrects their defect in repair of ultraviolet radiation damage. *Proceedings of the American Association for Cancer Research*, 31:2(9), 1990.
9. Lambert WC, Tsongalis GJ, Tanz WS and Lambert MW. Damage-resistant DNA synthesis in xeroderma pigmentosum cells: Reversal following electroporation of normal chromatin-associated endonucleases. *Clinical Res.*, 38(2):670A, 1990.
10. Huang B, Tsongalis GJ, Parrish DD, Lambert WC and Lambert MW. Correction of the defect in repair of DNA interstrand cross-links in Fanconi's Anemia cells by two normal human endonucleases. *Proceedings of the American Association of Cancer Research*, 32:8(44), 1991.
11. Tsongalis GJ, Coleman WB, Smith GJ and Kaufman DG. Isolation of DNA nuclear matrix attachment regions (MARs) using Alu-PCR. *FASEB: Growth Factors, Receptors and Signal Transduction*, Anaheim, California, 1992.
12. Tsongalis GJ, Brylawski BP, Cordeiro-Stone M, May WT, Comeau LD, and Kaufman DG. Cloning and initial characterization of nuclear matrix associated DNA isolated from normal human fibroblasts. *FASEB: Experimental Biology*, New Orleans, LA, 1993.
13. Tsongalis GJ, Farber RA, and Silverman LM. Molecular diagnosis of the fragile X syndrome. *University of North Carolina Hospital Laboratories Bulletin Lab Med*, 130:5, 1993.
14. Tsongalis GJ, Ellison DA, Chapman JF, and Silverman LM. Single gene amplification using a localized in situ amplification (LISA) reaction. *University of North Carolina Hospital Laboratories Bulletin*, 130:5, 1993.

15. Tsongalis GJ and Silverman LM. Molecular Diagnosis of the Fragile X Syndrome. *Clin Chem*, 39(6):1183, 1993.
16. Tsongalis GJ, Chapman JF, and Silverman LM. Localized in situ amplification (LISA): Rethinking clinical applications. University of North Carolina Hospital Laboratories Retreat, Pine Needles Resort, NC, 1994.
17. Tsongalis GJ, Chapman JF, and Silverman LM. A novel approach to in situ amplification. Academy of Clinical Laboratory Physicians and Scientists, Los Angeles, CA, 1994.
18. Tsongalis GJ, Chapman JF, and Silverman LM. Detection of *Pneumocystis carinii* in rat lung tissues using a localized in situ amplification (LISA) reaction. *Clin Chem* 40(6):1090, 1994.
19. Tsongalis GJ, Johnson RC, and Moore RE. Increasing estrogen receptor levels in breast cancer. *AACR Proceedings*, 35:257(1531), 1995.
20. Johnson RC, Anamani DE, Moore RE, Tsongalis GJ. Identification of a p53 nonsense mutation in a poorly differentiated ductal carcinoma of the breast. *Clin Chem* 41(S6):857, 1995.
21. Contois JH, Anamani DE, Tsongalis GJ. Allelic variation of the apolipoprotein E gene as determined by a PCR-mediated RFLP analysis. *AACC Clin Chem*, Teaneck, NJ, 1995.
22. Huang JC, Anamani DE, Rezuke WN, Tsongalis GJ. Resistance to activated protein C as determined by a PCR-mediated RFLP assay for a factor V mutation. *AACC Clin Chem*, Teaneck, NJ, 1995.
23. Johnson RC, Pedersen CA, Cartun RW, Moore RE, Ricci A Jr, Tsongalis GJ. Detection of a p53 nonsense mutation by immunohistochemical and molecular analyses. *AACC Clin Chem*, Teaneck, NJ, 1995.
24. Mandavilli S, Johnson R, Cartun R, Ricci A Jr, Tsongalis G, Coleman WB, Esch G, Smith G. bcl-2 immunoreactivity in benign and malignant breast lesions: correlation with p53 mutations and estrogen receptor status. International Academy of Pathology, Washington, DC, 1995.
25. Tsongalis GJ, Rezuke WN, Salonia C, Anamani DE, Maljanian R, Wu AHB. The diagnostic dilemma of hereditary thrombophilia. *Ann. Clin Laborat. Sci.* 26:355, 1996.
26. Tsongalis GJ, Hodges KA, Adkins S, Silverman LM. Chemiluminescent detection of the CGG trinucleotide repeat expansion in Fragile X Syndrome. *Clin. Chem.* 42 (S6):441, 1996.
27. Wu AHB, Anamani DE, Tsongalis GJ. Identification of urine specimen donors by the PM+DQA1 PCR amplification and typing kit. *Clin. Chem.* 41(S6):521, 1996.
28. Huang JC, Pedersen CA, Muller R, Cartun RW, Tsongalis GJ. Distribution of WT-1 and EGR-3 transcription factors in human prostate tissues. *Clin. Chem.* 41(S6):628, 1996.
29. Vadlamudi G, Rezuke WN, Abernathy EC, Ross JW, Tsongalis GJ, Cartun RW. The use of monoclonal antibody R92F6 and PCR to confirm parvovirus infection in bone marrows of HIV patients. IAP, Orlando, FL, 1997.
30. Rose DC, Takano A, Anamani DE, Abernathy E, Rezuke W, Tsongalis GJ. Detection of bcl-1 gene rearrangements in mantle cell lymphomas using the polymerase chain reaction. IAP, Orlando, FL, 1997.
31. Linfert DR, Tsongalis GJ. Rapid screening for select BRCA1 and BRCA2 mutations. N.E. Association for Cancer Research Meeting, Rhode Island Hospital, 1997.
32. Tsongalis GJ, Stevenson A, Vadlamudi G, Hodges K, Rezuke W. Clonal analysis of B-cell lymphoproliferative disorders: Comparison of Southern blot and PCR. *Clin. Chem.*, 43 (#11):2214-2215, 1997. (AACC San Diego Conference on Nucleic Acids).

33. Tsongalis GJ, Mandavilli B, Hodges K, Epp E, Rezuke W. The use of a PCR-based assay for the detection of TCR γ rearrangements in the evaluation of T-cell neoplasms. *Am. J. Pathol.*, 151(#H8):1493, 1997. (Association for Molecular Pathology, San Diego, CA.)
34. Gordon J, Tsongalis G, Rundell C, Nagle J, Vary CPH. Stable encapsulated nucleic acids for use as controls or standards in PCR and LCX based diagnostic assays. *Am. J. Pathol.*, 151(#G2):1488, 1997. (Association for Molecular Pathology, San Diego, CA.)
35. Linfert DR, Tsongalis GJ. Confirmation of BRCA1 and BRCA2 mutations using the universal GeneComb kit. *Clin. Chem.*, 43 (#12):2215, 1997. (AACC San Diego Conference on Nucleic Acids).
36. Lai T, Ma L, Linfert D, Wu WC, Olatidoye A, Gillam L, Waters D, Tsongalis GJ, Chen C. Reperfusion prevents apoptosis in hibernating myocardium. *Am Col Cardiol.*, 1998.
37. Gawblich K, Feng YJ, Wu AHB, Tsongalis GJ. The use of a multiplex RFLP assay to detect mutations in the Factor V and Factor II genes of acute myocardial infarction patients. *J Assoc Genet Technolog* 24(4):153, 1998. (AGT National meeting, Indianapolis, IN).
38. Feng YJ, Linfert DR, Tsongalis GJ, Wu AHB. Detection of genotypes and allele frequencies for the factor VII by PCR assay in coronary artery disease patients. Association of Clinical Scientists, Providence, RI, 1998.
39. Liu J, Lai T, Linfert D, Tsongalis GJ, Chen C. Is there an ongoing myocyte apoptosis in chronic hibernating myocardium? American Heart Association, 1998.
40. Almeida LA, Ricci A Jr, Silver H, Wu AHB, Tsongalis GJ. Applications of identity testing in the clinical laboratory. Ninth International Symposium on Human Identification, Orlando, FL, 1998.
41. Anamnai DE, Hodges KA, Tsongalis GJ. HIV-1 viral load testing in a pediatric population. AACC Symposium on Viral Testing in the Clinical Laboratory, Atlanta, GA, 1998.
42. Hodges KA, Linfert DR, Tsongalis GJ. Rapid multiplex analysis for the Factor V Leiden and prothrombin G20210A mutations. *Am. J. Pathol.* 153:1648, 1998.
43. Chaffee L, Almeida L, Tsongalis G, Gordon J, Nagle J, Vary CPH, Rundell C. Evaluation of stable encapsulated nucleic acids as controls in LCX based diagnostic assays. *Am. J. Pathol.* 153:1659, 1998.
44. Cartun RW, Taliano RJ, Perkins ML, Tsongalis GJ, Ricci A Jr. Evaluation of a commercially available kit for the detection of the HER-2/neu gene product. IAP, San Francisco, CA, 1999.
45. Marshall DS, Linfert DR, Tsongalis GJ. Prevalence of hereditary hemochromatosis polymorphisms (C282Y, H63D) in a multi-ethnic control population. IAP, San Francisco, CA, 1999.
46. Stolle CA, Kasparkova V, Tsongalis GJ, Inzucchi, S. Silent codon substitution in the VHL gene results in exon skipping and familial pheochromocytoma. *Am Soc Hum Genet.*, 1999.
47. Hodges KA, Rezuke WN, Tsongalis GJ. Chemiluminescent detection of B and T cell gene rearrangements in the diagnosis of lymphoma. *J Molec Diagnosis* 1:49, 1999.
48. Moyna NM, Tsongalis G, Meckes CL, Zoller R, Gordan P, Visich P, Miles M, Angelopoulos T, Pescatello L, Thompson PD. ApoE Genotype Affects The Increase In Maximal Oxygen Uptake With Exercise Training. *Am Heart Assoc*, 2000.
49. Cole SR, Tsongalis GJ, Khetani K, Rainey BJ, Coleman WB, Furmaga W. Use of molecular markers in differentiating between simultaneous primary tumors and intra-pulmonary metastasis in multicentric lung tumors. *Modern Pathol* 14:217A (1281), 2001.

50. Meckes C, Moyna N, Tsongalis G, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos T, Pescatello L, Bausserman L, Ordovas J, Mather J, Thompson P. The increase in VO₂max with exercise training is reduced in subjects homozygous for the Apo E3 allele. *Am Heart Assoc.*, 2001.
51. Meckes C, Moyna N, Tsongalis G, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos T, Pescatello L, Bausserman L, Ordovas J, Mather J, Thompson P. ApoE genotype does not affect the changes in serum lipids with exercise training. *Am Heart Assoc*, 2001.
52. Krueger L, Moyna N, Tsongalis G, Meckes C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos T, Pescatello L, Bausserman L, Ordovas J, Mather J, Thompson P. Variants in ACE genotype do not affect the VO₂max response to exercise training. *Am Heart Assoc*, 2001.
53. Krueger L, Moyna N, Tsongalis G, Meckes C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos T, Pescatello L, Bausserman L, Ordovas J, Mather J, Thompson P. ACE genotype does not affect the blood pressure response to exercise training. *Am Heart Assoc*, 2001.
54. Fiel-Gan MD, Ali SZ, Tsongalis GJ, Mandavilli SR. Value of high risk HPV typing in cases of atypical squamous cells of undetermined significance – atypical metaplastic type (AASM) in cervical cytology. *Modern Pathol* 15:72A (292), 2002.
55. Furmaga WB, Foss-Feig M, Cole SR, Coleman WB, Tsongalis GJ. Use of molecular markers to distinguish between carcinomas of lung with limited intrapulmonary metastases versus carcinoma with distant extrapulmonary metastases. *Modern Pathol* 15:319A (1329), 2002.
56. Hodges KA, Anamani DE, Tsongalis GJ. Clinical validation of the Bayer Versant HIV-1 RNA 3.0 bDNA assay and workflow consolidation. *J. Molec Diagnos* 4:245(15), 2002.
57. Furmaga WB, Fox K, Tsongalis GJ. Automated DNA extraction using the Kingfisher mL Robotic workstation. *J Molec Diagnos* 4:256(T7), 2002.
58. LaBelle LA, Vicki SL, Tsongalis GJ. Comparison of RFLP, READIT, and Nanochip Assays for the detection of SNPs. *J Molec Diagnos* 4:257(T16), 2002.
59. Frasca Jr. S, Draghi II A, Popov VL, Stanton JB, Brown CC, Bebak-Williams J, Tsongalis GJ, West AB. Molecular Characterization Of The Chlamydia-Like Bacterium Associated With Epitheliocystis In Farmed Atlantic Salmon (*Salmo Salar*). Eastern Fish Health Workshop, Gettysburg, PA, 2003.
60. Nasir A, Granitto S, Anamani D, Tsongalis G, Mandavilli S. Utility of a novel fluorescence in situ hybridization (FISH) assay for accurate detection of transitional cell carcinoma (TCC) of urinary bladder. American Society for Cytology, Orlando, FL, 2003.
61. Poulin M, LaBelle LA, Ballesteros E, Tsongalis GJ. Validation of the Nanochip® microarray for multiplex genotyping of Factor V Leiden and prothrombin G20210A mutations. *J Mol Diagnos* 5:257(G6), 2003.
62. Hodges KA, Anamani DE, Tsongalis GJ. HCV Viral load testing using the Bayer® Versant™ HCV RNA 3.0 bDNA assay. *J Mol Diagnos* 5:273(I16), 2003.
63. Hodges KA, Tsongalis GJ. A robust chemiluminescent detection system for diagnostic Southern blot transfer applications. *J Mol Diagnos* 5:285(T13), 2003.
64. Jannetto PJ, Kaul K, Tsongalis GJ, Poulin M, Laleli-Sahin E, Schur C, Wong SH. Validation of factor II (Prothrombin) and Factor V Leiden polymorphisms in clinical DNA samples using the Verigene™ ID chip-based nanoparticle technology. *Clin Chem* 50(6):A117 (D-34), 2004.

65. Tooke LS, Curtis M, Ornvold K, Bentley HA, Mohandas TK, Tsongalis GJ. Analysis of products of conception using the aneuploidy Invader assay. *J Molec Diagn* 6(4):409 (G15), 2004. (Association for Molecular Pathology National Meeting, Los Angeles, CA, November 2004).
66. Belloni DR, Tsongalis GJ. High resolution genotyping using the Smartcycler II and SYBR Green I for melting curve analysis. *J Molec Diagn* 6(4):435 (TT10), 2004. (Association for Molecular Pathology National Meeting, Los Angeles, CA, November 2004).
67. Zarovnaya EL, Tooke LS, Ornvold K, Curtis M, Mohandas TK, Tsongalis GJ. Enzymatic detection of aneuploidy in chromosomes 13, 18, 21 X and Y in paraffin-embedded products of conception. *Mod Pathol* 2005;18(Suppl 1):336A (1562). (USCAP Annual Meeting, San Antonio, TX).
68. Adeyi O, Belloni D, Dufresne S, Schned A, Tsongalis G. Detection of BK virus in laser capture microdissected kidney biopsies using real time PCR. *Mod Pathol* 2005;18(Suppl 1):264A (1224). (USCAP Annual Meeting, San Antonio, TX).
69. Dufresne SD, Belloni DR, Wells W, Tsongalis GJ. BRCA1 and BRCA2 mutation screening using high resolution melt curve analysis. *Mod Pathol* 2005;18(Suppl 1):328A (1523). (USCAP Annual Meeting, San Antonio, TX).
70. Caliendo AM, Young S, Gonzalez A, Zhou Y, Andersen J, Valsamakis A, Tsongalis G, Yen-Lieberman B, Pyles R, Bremer JW, Lurain N. Multi-laboratory comparison of two commercial real-time HCV viral load assays. Conference on Retrovirology and Opportunistic Infections (CROI). Boston, MA (Feb, 2005).
71. Belloni DR, Wong W, Ching J, Park JP, Levy NB, Tsongalis GJ. Detection of the p210Bcr-Abl translocation associated with chronic myeloid leukemia using the Cepheid Smartcycler II real time PCR platform. American Association for Cancer Research Annual meeting, Anaheim, CA (April, 2005).
72. Tsongalis GJ, Belloni DR, Schned AR. Real time PCR detection of viruses from formalin fixed paraffin embedded renal tissues. Clinical Virology Symposium, Clearwater, FL (May 8-11).
73. Caliendo AM, Young S, Gonzalez A, Zhou Y, Andersen J, Valsamakis A, Tsongalis GJ, Yen-Lieberman B, Pyles R, Bremer JW, Lurain N. Multi-laboratory comparison of HCV viral load assays. Clinical Virology Symposium, Clearwater, FL (May 8-11).
74. Tsongalis GJ. A molecular diagnostics update. Clinical Ligand Assay Society annual meeting. San Diego, CA (May 11-14, 2005).
75. Tsongalis GJ. Bringing molecular diagnostics into the clinical laboratory. Clinical Ligand Assay Society annual meeting. San Diego, CA (May 11-14, 2005).
76. Tsongalis GJ. A new era in the war on cancer. Clinical Ligand Assay Society annual meeting. San Diego, CA (May 11-14, 2005).
77. Tsongalis GJ, Belloni DR, Bentley HA, Wong W, Chang R, Hawk AB, Tooke LS, Ching J. DNA STAT: Clinical analysis using real time PCR in real time. *J Clin Ligand Assay* 2005;27:285 (10).
78. McAllister TW, Flashman LA, Rhodes CH, McDonald BC, Belloni DR, Curtis ML, Ferrell RB, Tsongalis GJ, Saykin AJ. Two CHRM2 SNPs Modulate Working Memory Performance and Anxiety Shortly After Mild/Moderate TBI (MTBI).
79. Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, Roth RM, Tsongalis GJ, Rhodes CH. Gray Matter Reduction in Cognitively Intact Adults with the APOE E4 Allele. Alzheimer's Association International Conference on Prevention of Dementia: Early diagnosis and intervention, Washington, D.C. (June 18-21, 2005).

80. Bentley HA, Tsongalis GJ. Cystic fibrosis mutation screening using the Third Wave InPlex CFTR ASR in a microfluidic card format. *J Molec Diagn* 2005;7:648(G02). (Association for Molecular Pathology National Meeting, Scottsdale, AZ, November 2005).
81. Jannetto PJ, Tooke L, Schur BC, Shi RZ, Tsongalis GJ. Validation of a novel microarray-based gold nanoparticle method (Verigene ID System) for the multiplexed detection of Factor II and Factor V Leiden polymorphisms in unamplified human genomic DNA. *J Molec Diagn* 2005;7:649(G07). (Association for Molecular Pathology National Meeting, Scottsdale, AZ, November 2005).
82. Park JP, Mohandas TK, Hawk AB, Moeschler JB, Berg SZ, Tsongalis GJ. Comparative genomic hybridization analysis of amplifications and deletions using the Genosensor array system. *J Molec Diagn* 2005;7:652(G17). (Association for Molecular Pathology National Meeting, Scottsdale, AZ, November 2005).
83. Lee H, Tsongalis GJ, Lewis LD, Schur BC, Jannetto PJ, Wong SH, Yeo KJ. Validation of the Nanochip molecular biology workstation electronic microarray for CYP2D6 genotyping. *J Molec Diagn* 2005;7:653(G24). (Association for Molecular Pathology National Meeting, Scottsdale, AZ, November 2005).
84. Dufresne SD, Belloni DR, Levy NB, Tsongalis GJ. Detection of the BCR-ABL fusion gene using the GeneXpert RT-PCR ASR. *J Molec Diagn* 2005;7:662(H15). (Association for Molecular Pathology National Meeting, Scottsdale, AZ, November 2005).
85. Belloni DR, Cornell CJ, Fairweather RB, Hill JM, Ketchum SL, Tsongalis GJ. Quantification of PRV-1 expression in patients with polycythemia vera. *J Molec Diagn* 2005;7:667(H36). (Association for Molecular Pathology National Meeting, Scottsdale, AZ, November 2005).
86. Lewis LD, Lee HK, Schur BC, Jannetto PJ, Wong SH, Tsongalis GJ, Yeo KTJ. A Novel Microarray Technology for CYP2D6 Genotyping. *British Pharmacology Society.*, 2005
87. Lee HK, Lewis LD, Schur BC, Jannetto PJ, Wong SH, Tsongalis GJ, Yeo KTJ. The Nanochip[®] Molecular Biology Workstation Electronic Microarray for CYP2D6 Genotyping. *ASCPT*, 2006.
88. Zarovnaya E, Tooke LS, Gonzalez J, Tsongalis GJ. Comparison of the Third Wave ASR and the Digene hybrid capture 2 assays. *Mod Pathol* 2006;19(Suppl 1):75A (333).
89. Dufresne SD, Belloni DR, Ketchum SL, Cornell MK, Kominski A, Chaffee S, Ely P, Hill JM, Cornell CJ, Tsongalis GJ. Real time PCR detection of a JAK2 mutation in polycythemia vera patients. *Mod Pathol* 2006;19(Suppl 1):327A (1526).
90. Tafe LJ, Belloni DR, Tsongalis GJ. Evaluation of the ABI 7500 Fast real time PCR instrument for detecting two common polymorphisms associated with hemochromatosis. *Mod Pathol* 2006;19(Suppl 1):335A (1560).
91. Lewis LD, Lee HK, Schurr BC, Jannetto PJ, Wong SH, Tsongalis GJ, Yeo KJ. The Nanochip molecular biology workstation electronic microarray for CYP2D6 genotyping. *Clin Pharmacol Therap* 2006;79:140 (PII-28).
92. MacRae S, Bolton D, Belloni DR, Tsongalis GJ. The use of real time PCR assays in the surveillance of West Nile virus. *Clinical Virology Symposium*, Clearwater, FL (April 30- May 3, 2006).
93. Chan DC, Wells WA, Gonzalez J, Memoli VA, Tsongalis GJ. Detecting estrogen receptor using the luminex 100 xMap platform. *Clin Chem* 2006;S6:A51 (B-42). (AACCC National meeting, Chicago, IL).

94. Park JP, Belloni DR, Mohandas TK, Tsongalis GJ. Detection of maternal cell contamination using an STR panel and the Beckman Coulter Vidiera NsD. Clin Chem 2006;S6:A56 (B-58). (AACC National meeting, Chicago, IL).
95. Conklin JA, Bentley HA, Yeo K, Tsongalis GJ. Cystic fibrosis mutation screening using the NGEN CFTR ASRs for genotyping the ACOG/ACMG 23 recommended mutations. J Molec Diagn 2006;626 (G21) (AMP Annual meeting, Orlando, FL).
96. Meyer EK, Belloni DR, Bentley HA, Casella SJ, Moeschler JB, Ornvold KT, Mohandas TK, Tsongalis GJ. Real time PCR detection of the SRY gene in cases of ambiguous genitalia and other clinical scenarios. J Molec Diagn 2006;628 (G31) (AMP Annual meeting, Orlando, FL).
97. Dufresne SD, Belloni DR, Levy NB, Tsongalis GJ. Evaluation of the Cepheid Xpert BCR-ABL monitor assay. J Molec Diagn 2006;636 (H11) (AMP Annual meeting, Orlando, FL).
98. Tooke LS, Kirkland KB, McLellan RK, Talbot EA, Belloni DR, Bentley HA, Tsongalis GJ. Molecular monitoring of Bordetella pertussis during an apparent outbreak. J Molec Diagn 2006;652 (ID45) (AMP Annual meeting, Orlando, FL).
99. Chan DC, Suriawinata AA, Pipas J, Fadul CE, Lewis LD, Yeo K, Tsongalis GJ. UGT1A1 polymorphism analysis- the Dartmouth experience. J Molec Diagn 2006;661 (ST22) (AMP Annual meeting, Orlando, FL).
100. Byrd RH, Belloni DR, Suriawinata AA, Zaki BI, Tsongalis GJ. Evaluation of the Beckman Coulter hexaplex MSI assay in paraffin embedded rectosigmoid cancers. J Molec Diagn 2006;664 (ST43) (AMP Annual meeting, Orlando, FL).
101. Winn-Deen E, Helton B, van Atta R, Peralta J, Wang J, Radich J, Tsongalis G, Belloni D, Chan D, Eschleman J, Jobbagy Z, Gocke C. Development of an integrated assay for quantitative real time detection of BCR-ABL RNA from peripheral blood. Haematologica 2006;91:19-20.
102. Liu X, Ma Y, Fiering S, Black C, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E. Transgenic Cyclin E Triggers Dysplasia and Multiple Pulmonary Adenocarcinomas. American Association for Cancer Research (AACR) Annual Meeting 2007, (abstract # 2492), Los Angeles, CA, April 2007.
103. Yeo TK, Lee HK, Raffensperger JC, Lewis LD, Tsongalis GJ, Yeo KT. Validation of CYP2C9/VKORC1 RUO on the nanoChip 400 System using DNA extracted by the Roche MagNA Pure Compact system. Clin Chem 2007;S6:A155 (C-165).
104. Lefferts JA, Schneider R, Jannetto PJ, Tsongalis GJ. Detection of factor V, prothrombin, MTHFR, CYP2C9 and VKORC1 variations in unamplified genomic DNA with the Verigene System. J Molec Diagn 2007; 652 (G11) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
105. Belloni DR, Tsongalis GJ. A multicenter survey and sample exchange. J Molec Diagn 2007; 681 (ID46) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
106. Schwab MC, Wells WA, Pogue BW, Meaney PM, Hartov A, Weaver JB, Paulsen KD, Kaufman PA, Tsongalis GJ. Assessing neo-adjuvant treatment response using pathway specific genomic correlates with morphologic and imaging signatures. J Molec Diagn 2007; 686 (ST04) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
107. Belloni DR, Tsongalis GJ. Comparison of the B. pertussis assay developed with the nanogen MGB Alert ASR to a user developed assay. J Molec Diagn 2007; 681 (ID45) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
108. Edmunds HS, Szafranska AE, Gordon SR, Doleshal M, Barth RJ, Gutmann EJ, Suriawinata AA, Korc M, Labourier E, Tsongalis GJ. Analysis of pancreatic microRNA biomarker candidates in fine

needle aspirates preserved in RNARetain. J Molec Diagn 2007;690 (ST30) (Association for Molecular Pathology annual meeting, Los Angeles, CA).

109. Tafe LJ, Schwab MC, Rizzo EJ, Lefferts JA, Wells WA, Tsongalis GJ. A novel real time reverse transcriptase polymerase chain reaction assay in evaluation of breast cancer sentinel lymph nodes. J Molec Diagn 2007; 686 (ST05) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
110. Lefferts JA, Spyris CT, Schwab MC, Padmanabhan V, Tsongalis GJ. Development of a real time PCR assay to detect the BRAF V600E mutation in papillary thyroid carcinoma samples obtained by fine needle aspirate. J Molec Diagn 2007; 693 (ST41) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
111. Bartels CL, Kaur P, Levy N, Tsongalis GJ. Quality control and the Xpert BCR-ABL Monitor assay. J Molec Diagn 2007; 668 (H28) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
112. Lefferts JA, Tsongalis GJ. Development of a Parvovirus B19 real time PCR assay on the Smartcycler II. J Molec Diagn 2007; 676 (ID20) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
113. Bartels CL, Campbell D, Schuetz A, Caliendo AM, St. Jean PR, Tsongalis GJ. Comparison of methicillin resistant Staphylococcus aureus (MRSA) detection methods: culture vs real time PCR. J Molec Diagn 2007; 685 (ID61) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
114. Dang JP, Bentley HA, Tsongalis GJ. Evaluation of the Qiagen EZ1 Virus Mini Kit (v 2.0) for the determination of HCV viral load using the Roche Cobas TaqMan48 HCV ASR. J Molec Diagn 2007; 676 (ID19) (Association for Molecular Pathology annual meeting, Los Angeles, CA).
115. Tafe LJ, Schwab MC, Rizzo EJ, Lefferts JA, Wells WA, Tsongalis GJ. Real time reverse transcriptase – polymerase chain reaction assay as an adjuvant tool in evaluation of breast cancer sentinel lymph nodes. Accepted for presentation at the 2007 San Antonio Breast Conference.
116. Tafe LJ, Schwab MC, Lefferts JA, Wells WA, Tsongalis GJ. Standardizing Breast Sentinel Lymph Node Processing: The Role of a Real Time Reverse Transcriptase Polymerase Chain Reaction Assay. Mod Pathol 2008; 21 (Suppl 1):56A (#246). (United States and Canadian Academy of Pathology's 97th Annual Meeting, March 1-7, 2008 in Denver, CO).
117. Conklin JA, Lefferts JA, Park D-Y, Siegel C, Mino-Kenudson M, Deshpande V, Sands BE, Lauwers GY, Tsongalis GJ, Srivastava A. BRAF (V600E) mutation and microsatellite instability in Crohn's disease associated adenocarcinoma. Mod Pathol 2008; 21 (Suppl 1):116A (#528). (United States and Canadian Academy of Pathology's 97th Annual Meeting, March 1-7, 2008 in Denver, CO).
118. Gallagher SL, Dang JP, Dokus BJ, Padmanabhan V, Tsongalis GJ. Comparison of the Digene hybrid capture 2 assay and the Third Wave Technologies Invader HPV ASR. Clinical Virology Symposium, Daytona, FL (April 25-30, 2008).
119. Lefferts JA, Gallagher SL, Dokus BJ, Tsongalis GJ. Comparison of the MGB Alert® BK Virus 2.0 detection reagent ASR (Nanogen) with a "home-brew" Taqman assay for detection of BK Virus. Clinical Virology Symposium, Daytona, FL (April 25-30, 2008).
120. Rhodes CH, Haroutunian V, Katsel P, Tsongalis GJ, Lefferts JA, Sibille, E, Lathrop MJ, Fiering SN. Transcriptional regulation in the MAPT H1/H2 haplotype block. Experimental Biology, San Diego, CA (April 5-9, 2008).

121. Rivenbark AG, Livasy CA, Wells WA, Tsongalis GJ, Coleman WB, Strahl BD. Global histone H3 lysine 4 methylation patterns in human breast cancer. *Experimental Biology*, San Diego, CA (April 5-9, 2008).
122. Goranson LL, Bartels CL, Tsongalis GJ, Pschirer ER. Efficacy of an Automated PCR Assay for GBS Determination in Pregnant Women. Annual meeting of Obstetrics and Gynecology, 2008.
123. White KK, Wells WA, Bowser R, Tsongalis GJ, Coleman WB. Expression of BRCA1 and FAC1 in primary sporadic breast cancers. *Experimental Biology*, San Diego, CA (April 5-9, 2008).
124. Ahles T, Saykin A, McDonald B, Rhodes CH, Moore J, Urbanowitz R, Tsongalis G, Tosteson T. Genetics of Cognitive Decline Post Cancer Chemotherapy. The NCI Translational Science Meeting, Grand Hyatt Hotel, Washington D.C. (November 7-9, 2008)
125. Bartels CL, Gallagher SL, Dokus BJ, Padmanabhan V, Tsongalis GJ. Evaluation of the Third Wave Technologies Invader® HPV ASR. *J Molec Diagn* 2008;10:588 (ID16) (Association for Molecular Pathology, Grapevine, TX).
126. Bentley HA, Hill J, Tsongalis GJ. Assessment of Bone Marrow Transplant Chimerism in a Multi-Transplant Case. *J Molec Diagn* 2008;10:579 (H21) (Association for Molecular Pathology, Grapevine, TX).
127. Bentley HA, Levy N, Tsongalis GJ. Identification of T-cell Clonality Using the Invivoscribe® TCR Beta and TCR Gamma Mastermix Megakit. *J Molec Diagn* 2008;10:580 (H24) (Association for Molecular Pathology, Grapevine, TX).
128. Lefferts JA, Hicks ND, Gallagher SL, Dokus BJ, Axelrod DA, Chobanian MC, Zuckerman RA, Tsongalis GJ. Evaluation of the MGB Alert® BK Virus 2.0 Detection Reagent for Quantitative PCR of BK Virus. *J Molec Diagn* 2008;10:591 (ID27) (Association for Molecular Pathology, Grapevine, TX).
129. Marchetti AL, Bartels CL, Bentley HA, Lefferts JA, Highsmith WE, Tsongalis GJ. Alpha-1 Antitrypsin (A1AT): a Real Time PCR Genotyping Assay vs. Isoelectric Focusing Phenotyping. *J Molec Diagn* 2008;10:570 (G20) (Association for Molecular Pathology, Grapevine, TX).
130. Schwab MC, Ninteanu NR, Bentley HA, Wells WA, Tsongalis GJ. Evaluation of topoisomerase 2A gene amplification in patients with invasive breast cancer previously evaluated for HER2 status. *J Molec Diagn* 2008;10:605 (ST33) (Association for Molecular Pathology, Grapevine, TX).
131. Dandamudi UB, Lefferts JA, Schwab MC, Bean JR, Lee HK, Tsongalis GJ, Lewis LD. Comparative Study of CYP2C9 *2/*3 and VKORC1 (-1639G>A) Genotyping with the Nanosphere Verigene System and the Third Wave Technologies Invader Assay. IXth World Conference on Clinical Pharmacology and Therapeutics, Quebec, Canada (2008).
132. Gupta M, Gonzalez J, Lefferts J, Quer A, Tsongalis G, Oliva E. Primary ovarian mucinous tumors do not show loss of MLH-1 or MGMT and are characterized by KRAS mutation and aberrant p53 expression during later stages of progression to carcinoma. *Mod Pathol* 2009;22(S1):216A#984 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
133. Lefferts JA, Belanger G, Brennick JB, Schned AR, Tsongalis GJ. Development of Methods for Loss of Heterozygosity Studies When Normal Specimens Are Not Available. *Mod Pathol* 2009;22(S1):384A#1739 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
134. Sethi S, Bartels CL, Gallagher SL, Dokus BJ, Hawk A, Feher SA, Tsongalis GJ, Padmanabhan V. Assessing HPV Status Using The Third Wave Technologies Invader® HPV ASR. *Mod Pathol*

- 2009;22(S1):387A#1755 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
135. Lefferts JA, Bentley H, Le Corre D, Laurent-Puig P, Suriawinata A, Tsongalis GJ. KRAS Mutation Detection by a PCR-based TaqMan Assay Compared to Traditional DNA Sequencing. *Mod Pathol* 2009;22(S1):384A#1740 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
 136. Baker ML, Marchetti AL, Bartels CL, Pipas JM, Fadul CE, Suriawinata AA, Tsongalis GJ. A Real Time PCR Assay for the Detection of the GSTP1 Single Nucleotide Polymorphism A313G. *Mod Pathol* 2009;22(S1):379A#1719 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
 137. Kaur P, Bartels CL, Tsongalis GJ. Detection of microRNAs in Frozen Peripheral Blood Samples from Patients with Chronic Lymphocytic Leukemia. *Mod Pathol* 2009; 22(S1): 383A#1737 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
 138. Sidiropoulos N, Tafe LJ, Schwab MC, Rizzo EJ, Schutz SN, Boyle SH, Seery PP, Wells WA, Tsongalis GJ. Use of the Veridex GeneSearch™ BLN Assay in Clinical Practice to Evaluate Breast Sentinel Lymph Nodes. *Mod Pathol* 2009;22(S1):68A#295 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
 139. Petras ML, Tsongalis GJ. Array based comparative genomic hybridization for the detection of genetic aberrations in cases of congenital anomalies and developmental delays. *Mod Pathol* 2009;22(S1):386A#1748 (United States and Canadian Academy of Pathology, (March 7-13, 2009), Boston, MA).
 140. Chalret du Rieu M, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P. MicroRNA miR-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. European Pancreatic Cancer meeting.
 141. Caliendo AM, Bremer JW, Ferriera-Gonzalez A, Granger S, Sabitini L, Tsongalis G, Valsamakis A, Wang Y, Yen-Liebermen B, Young S, Lurain N. Multi-laboratory evaluation of quantitative real time PCR Hepatitis B virus tests. *J Molec Diagn* 2009;11(6):635 (ID11). (Association for Molecular Pathology, Orlando, FL, November 2009).
 142. Lefferts JA, Hicks ND, Bentley HA, Gallagher SL, Calderon SF, Dokus BJ, Marchetti AL, Tsongalis GJ. Comparison of Two Quantitative Real-Time PCR BK Virus Assays Using MGB Alert® BK Virus ASR Reagents and a Reagent Set Designed by IntelligentMDx, Inc. *J Molec Diagn* 2009;11(6):637 (ID17). (Association for Molecular Pathology, Orlando, FL, November 2009).
 143. Dokus BJ, Gallagher SL, Hawk A, Padmanabhan V, Tsongalis GJ. Routine Use of the Cervista HPV HR Assay on Surepath Liquid Cytology Specimens. *J Molec Diagn* 2009;11(6):637 (ID18). (Association for Molecular Pathology, Orlando, FL, November 2009).
 144. Lebel KA, Mueller JD, Hicks ND, Bentley HA, Tsongalis GJ. Evaluation of the Qiagen EZ1 Advanced XL Automated DNA Extraction System. *J Molec Diagn* 2009;11(6):673 (TT22). (Association for Molecular Pathology, Orlando, FL, November 2009).
 145. Bartels CL, Calderon SF, Tsongalis GJ. Evaluation of the Asuragen Signature® NPM1 Mutations RUO Assay. *J Molec Diagn* 2009;11(6):629 (H10) (Association for Molecular Pathology, Orlando, FL, November 2009).
 146. Dokus BJ, Marchetti AL, Bentley HA, Bartels CL, Tsongalis GJ. Comparison of the Roche COBAS® AmpliPrep / COBAS® TaqMan® HIV-1 and the Seimens Versant bDNA HIV-1 Version 3.0. *J Molec Diagn* 2009;11(6):639 (ID26). (Association for Molecular Pathology, Orlando, FL, November 2009).

147. Schwab M, Lefferts JA, Black CC, Transue SB, Memoli VA, Srivastava A, Suriawinata AA, Tsongalis GJ. KRAS mutation detection by a PCR-based TaqMan assay: A clinical experience. *J Molec Diagn* 2009;11(6):652 (ST09). (Association for Molecular Pathology, Orlando, FL, November 2009).
148. Bentley HA, Black CC, Marchetti AL, Tsongalis GJ. Genotyping HPV identified in head and neck tumors. *J Molec Diagn* 2009;11(6):661 (ST49). (Association for Molecular Pathology, Orlando, FL, November 2009).
149. Kreuter J, Bentley H, Hicks N, Padmanabhan V, Tsongalis GJ. Thyroid transcription factor-1 gene expression reliably identifies primary pulmonary carcinoma in pleural fluid. *J Molec Diagn* 2009;11(6):663 (ST60). (Association for Molecular Pathology, Orlando, FL, November 2009).
150. Lefferts JA, Schwab MC, Lee HK, Lewis L, Tsongalis GJ. Genotyping CYP2C9 and VKORC1 SNPs Using Three Different Platforms. *J Molec Diagn* 2009;11(6):674 (TT24). (Association for Molecular Pathology, Orlando, FL, November 2009).
151. Petras M, Lefferts JA, Schwab MC, Tsongalis GJ. KRAS detection in Colonic Tumors via DNA Extraction from FTA Paper: The Molecular Touch-Prep. *J Molec Diagn* 2009;11(6):667 (ST78). (Association for Molecular Pathology, Orlando, FL, November 2009).
152. Curtis M, Polito F, Abbott D, Antonioni G, Boss D, Brough T, Feix M, Forward B, Juanes R, Laramie K, Lee HK, Moore N, Park L, Smith C, Smith D, Stella M, Tapply C, Boulanger J, Foster M, McKee D, Roberts B, Schutz E, Yearke G, Tsongalis GJ. Implementation of total lab automation in a rural tertiary care medical center. *Clin Chem* 2009;55(S6):A6 (A111) (AACC National meeting, Chicago, IL).
153. Chen H, Lefferts J, Tsongalis GJ, Suriawinata AA. Preexisting Villous Adenoma in Colorectal Adenocarcinoma Predicts the Status of KRAS Mutation in Targeted Therapy. *Arch Pathol Lab Med* 2009;133(10), 1621.
154. Chen H, Lefferts JA, Tsongalis GJ, Suriawinata AA. Correlation of KRAS Mutation and Villous adenoma in Colorectal Adenocarcinoma Guides Pretreatment Screening and Targeted Therapy. United States and Canadian Academy of Pathology, 2010, Washington, DC.
155. Lefferts JA, Chen H, Suriawinata AA, Tsongalis GJ. Comparison of TaqMan PCR and Pyrosequencing Assays for Assessment of KRAS Mutations in FFPE Colorectal Cancer Specimens. United States and Canadian Academy of Pathology, 2010, Washington, DC.
156. Lefferts JA, Petras ML, Suriawinata AA, Tsongalis GJ. A Molecular Touch-Prep Method for Preserving Tumor DNA from Fresh Clinical Specimens. United States and Canadian Academy of Pathology, 2010, Washington, DC.
157. Pettus JR, Brown JL, Yang X, Coleman WB, Tsongalis GJ. Molecular determination of primary versus metastatic squamous cell carcinoma (SCC) of the lung in the context of SCC of the head and neck (H/N)—comparison of methodologies. United States and Canadian Academy of Pathology, 2010, Washington, DC.
158. Rauwerdink CA, Tsongalis GJ, Hill JM, Meehan KR. Peripheral Blood Chimerism Can Replace Marrow Chimerism Analyses Following Adult Allogeneic Stem Cell Transplant. United States and Canadian Academy of Pathology, 2010, Washington, DC.
159. Hammour T, Tsongalis GJ, Langweiler MH, Levy NB, Kaur P. Reduced Expression of CD81 on CD34+ B Lymphoblastic Leukemia (B-ALL) as Compared to Benign Precursor B-cells (Hematogones), a Helpful Flow Cytometric (FC) Marker for Minimal Residual Disease (MRD) Detection. United States and Canadian Academy of Pathology, 2010, Washington, DC.

160. Ward BP, Froehlich HM, Lebel KA, Bissaillon CL, Lefferts JA, Tsongalis GJ. Comparison of Three DNA Extraction Methods from Formalin Fixed Paraffin Embedded Tissues. *J Molec Diagn* 2010;12(6):912 (TT06) (Association for Molecular Pathology, San Jose, CA, November 2010).
161. Schwab MC, Lefferts JA, Suriawinata AA, Pipas JM, Tsongalis GJ. KRAS Mutation Detection: Comparison of a PCR-based Taqman Assay and the Asuragen Signature KRAS Assay. *J Molec Diagn* 2010;12(6):900 (ST21) (Association for Molecular Pathology, San Jose, CA, November 2010).
162. Cervinski M, Schwab MC, Lefferts JA, Lewis LD, Lebel KA, Pflueger SVM, Tsongalis GJ. Establishing a CYP2C19 genotyping assay for clinical use. *J Molec Diagn* 2010;12(6):916 (TT25) (Association for Molecular Pathology, San Jose, CA, November 2010).
163. Lebel KA, Tyropolis AM, Bentley HA, Tsongalis GJ, Pflueger SMV. Assessing the FMR-1 Locus in Fragile X Syndrome Using a Novel Fragment Sizing Assay. *J Molec Diagn* 2010;12(6):859 (G11) (Association for Molecular Pathology, San Jose, CA, November 2010).
164. Bentley HA, Lebel KA, Tyropolis AM, Pflueger SMV, Lefferts CL, Hawk A, Tsongalis GJ. Optimization of the Asuragen Human FMR-1 PCR Assay for the Beckman Vidiera Capillary Electrophoresis System. *J Molec Diagn* 2010;12(6):916 (TT24) (Association for Molecular Pathology, San Jose, CA, November 2010).
165. Schwab MC, Lefferts JA, Black CC, Memoli VA, Padmanabhan V, Gutmann E, Tsongalis GJ. A Comparison of EGFR and KRAS Mutational Status in Cytology and Surgical Resection Specimen Types. *J Molec Diagn* 2010;12(6):903 (ST34) (Association for Molecular Pathology, San Jose, CA, November 2010).
166. Lefferts JA, Chen H, Tafe LJ, Schwab MC, Suriawinata AA, Tsongalis GJ. Detection of BRAF V600E Mutations in Cases of Medullary Colorectal Cancer. *J Molec Diagn* 2010;12(6):901 (ST23) (Association for Molecular Pathology, San Jose, CA, November 2010).
167. Lefferts CL, Lee HK, Hicks N, Lewis LD, Lefferts JA, Tsongalis GJ. Evaluation of the Luminex xTAG CYP2D6 v2 Assay. *J Molec Diagn* 2010;12(6):917(TT26) (Association for Molecular Pathology, San Jose, CA, November 2010).
168. Gallagher SL, Lefferts JA, Ward BP, Tsongalis GJ. An Evaluation of the Roche Cobas Ampliprep TNAI Kit for isolation of BKV DNA from both Plasma and Urine Specimens for Quantitative Analysis. *J Molec Diagn* 2010;12(6):915(TT19) (Association for Molecular Pathology, San Jose, CA, November 2010).
169. Bentley HA, Lefferts JA, Ward BP, Gallagher SL, Allen SF, Dokus BJ, Reader EI, Tsongalis GJ. A Comparison of Two Sets of Analyte-Specific Reagents for Quantitative Detection of BK Virus. *J Molec Diagn* 2010;12(6):878(ID18) (Association for Molecular Pathology, San Jose, CA, November 2010).
170. Kreuter JD, Lefferts JA, Lewis LD, Kaur P, Tsongalis GJ. The Clinical Utility of Warfarin Sensitivity Genotyping at Our Institution: Not the Test We Thought. *J Molec Diagn* 2010;12(6):861 (G21) (Association for Molecular Pathology, San Jose, CA, November 2010).
171. Lebel KA, Bissaillon CL, Gallagher SL, Tsongalis GJ. Quantitative Detection of the BKV Using the Primera Dx ViraQuant Assay and the ICEPlex System. *J Molec Diagn* 2010;12(6):878 (ID20) (Association for Molecular Pathology, San Jose, CA, November 2010).
172. Schwab MC, Memoli VA, Black CC, Bentley HA, Wells WA, Tsongalis GJ. Evaluation of the BioGenex xMatrix Automated Slide Staining System for Automation of the Abbott PathVysion HER-2 DNA Probe Kit in Previously Examined Breast Cancer Specimens. *J Molec Diagn* 2010;12(6):917 (TT29) (Association for Molecular Pathology, San Jose, CA, November 2010).

173. Diankov V, Lebel KA, Lee MC, Wojcik E, Voronov S, Tsongalis GJ, Kong L. Comparison of Different Systems for DNA Extraction and Subsequent Quantification of CMV, BKV and EBV Using ViraQuant™ on ICEPlex™. *J Molec Diagn* 2010;12(6):879 (ID21) (Association for Molecular Pathology, San Jose, CA, November 2010).
174. Marotti JD, Lefferts JA, Memoli VA, Golding AC, Tsongalis GJ, Padmanabhan V. Should Reflexive BRAF Testing Be Performed on Atypical/Borderline Thyroid Nodules? *Modern Pathology*, Vol. 24(S1), 2011:140A. (2011 USCAP Annual Meeting, San Antonio, TX).
175. Lisovsky M, Mino-Kenudson M, Lefferts J, Courville E, Zaki B, Calvo LN, Hong TS, Tsongalis GJ, Lauwers GY, Srivastava A. MGMT (O6-Methylguanine DNA Methyltransferase) Is Inactivated in a Significant Subset of Distal Esophageal Adenocarcinomas: Implications for Neoadjuvant Chemoradiation Therapy. *Modern Pathology*, Vol. 24(S1), 2011:157A. (2011 USCAP Annual Meeting, San Antonio, TX).
176. Srivastava A, Rege TA, Kim KM, Lefferts JA, Park CK, Tsongalis GJ, Odze RD. Duodenal Serrated Adenomas: Evidence for Serrated Carcinogenesis in the Proximal Small Intestine. *Modern Pathology*, Vol. 24(S1), 2011:168A. (2011 USCAP Annual Meeting, San Antonio, TX).
177. Tafe LJ, Schwab MC, Lefferts JA, Hart C, Black CC, Memoli VA, Padmanabhan V, Tsongalis GJ. EGFR Mutation Analysis: What's Being Tested? The Experience of a Single Academic Medical Center. *Modern Pathology*, Vol. 24(S1), 2011:439A. (2011 USCAP Annual Meeting, San Antonio, TX).
178. Lefferts JA, Hourdequin KC, Hitzelberger W, Laura Tafe LJ, Pipas JM, Ernstoff MS and Tsongalis GJ. Merkel Cell Polyomavirus Detection in Extrapulmonary Small Cell Carcinoma. *Modern Pathology*, Vol. 24(S1), 2011:394A. (2011 USCAP Annual Meeting, San Antonio, TX).
179. Bissaillon CL, Lebel KA, Marconi SA, Flaherty RL, Tsongalis GJ. A utility comparison of clinical DNA samples before and after dehydration with GenTegra™ for use on several common molecular platforms. *J Molec Diagn* 2011;13(6):776 (TT25). (Association for Molecular Pathology, Grapevine, TX).
180. Cervinski MA, Steinmetz HB, Lefferts CL, Wood B, Tsongalis GJ. Establishment of an IL28B genotyping assay for clinical use. *J Molec Diagn* 2011;13(6):744 (ID41). (Association for Molecular Pathology, Grapevine, TX).
181. Froehlich HM, Schwab MC, Tsongalis GJ, Brennick JB. Rapid identification of EGFR pathway somatic mutations in melanoma of varying subtypes. *J Molec Diagn* 2011;13(6):763 (ST52). (Association for Molecular Pathology, Grapevine, TX).
182. Hagen CE, Lefferts JA, Pipas JM, Fadul CE, Tsongalis GJ, Tafe LJ. MGMT promoter methylation in colorectal cancer is associated with G>A KRAS mutations and high stage at presentation. *J Molec Diagn* 2011;13(6):764 (ST53). (Association for Molecular Pathology, Grapevine, TX).
183. Kaur P, Steinmetz HB, Lefferts CL, Danilov AV, Tsongalis GJ. Micro RNA profiles in chronic lymphocytic leukemia. *J Molec Diagn* 2011;13(6):728 (H15). (Association for Molecular Pathology, Grapevine, TX).
184. Lebel KA, Tyropolis AM, Moore F, Pflueger SMV, Tsongalis GJ. A Fragile X screening program utilizing the Amplidex FMR-1 and mPCR-CE kits by Asuragen. *J Molec Diagn* 2011;13(6):720 (G44). (Association for Molecular Pathology, Grapevine, TX).
185. Lebel KA, Bissaillon CL, Steinmetz HB, Tsongalis GJ, Moore F. Verification of the COBAS® AmpliPrep / COBAS® TaqMan HIV Test ver. 2.0. *J Molec Diagn* 2011;13(6):742 (ID31). (Association for Molecular Pathology, Grapevine, TX)

186. Lebel KA, Suprenant G, Newmark J, Johari V, Friedberg R, Tsongalis GJ. The rapid expansion of a Molecular Pathology Laboratory. *J Molec Diagn* 2011;13(6):750 (OTH02). (Association for Molecular Pathology, Grapevine, TX).
187. Lefferts JA, Chen H, Suriawinata AA, Tsongalis GJ. Targeted screening of colorectal cancers for a novel BUB1B mutation. *J Molec Diagn* 2011;13(6):770 (ST76). (Association for Molecular Pathology, Grapevine, TX).
188. Marconi SA, Bissaillon CL, Tamsin JT, Lebel KA, Tsongalis GJ, Moore F. Comparative study of xTag 60 Cystic Fibrosis test v2 with CF InPlex® panel utilizing archived and freshly extracted DNA. *J Molec Diagn* 2011;13(6):718 (G39). (Association for Molecular Pathology, Grapevine, TX).
189. Moses ZB, Lefferts JA, Fadul CE, Tsongalis GJ. Evaluation of real-time PCR assay options for detection of MGMT promoter methylation. *J Molec Diagn* 2011;13(6):769 (ST74). (Association for Molecular Pathology, Grapevine, TX).
190. Pettus JR, Srivastava A, Tafe LJ, Tsongalis GJ, Lefferts JA. Role of laser capture microdissection and real-time, allele-specific PCR in determining clonality in biphasic tumors. *J Molec Diagn* 2011;13(6):760 (ST38). (Association for Molecular Pathology, Grapevine, TX).
191. Reader E, Steinmetz HB, Lefferts CL, Wood B, Tsongalis GJ, Tafe LJ. Rapid high throughput TaqMan SNP genotyping assays for FVL, PT and MTHFR. *J Molec Diagn* 2011;13(6):781 (TT45). (Association for Molecular Pathology, Grapevine, TX).
192. Sabbath-Solitare M, Tafe LJ, Tsongalis GJ, Lara J, Cuyekeng Redondo T. Clinical validation of HER2 testing in gastric cancer. *J Molec Diagn* 2011;13(6):760 (ST39). (Association for Molecular Pathology, Grapevine, TX).
193. Schwab MC, Padmanabhan V, Johncox VE, Tafe LJ, Tsongalis GJ. Improved performance of cervical cancer screening using HPV E6, E7 mRNA quantification with polygonal gating and cellular normalization. *J Molec Diagn* 2011;13(6):746 (ID50). (Association for Molecular Pathology, Grapevine, TX).
194. Schwab MC, Jung S, Fisher JL, Ernstoff MS, Tsongalis GJ. Rapid identification of somatic mutations in melanoma cell lines. *J Molec Diagn* 2011;13(6):772 (TT07). (Association for Molecular Pathology, Grapevine, TX).
195. Steinmetz HB, Hong MH, Allen SF, Lefferts CL, Lebel KA, Ornstein DL, Tsongalis GJ, Tafe LJ. Evaluation of the Asuragen Signature LTx Leukemia Translocation Panel. *J Molec Diagn* 2011;13(6):779 (TT35). (Association for Molecular Pathology, Grapevine, TX).
196. Tafe LJ, Steinmetz HB, Tsongalis GJ. Detection of clonality using the *InVivoScribe* Technologies Assays for B IGH, TCRB and TCRG gene rearrangements by capillary electrophoresis on the Applied Biosystems® 3500. *J Molec Diagn* 2011;13(6):771 (TT04). (Association for Molecular Pathology, Grapevine, TX).
197. Xue Y, Tafe LJ, Lefferts JA, Suriawinata AA, Lisovsky M, Pipas JM, Ripple GH, Tsongalis GJ. Implication of BRAF V600E mutation status for prognosis in colorectal cancer. *J Molec Diagn* 2011;13(6):751 (ST03). (Association for Molecular Pathology, Grapevine, TX).
198. Szafranska-Schwarzbach AE, Adai AT, Lloyd MB, Sanders MS, Brand RE, Lee LS, Rateb G, Menard C, Centeno BA, Hartleb M, Wiechowska-Kozłowska A, Stefanczyk L, Lefferts CL, Mundig JB, Tannapfel A, Whitcomb DC, Conwell DC, Morisset JA, Vignesh S, Tsongalis GJ, Hahn S, Andruss BF. Development of a microRNA-based classification model for differential diagnosis of pancreatic ductal adenocarcinoma in fine needle aspirates: Results from a multi-center study. *J Molec Diagn* 2011;13(6):754 (ST15). (Association for Molecular Pathology, Grapevine, TX).

199. Boni A, Ernstoff MS, Schwab MC, Fisher JL, Tafe LJ, Tsongalis GJ. Exploration of a genotype-phenotype correlation in a panel of metastatic human melanoma cell lines. *Lab Invest* 2012; 92(S1):115A (467). (USCAP, Vancouver, Ca).
200. Tafe LJ, Davis TH, Schwab MC, Tsongalis GJ. MicroRNA expression in archived FFPE head and neck squamous cell carcinomas utilizing multiplex miRNA expression assays. *Lab Invest* 2012; 92(S1):317A (1332). (USCAP, Vancouver, Ca).
201. Kaur P, Steinmetz HB, Lefferts CL, Danilov AV, Tsongalis GJ. MicroRNA 16-1 predicts time-to-treatment (TTT) in chronic lymphocytic leukemia. *Lab Invest* 2012; 92(S1):346A (1451). (USCAP, Vancouver, Ca).
202. Srivastava S, Steinmetz H, Tsongalis GJ, Kaur P. Target genes associated with micro RNA profiles in patients with chronic lymphocytic leukemia. *Lab Invest* 2012; 92(S1):372A (1559). (USCAP, Vancouver, Ca).
203. Ng DP, Dumont LJ, Tsongalis GJ, Memoli VA. A method for decreasing interobserver variability in quantitative HER2 immunohistochemistry. *Lab Invest* 2012; 92(S1):504A (2104). (USCAP, Vancouver, Ca).
204. Allen SF, Lebel KA, Tafe LJ, Tsongalis GJ, Lefferts JA. Interlaboratory verification of the xTAG cystic fibrosis 60 v2 assay. *J Molec Diagn* 2012;14(6):643 (G26). (Association for Molecular Pathology, Long Beach, CA).
205. Schwab MC, Tsongalis GJ, Lefferts JA. Evaluation of a multiplexed qPCR assay for the detection of BCR-ABL fusion transcripts on the ICEPlex system. *J Molec Diagn* 2012;14(6):659 (H28). (Association for Molecular Pathology, Long Beach, CA).
206. Sam SS, Steinmetz HB, Tsongalis GJ, Tafe LJ, Lefferts JA. Validation of an HCV genotyping assay to predict antiviral therapy response. *J Molec Diagn* 2012;14(6):673 (ID22). (Association for Molecular Pathology, Long Beach, CA).
207. Lebel KA, Bissaillon CL, Steinmetz HB, Tsongalis GJ, Moore F. Verification of the COBAS Ampliprep/COBAS Taqman HBV test ver. 2.0. *J Molec Diagn* 2012;14(6):676 (ID37). (Association for Molecular Pathology, Long Beach, CA).
208. Steinmetz HB, Padmanabhan V, Tsongalis GJ. Evaluation of the Cobas 4800 high risk HPV assay. *J Molec Diagn* 2012;14(6):681 (ID57). (Association for Molecular Pathology, Long Beach, CA).
209. Tafe LJ, Cao J, Tsongalis GJ. HER2 testing in gastric cancer- an interlaboratory IHC and FISH correlation study. *J Molec Diagn* 2012;14(6):703 (ST27). (Association for Molecular Pathology, Long Beach, CA).
210. Abou Tayoun AN, Xue Y, Axelrod DA, Freeman RB, Suriawinata AA, Tsongalis GJ. MiR-217 as a diagnostic marker for hepatocellular carcinoma. *J Molec Diagn* 2012;14(6):706 (ST40). (Association for Molecular Pathology, Long Beach, CA).
211. Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ Jr, Suriawinata AA, Tsongalis GJ. MiRNA-148a as a diagnostic marker for pancreatic ductal adenocarcinoma. *J Molec Diagn* 2012;14(6):710 (ST53). (Association for Molecular Pathology, Long Beach, CA).
212. Lefferts JA, Schwab MC, Steinmetz HB, Tsongalis GJ, Tafe LJ. EML4-ALK fusion transcript detection by a multiplex reverse transcriptase PCR, real time capillary electrophoresis assay in FFPE lung adenocarcinoma samples. *J Molec Diagn* 2012;14(6):712 (ST61). (Association for Molecular Pathology, Long Beach, CA).
213. Levy RA, Bissaillon CL, Lebel KA, Schwab MC, Pflueger SM, Tafe LJ, Lefferts JA, Tsongalis GJ, Moore F. Agreement study of BRAF V600E testing with SYBR Green allele specific PCR and

- Taqman allelic discrimination assays. *J Molec Diagn* 2012;14(6):713 (ST65). (Association for Molecular Pathology, Long Beach, CA).
214. Tafe LJ, Marrotti JD, Schwab MC, Padmanabhan V, Tsongalis GJ. Identification of BRAF and RAS mutations in 13 atypical thyroid nodules using the qBiomarker thyroid cancer mutation array. *J Molec Diagn* 2012;14(6):714 (ST69). (Association for Molecular Pathology, Long Beach, CA).
 215. Morrison TB, Austermler B, Chen W, Vaidya A, Henley D, Lefferts J, Quigley N, Lazaridis N, Marella N, Tsongalis G. Standardizing BCR-ABL MBr monitoring without external standards. *J Molec Diagn* 2012;14(6):733 (TT24). (Association for Molecular Pathology, Long Beach, CA).
 216. Schwab MC, Zuckerman RA, Chobanian MC, Tsongalis GJ. Development of a quantitative assay for the assessment of T-cell receptor excision circles (TRECcs). *J Molec Diagn* 2012;14(6):736 (TT34). (Association for Molecular Pathology, Long Beach, CA).
 217. Lebel KA, Pflueger SM, Lefferts JA, Tafe LJ, Steinmetz HB, Tsongalis GJ. Selecting a platform for chromosomal microarray analysis testing in a clinical setting. *J Molec Diagn* 2012;14(6):745 (TT70). (Association for Molecular Pathology, Long Beach, CA).
 218. Bissaillon CL, Tyropolis AM, Lebel KA, Moore F, Pflueger SM, Lefferts JL, Tafe LJ, Steinmetz HB, Tsongalis GJ. Concurrent validation of chromosome microarray testing in separate molecular pathology laboratories. *J Molec Diagn* 2012;14(6):746 (TT73). (Association for Molecular Pathology, Long Beach, CA).
 219. Weldon C, Trosman J, Benson A III, Tsongalis GJ, Siziopikou K, Gradishar W, Schink J. Are oncologists involved in cancer biomarker decisions at their institutions? ACO annual meeting, Chicago, IL.
 220. Abou Tayoun AN, Tsongalis GJ, Lefferts JA. A synopsis of chromosomal microarray cases at Dartmouth-Hitchcock Medical Center. *Experimental Biology*, Boston, MA. (Apr 2013).
 221. Abou Tayoun AN, Tunkey CD, Tafe LJ, Levandowsky E, Spangler J, Dindinger M, Ross T, Shah M, McLaughlin S, Lee CC, Harkins TT, Raia G, Amos CI, Wells WA, Tsongalis GJ. A Comprehensive Assay for CFTR Mutational Analysis Using Next-Generation Sequencing. *Experimental Biology*, Boston, MA. (Apr 2013).
 222. Burchard PR, Malhotra S, Kaur P, Tsongalis GJ. Genotyping the FCGR3a Polymorphism Using Melt Curve Analysis. *Experimental Biology*, Boston, MA. (Apr 2013).
 223. Tunkey CD, Amos CI, Wells WA, Tsongalis GJ. Evaluation of Ion Torrent's AmpliSeq Cancer Hotspot Panelv2 on FFPE Tissues. *Experimental Biology*, Boston, MA. (Apr 2013).
 224. Gardner TB, Hessami N, Smith K, Colacchio TA, Gordon SR, Barth R, Suriawinata AA, Putra J, Tsongalis GJ, Pipas M. The Effect of Neoadjuvant Chemoradiation on Pancreatic Cancer Associated Diabetes Mellitus. *Digestive Disease Week*, May 18, 2013, Orlando, Florida. *Gastroenterology* 2013; 144(supp1):663-4.
 225. de Abreu FB, Tsongalis GJ, Lefferts JA. Analysis of SNP Genotype Calls Made with Chromosomal Microarrays in Reference and Case Samples. AACC, Houston, TX (August 2013).
 226. de Abreu FB, Schwab MC, Tafe LJ, Tsongalis GJ. Detection of Microsatellite Instability in Colorectal Cancers. AACC, Houston, TX (August 2013).
 227. Peterson JD, de Abreu F, Gallagher TL, Burchard PR, Amos CI, Wells WA, Pipas JM, Ernstoff MS, Fadul CE, Rigas JR, Tsongalis GJ. Targeted next generation sequencing for somatic mutations in human cancer. AACR Molecular targets and Cancer Therapeutics, Boston, MA (Oct 2013).

228. Peterson JD, Tunkey CD, Strausbaugh LD, Pipas JM, Riggs ER, Bloch KJ, Suriawinata AA, Liu X, Lisovsky M, Amos CI, Wells WA, Tsongalis GJ, Tafe LJ. The Development of a Mismatch Repair Gene Sequencing Panel Utilizing Semiconductor Sequencing Technology. *J Molec Diagn Nov* 2013;15(6):931 (TT21).
229. Peterson JD, Tunkey CD, Strausbaugh LD, Gonzalez JL, Memoli VA, Schned AR, Brennick JB, Wells WA, Amos CI, Tsongalis GJ. Validation of the Ampliseq Cancer Hotspot Mutation Panel Using the Ion Torrent PGM. *J Molec Diagn Nov* 2013;15(6):913 (ST42).
230. Burchard PR, Abou Tayoun AN, Scherer A, Tsongalis GJ. A Multiplex PCR Assay for the Detection of Chlamydia, Gonorrhea, and Trichomonas Using Melt Curve Analysis. *J Molec Diagn Nov* 2013;15(6):933 (TT27).
231. Abou Tayoun AN, de Abreu FB, Suriawinata AA, Pipas JM, Ripple GH, Steinmetz HB, Allen SF, Tafe LJ, Tsongalis GJ, Lefferts JA. UGT1A1 TA Dinucleotide Repeat Sizing Using Fragment Analysis. *J Molec Diagn Nov* 2013;15(6):919 (ST66).
232. de Abreu FB, Schwab MC, Smith TM, Rhodes CH, Hickey WF, Fadul CE, Storm CA, Seidel GD, Yan S, Brennick JB, Ernstoff MS, Tsongalis GJ. Design and Validation of a SNaPshot Assay For Melanoma and Glioblastoma Patients. *J Molec Diagn Nov* 2013;15(6):942 (TT61).
233. de Abreu FB, Schwab MC, Black CC, Gutmann EJ, Padmanabhan V, Marotti JD, Rigas JR, Erkmen CP, Liu X, Suriawinata AA, Tsongalis GJ, Tafe LJ. Genotyping multiple somatic mutations in non-small cell lung cancer and colorectal carcinoma using the SNaPshot technology. *J Molec Diagn Nov* 2013;15(6):921 (ST71).
234. Dokus BJ, Allen SF, Steinmetz HB, Marotti JD, Tsongalis GJ, Tafe LJ. Rapid fluorescence in-situ hybridization (FISH) for *HER2* assessment in breast and gastro-esophageal cancer. *J Molec Diagn Nov* 2013;15(6):908 (ST23).
235. Lefferts JA, Steinmetz HB, Reader E, Dinulos MB, Tsongalis GJ. Buccal swabs as an alternative specimen type for chromosome microarray (CMA). *J Molec Diagn Nov* 2013;15(6):931 (TT19).
236. de Abreu FB, Smith TM, Rhodes CH, Hickey WF, Fadul CE, Tsongalis GJ, Lefferts JA. Analysis of MGMT promoter methylation in glioblastoma using the MethyLight assay. *J Molec Diagn Nov* 2013;15(6):911 (ST36).
237. Burchard PR, Abou Tayoun AN, Schwab MC, Lewis LD, Tsongalis GJ, Cervinski MA. Development of a novel *TPMT* genotyping assay. *J Molec Diagn Nov* 2013;15(6):941 (TT59).
238. Kapp JR, Hamoudi RA, Diss T, Schrijver I, Jennings LJ, Li M, Tsongalis GJ, de castro D, Bridge J, Butler R, Wallace A, Hing S, Spicer J, Verghese E, Latham G. Anglo-American Ring trial unveils pre-PCR error and false-negative results in BRAF and EGFR clinical cancer diagnostics. *J Molec Diagn Nov* 2013;15(6):927 (TT04).
239. Li S, Divakar KM, Voronov S, Shea J, Patti S, de Abreu FB, Tsongalis GJ, Kong L, Riley J. Highly sensitive and specific multiplex mutation panel for simultaneous detection of 17 KRAS and BRAF clinically actionable point mutations in a single tube. *J Molec Diagn Nov* 2013;15(6):909 (ST28).
240. Thomas AA, Fisher JL, Baron U, Olek S, Rhodes CH, Gui J, Hampton T, Tafe LJ, Tsongalis GJ, Lefferts JA, Wishart H, Kleen J, Miller M, Ernstoff MS, Fadul CE. Prognostic implications of regulatory T cells in patients with glioblastoma. Society of Neuro-Oncology meeting. San Francisco, CA. Nov 2013: IT-025.
241. Stenquist DS, Bejarano S, Kennedy LS, Portillo S, Burgos SP, Zelaya RAE, Averill C, Liu E, de Abreu F, Burchard P, Gallagher T, **Tsongalis GJ**, Onega T, Chamberlin MD. Partnering for success: lessons from Breast and Cervical Cancer Screening in Rural Honduras. 2014 Global Oncology Symposium, Boston, MA.

242. Liu X, Mody K, Pipas JM, Smith KD, Peterson JD, de Abreu F, Gallagher TL, Amos CI, Suriawinata A, **Tsongalis GJ**. Analysis of Epithelial Neoplasms of the Appendix Using the Ampliseq Cancer Hotspot Mutation Panel. USCAP, San Diego, CA (March 2014).
243. Jacobs MS, Peterson JD, de Abreu F, Gallagher TL, Amos CI, Ernstoff MS, **Tsongalis GJ**, Brennick JB. Melanoma Genotypes Using Targeted Next Generation Sequencing. United States and Canadian Academy of Pathology Annual Meeting, March 1-7, 2014, San Diego, California. *Modern Pathology* 2014; 27(supp2s):135-136a.
244. Pettus J, Peterson JD, de Abreu F, Suriawinata AA, **Tsongalis, GJ**. Routine Somatic Mutation Testing in Colorectal Adenocarcinoma by Next Generation Sequencing using the Ion Torrent AmpliSeq Cancer Hotspot Panel v2. United States and Canadian Academy of Pathology Annual Meeting, March 1-7, 2014, San Diego, California. *Modern Pathology* 2014; 27(supp2s):197-198a.
245. Hartley CP, Peterson JD, de Abreu FB, Gutmann EJ, Padmanabhan V, Marotti JD, Tafe LJ, Wells WA, **Tsongalis GJ**, Amos CI, Liu X. Adequacy of formalin-fixed paraffin-embedded (FFPE) cytology specimens for next-generation sequencing (NGS) with the ion torrent PGM: a 10 month experience at a tertiary care center. CAP Meeting, 2014.
246. De Abreu FB, Peterson JD, Samara R, Collins J, **Tsongalis GJ**. Evaluation of a multiplex PCR targeted enrichment approach for the detection of actionable mutations in FFPE samples via Next-Generation Sequencing. ASHG, San Diego, CA (October 2014).
247. Putra J, De Abreu FB, Burchard PR, Toor A, Tsongalis GJ, Suriawinata AA. Altered Expression of MiR-21, MiR-27b, MiR-10b, and MiR-146a in Different Stages of Nonalcoholic Fatty Liver Disease. United States and Canadian Academy of Pathology Annual Meeting, March 1-7, 2014, San Diego, California. *Modern Pathology* 2014; 27(supp2s):426-427a.
248. Putra J, De Abreu FB, Hartley CP, Burchard PR, Tsongalis GJ, Suriawinata AA. Underexpression of MicroRNA-370 is Associated with Nonalcoholic Steatohepatitis. Digestive Disease Week 2014, May 4-6, 2014, Chicago, Illinois. *Gastroenterology* 2014; 146: 956-957.
249. Putra J, De Abreu FB, Suriawinata AA, Pipas JM, Gardner TB, Smith KD, Gordon SR, Tsongalis GJ, Liu X. Utilization of MicroRNA Analysis to Differentiate Autoimmune Pancreatitis from Pancreatic Malignancy: Single Case Demonstration. College of American Pathologists' Annual Meeting. September 7-10, 2014. Chicago, Illinois.
250. Allen S, Peterson JD, Wells WA, Tsongalis GJ, de Abreu FB. Evaluation of whole-genome amplification for next-generation sequencing using the Illumina TruSeq Amplicon Cancer Panel. *J Molec Diagn* 2014(Nov);16(6):788, TT72.
251. Bissaillon CM, Tyropolis A, Marconi SM, Young M, Allen AS, Turner S, Gallagher TL, Steinmetz HB, Lebel KA, Tsongalis GJ, Pflueger SMV. Troubleshooting the identification of a rare CFTR mutation which occurred twice in one run. *J Molec Diagn* 2014(Nov);16(6):775, TT16.
252. Bissaillon CM, Lebel KA, Tsongalis GJ, Otis CN. Improvement of an efficient process to identify, test and report oncology marker testing on FFPE specimens. *J Molec Diagn* 2014(Nov);16(6):764, ST81.
253. Bissaillon CM, Rios KM, Lebel KA, Tsongalis GJ. Quantitative method for the assessment of JAK2 V617F mutant allele burden. *J Molec Diagn* 2014(Nov);16(6):722, H39.
254. Bond JS, de Abreu FB, Peterson JD, Pipas JM, Hourdequin KC, Suriawinata AA, Tsongalis GJ, Liu X. Mutation analysis in colorectal carcinoma using targeted massively parallel sequencing. *J Molec Diagn* 2014(Nov);16(6):757, ST51.

255. Danilova OV, Peterson JD, de Abreu FB, Kaur P, Ornstein DL, Tsongalis GJ. The importance of reference transcripts when annotating next generation sequencing data. *J Molec Diagn* 2014(Nov);16(6):786, TT37.
256. De Abreu FB, Peterson JD, Kasinskas RW, Komorous B, Tsongalis GJ. Assessing gDNA quantity and quality from FFPE samples prior to next-generation sequencing using KAPA Human Genomic DNA Quantification and QC Kit. *J Molec Diagn* 2014(Nov);16(6):788, TT69.
257. De Abreu FB, Soares BL, Dos Santos LL, Kaur P, Ornstein DL, Tsongalis GJ. Design and validation of a CALR fragment analysis assay for patients with myeloproliferative neoplasm and negative for *JAK2* mutations. *J Molec Diagn* 2014(Nov);16(6):779, TT33.
258. De Abreu FB, Burchard PR, Steinmetz HB, Tsongalis GJ. Workflow comparison of the Maxwell® 16 FFPE Plus LEV DNA Purification Kit and the Qiagen Gentra Puregene Tissue Kit for extraction from FFPE tissues. *J Molec Diagn* 2014(Nov);16(6):779, TT31.
259. Fernandes H, Luthra R, Pate KP, Singh R, Routbort M, Zhang P, Peterson JD, de Abreu FB, Barokh B, Tsongalis GJ. Multicenter specimen exchange shows a high concordance for next generation sequencing-based *multi-gene* mutation *profiling* of solid tumors. *J Molec Diagn* 2014(Nov);16(6):746, ST04.
260. Gallagher TL, Soares BL, Fischer DA, dos Santos LL, Burchard PR, Suriawinata AA, Padmanabhan V, Smith KD, Tsongalis GJ. Identifying human DNA in a cfDNA component of pancreatic cancer patient derived xenograft (PDX) models. *J Molec Diagn* 2014(Nov);16(6):776, TT17.
261. Hoang MH, Tyropolis AM, Young M, Bissaillon CM, Lebel KA, Moore F, Steinmetz HB, Reader EI, Dokus BJ, Cook LJ, Wilson TL, Lefferts JA, Tsongalis GJ. Validation of the TIB MOLBIOL LightMix® Kit IL28B rs12979860. *J Molec Diagn* 2014(Nov);16(6):782, TT47.
262. Lebel KA, Marconi SA, Tyropolis AM, Bissaillon CM, Smith J, Phillips C, Casavant K, Tsongalis GJ, Pflueger SMV. Using chromosomal microarrays to further delineate traditional chromosome studies: A case report. *J Molec Diagn* 2014(Nov);16(6):707, G42.
263. Lebel KA, Marconi SA, Tyropolis AM, Bissaillon CM, Tsongalis GJ, Pflueger SMV. Findings from chromosomal microarray analysis in clinical practice: A study of 177 patients. *J Molec Diagn* 2014(Nov);16(6):708, G31.
264. Liu EZ, de Abreu FB, Gallagher TL, Tsongalis GJ. Routine screening for MGMT promoter methylation status in patients with malignant glioma using the MethyLight assay. *J Molec Diagn* 2014(Nov);16(6):780, TT36.
265. Liu EZ, de Abreu FB, Hickey WF, Ronan LK, Fadul CE, Otis C, Moral L, Fernandes H, Tsongalis GJ, Tafe LJ. Development of a 1p19q LOH Assay for Glioma Patients Using Capillary Electrophoresis. *J Molec Diagn* 2014(Nov);16(6):789, TT73.
266. Liu EZ, Reader EI, Tafe LJ, Tsongalis GJ, Lefferts JA. Detection of somatic copy number changes in breast cancer using the OncoScan FFPE assay. *J Molec Diagn* 2014(Nov);16(6):771, ST110.
267. Maloku E, Tafe LJ, Peterson JD, de Abreu FB, Hickey WF, Ronan LK, Fadul CE, Wells WA, Amos CI, Tsongalis GJ. Clinical genotyping of somatic mutations in glioma. *J Molec Diagn* 2014(Nov);16(6):758, ST55.
268. Marconi SA, Bonomi LM, Bissaillon CM, Lebel KA, Dokus BJ, Allen SA, Steinmetz HB, Lefferts JA, Tafe LJ, Tsongalis GJ, Moore FR. Validation of HCV genotyping using the GenMark eSensor XT-8. *J Molec Diagn* 2014(Nov);16(6):783, TT50.

269. Marconi SA, Young M, Bissaillon CM, Lebel KA, Tsongalis GJ, Otis CN. Formalin fixed, paraffin embedded tissue extraction validation using the Cobas extraction kit from Roche. *J Molec Diagn* 2014(Nov);16(6):765, ST84.
270. Mirafior AP, de Abreu FB, Peterson JD, Ernstoff M, Amos CI, Wells WA, Tsongalis, GJ, Yan S. Somatic Mutation Analysis in Melanoma Using Targeted Next Generation Sequencing. *J Molec Diagn* 2014(Nov);16(6):756, ST47.
271. Peterson JD, de Abreu FB, Tsongalis GJ. Comparison of Ion Torrent AmpliSeq Cancer Hotspot Panel v2 workflow to Illumina TruSeq Amplicon Cancer Panel. *J Molec Diagn* 2014(Nov);16(6):788, TT71.
272. Pierce KJ, Peterson JD, de Abreu FB, Padmanabhan V, Black CC, EJ Gutmann, Rigas JR, Dragnev KH, Amos CI, Tsongalis GJ, Tafe LJ. Targeted clinical genotyping of non-small cell lung cancers (NSCLC) using next generation sequencing. *J Molec Diagn* 2014(Nov);16(6):756, ST49.
273. Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, Tsongalis GJ, Suriawinata AA. Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinoma Using Next Generation Sequencing. *J Molec Diagn* 2014(Nov);16(6):747, ST10.
274. Steinmetz HB, Dokus BJ, Cook LJ, Wilson TL, Tafe LJ, Tsongalis GJ, Lefferts JA. Converting to the eSensor HCVg Direct Test: An HCV genotyping validation. *J Molec Diagn* 2014(Nov);16(6):742, ID70.
275. Steinmetz HB, Liu EZ, Burchard PR, Gallagher TL, Bejarano S, Stenquist DS, Kennedy LS, Portillo S, Martinez MT, Martinez Membreno MT, Burgos SP, Elvir Zelaya RA, Averill C, Onega T, Chamberlin MD, Tsongalis GJ. HPV Screening in a Rural Region of Honduras: La Gran Jornada Is a Global Health Initiative. *J Molec Diagn* 2014(Nov);16(6):728, ID07.
276. Tafe LJ, Chamberlin MD, Miller TW, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Memoli VA, Schned AR, Suriawinata AA, Tsongalis GJ. Implementation of a molecular tumor board. *J Molec Diagn* 2014(Nov);16(6):744, OTH01.
277. Turner SA, Reader EI, Liu EZ, Tafe LJ, Tsongalis GJ, Lefferts JA. Evaluation of OncoScan FFPE Assay for detection of somatic mutations in cancer. *J Molec Diagn* 2014(Nov);16(6):758, ST56.
278. Turner SA, Steinmetz HB, Dinulos MB, Moeschler JB, Vallee SE, Upton SJ, Tafe LJ, Chen R, Garcia S, Church D, Tirch J, Huang A, Lefferts JA, Tsongalis GJ. The clinical utility of clinical whole exome sequencing. *J Molec Diagn* 2014(Nov);16(6):706, G31.
279. Vallee, SE, Lefferts, JA, Reader, EI, Steinmetz, HB, Tafe, LJ, Dinulos, MBP, Tsongalis, GJ. Detection of Copy Number Variants in Seizure Disorders: Support for Microarray as a First-Tier Diagnostic Test. (Abstract #185). American College of Medical Genetics and Genomics, Annual Clinical Genetics Meeting, March 24-29, 2015, Salt Lake City, UT.
280. Dinulos, MBP, Cervinski, MA, Lee, HK, Vallee, SE, Tsongalis, GJ. Genetic Testing Utilization Management: The DHMC Experience. (Abstract #466). American College of Medical Genetics and Genomics, Annual Clinical Genetics Meeting, March 24-29, 2015, Salt Lake City, UT.
281. Pierce K, Currens H, Tafe L, Tsongalis G, Padmanabhan V. An analysis of human papilloma virus (HPV) testing and endocervical component on Pap tests performed from the same vial. *Lab Invest* 2015:102A:398.
282. Mockus S, Stafford G, Potter C, Ananda G, Hinerfeld D, Tsongalis G. AURKA mutation commonly found in conjunction with BRAF V600E in skin melanoma. *Lab Invest* 2015:124A:482.

283. Andrew A, Li J, Koestler D, Tsongalis G, Marsit C, Butterly L, Amos C, Srivastava A. DNA methylation array shows overlapping methylation profiles in hyperplastic polyps (HP) and sessile serrated adenoma/polyps (SSA/P) of the colorectum. *Lab Invest* 2015;146A:574.
284. Mockus S, Stafford G, Potter C, Ananda G, Hinerfeld D, Tsongalis G. Genotype driven anti-cancer therapies for colon cancer. *Lab Invest* 2015;180A:710.
285. Ananda G, Simons A, Beane G, Srivastava A, Stafford G, Mockus S, Liu RR, Hanna C, Lakshminarayana A, Walton D, Hinerfeld D, Tsongalis G, Karuturi RKM. Clinical genome analytics (CGA): An automated analytical pipeline for detection and annotation of clinically relevant genomic variants. *Lab Invest* 2015;395A:1574.
286. Maloku E, Peterson J, Liu E, Amos C, Hickey W, Ronan L, Fadul C, Tsongalis G, de Abreu F. Targeted next generation sequencing and methylguanine-DNA methyltransferase methylation in glioma patients. *Lab Invest* 2015;432A:1726.
287. Hinerfeld D, Stafford G, Potter C, Ananda G, Tsongalis G, Mockus S. Expanded targeted panels increase the likelihood of identifying actionable mutations. *Lab Invest* 2015;515A:2069.
288. Pierce K, Putra J, de Abreu F, Peterson J, Pipas JM, Smith K, Tsongalis G, Liu X. KRAS variants in different tumor types: A study using next-generation sequencing (NGS). *Lab Invest* 2015;522A:2097.
289. Mirafior AP, de Abreu FB, Peterson JD, York EB, Tsongalis GJ, Yan S. Examining the heterogeneity of BRAF-mutated melanoma utilizing next generation sequencing. 52nd Annual Meeting of The American Society of Dermatopathology (ASDP), San Francisco, CA. Oct, 2015.
290. Putra J, Holubar SD, Pierce KJ, de Abreu FB, Mejaddam AY, Gleeson MW, Peterson JD, Suriawinata AA, Lisovsky M, Liu X, Tsongalis GJ, Utility of next generation sequencing in rectal cancer personalized medicine, CAP'15, Nashville, TN. Oct 2015.
291. Hedayat A, Linos K, Tsongalis GJ, Lefferts JA. Analysis of copy number variation in melanoma versus benign lesions using chromosomal microarray. 52nd Annual Meeting of The American Society of Dermatopathology (ASDP), San Francisco, CA. Oct, 2015.
292. Vallee SE, Tafe LJ, Reader EI, Dinulos MBP, Bao L, Tsongalis GJ, Lefferts JA. Bilateral Radial Ray Defects: An Atypical Presentation of 16p11.2 Microdeletion Syndrome. *Canc Genet.* 2015 (Jun) 208(6):365.
293. Lefferts JA, Turner SA, Liu EZ, Reader EI, Linos K, Tafe LJ, Tsongalis GJ. Analytical Validation of Chromosomal Microarray Analysis with Solid Tumor FFPE Specimens. *Canc Genet.* 2015 (Jun) 208(6):360–361.
294. de Abreu FB, Peterson JD, Amos CI, Wells WA, Tsongalis GJ. Somatic Mutation Profiling Using a 50 Gene Cancer Panel: The Dartmouth Experience. Northern New England Clinical Oncology Society annual meeting. Portland, ME (Oct 23-24,2015).
295. Gallagher TL, Gonzalez J, Tsongalis GJ, Wells WA. Implementation of a College of American Pathologists Accredited Institutional Biorpository. Northern New England Clinical Oncology Society annual meeting. Portland, ME (Oct 23-24,2015).
296. Peterson JD, Tafe LJ, Gorlov I, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Memoli VA, Schned AR, Suriawinata AA, Miller TW, Chamberlin MD, Tsongalis GJ. Using a Molecular Tumor Board to Review Potential Mutation Driven Treatment Decisions. Northern New England Clinical Oncology Society annual meeting. Portland, ME (Oct 23-24, 2015).
297. Turner SA, Rand JV, de Abreu FB, Toth LN, Peterson JD, Kaur P, Ornstein D, Tsongalis GJ, Loo EY. Somatic Mutation Analysis in Myeloid Disease Using a Targeted Gene Panel and Massively

Parallel Sequencing. Northern New England Clinical Oncology Society annual meeting. Portland, ME (Oct 23-24, 2015).

298. Turner SA, Cervinski MA, Allen SF, Tafe LJ, Tsongalis GJ, Lefferts JA. Validation and implementation of HLA genotyping for determination of Celiac disease. *J Molec Diagn* 2015 (Nov): 17(6):758, G21.
299. Toth LN, Peterson JD, Kaur P, Ornstein DL, Tsongalis GJ, de Abreu FB. Next generation sequencing of a 54 gene panel to assess myeloid disease. *J Molec Diagn* 2015 (Nov): 17(6):770, H23.
300. Mockus SM, Patterson SE, Statz C, Tsongalis GJ. Actionability assessment and theoretical utility of expanded targeted NGS panels. *J Molec Diagn* 2015 (Nov): 17(6):798, I09.
301. Mockus SM, Patterson SE, Potter CS, Statz C, Woo X, Stafford GA, Tsongalis GJ. Implementation of a tier ranking system for the reporting of therapy efficacy evidence in NGS oncology reports. *J Molec Diagn* 2015 (Nov): 17(6):799, I11.
302. Mockus SM, Durkin D, Liu R, Ananda G, Patterson SE, Bult CJ, Pipas JM, Tsongalis GJ. A proposal and method for initial reporting standards in precision oncology clinical trials with biomarkers. *J Molec Diagn* 2015 (Nov): 17(6):799, I13.
303. Lefferts JA, Peterson JD, Turner SA, de Abreu FB, Tafe LJ, Tsongalis GJ. Somatic copy number assessment in tumors based on amplicon coverage in a targeted NGS panel. *J Molec Diagn* 2015 (Nov): 17(6):808, I49.
304. Turner SA, Bejarano S, Alibozek RA, Kennedy L, Williams S, Tsongalis GJ. Evaluation of methods for high risk HPV screening in low resource countries. *J Molec Diagn* 2015 (Nov): 17(6):784, ID21.
305. Cook LJ, Allen SF, Dokus BJ, Reader EI, Wilson TL, Steinmetz HB, Tsongalis GJ, Lefferts JA. CMV quantification using COBAS AmpliPrep/COBAS Taqman CMV Test. *J Molec Diagn* 2015 (Nov): 17(6):796, ID72.
306. Turner SA, Dinulos MP, Lee H, Vallee SE, Tsongalis GJ, Cervinski MA. Effective genetic testing utilization management: Consolidation, internalization and review. *J Molec Diagn* 2015 (Nov): 17(6):811, OTH01.
307. Pierce KJ, de Abre FB, Peterson JD, Tsongalis GJ, Liu X. The genomic profile of pancreatic adenocarcinoma and its relationship to metastatic disease. *J Molec Diagn* 2015 (Nov): 17(6):821, ST35.
308. Turner SA, de Abreu FB, Liu EZ, Tsongalis GJ, Lefferts JA, Tafe LJ. Analysis of MLH1 promoter methylation in colorectal and endometrial carcinomas using the MethyLight assay. *J Molec Diagn* 2015 (Nov):17(6):821, ST37.
309. Bond JS, Mockus S, Putra J, Patterson S, Ananda G, Mitchell T, Spotlow V, York EB, Palisoul S, Pipas JM, Smith KD, Suriawinata AA, Tsongalis GJ, Liu X. Mutation analysis in pancreatic cancer using an expanded massively parallel sequencing gene panel. *J Molec Diagn* 2015 (Nov):17(6):826, ST56.
310. Dillon JL, Mockus S, Patterson S, Ananda G, Mitchell T, Spotlow V, York EB, Palisoul S, Wells WA, Tsongalis GJ, Marotti JD. Somatic gene mutation analysis of triple negative breast cancers. *J Molec Diagn* 2015 (Nov):17(6):826, ST58.
311. Muller KE, Marotti JD, Chamberlin MD, Tsongalis GJ, Tafe LJ. Targeted massively parallel sequencing of breast cancer metastases identifies potentially actionable molecular alterations. *J Molec Diagn* 2015 (Nov):17(6):835, ST95.

312. Helm S, Mitchell T, Ras A, Spotlow V, Kelly K, Mockus S, Statz C, Ananda G, Malcolm J, Tsongalis GJ. Evaluation of the Archer FusionPlex solid tumor panel in the JAX cancer treatment profile. *J Molec Diagn* 2015 (Nov):17(6):837, ST104.
313. Muller KE, Mockus S, Patterson S, Ananda G, Mitchell T, Spotlow V, York E, Palisoul S, Tsongalis GJ, Black CC. Targeted massively parallel sequencing of squamous cell carcinoma of the lung identifies potentially actionable molecular alterations. *J Molec Diagn* 2015 (Nov):17(6):838, ST105.
314. De Abreu FB, Peterson J, Linos KB, Pettus JB, LaBonte A, Mealmaker C, Teator A, Bowers T, Tsongalis GJ. Identification of fusion genes in sarcoma patients using the Archer FusionPlex sarcoma panel. *J Molec Diagn* 2015 (Nov):17(6):838, ST106.
315. De Abreu FB, Peterson J, Huang C, Ankella B, Garlick R, Tsongalis G. Quality controls for NGS somatic mutation testing. *J Molec Diagn* 2015 (Nov):17(6):839, ST111.
316. Padmanabhan V, Curren HS, Steinmetz HB, Rizzo EJ, Erskine AJ, Fairbank TL, de Abreu F, Tsongalis GJ, Tafe LJ. Improving adequacy of cytology specimens for molecular testing in patients with non-small cell lung cancer: Quality improvement study. *J Molec Diagn* 2015 (Nov):17(6):839, ST112.
317. De Abreu F, Mockus S, Potter C, Ananda G, Patterson S, Mitchell T, Spotlow V, York E, Palisoul SM, Tsongalis GJ, Liu X. Somatic mutation analysis in colon cancer using a 358 gene panel. *J Molec Diagn* 2015 (Nov): 17(6):839, ST113.
318. Spotlow V, Ras A, Helm S, Kelly K, Mitchell T, Ananda G, Malcolm J, Tsongalis GJ. Optimization of a next generation sequencing panel to reduce DNA input concentration, turn around time, and cost. *J Molec Diagn* 2015 (Nov):17(6):850, TT30.
319. Ras A, Mitchell T, Spotlow V, Kelly K, Helm S, Ananda G, Malcolm J, Tsongalis GJ. Evaluation of Qiacube versus EZ1 advanced XL for purification of genomic DNA from FFPE solid tumor tissue. *J Molec Diagn* 2015 (Nov):17(6):856, TT52.
320. Putra J, de Abreu F, York EB, Palisoul SM, Suriawinata AA, Liu X, Tsongalis GJ. MicroRNA expression in pancreatic ductal adenocarcinoma: A comparative study to predict metastasis after neoadjuvant chemoradiation. *Modern Pathol* 2016;29 (n2s):447a (1770) (United States and Canadian Academy of Pathology, Seattle, WA).
321. Biernacka A, Tsongalis PD, Peterson JD, de Abreu F, Black CC, Gutmann E, Liu X, Padmanabhan V, Tafe LJ, Amos CI, Tsongalis GJ. Frequency of KRAS subtypes in non-small cell lung cancer. *Modern Pathol* 2016;29 (n2s):451a (1787) (United States and Canadian Academy of Pathology, Seattle, WA).
322. Mockus S, Statz C, Helbig P, Patterson SE, Sanders V, Skacel M, Tsongalis GJ, Rueter J. Clinician experience with an NGS clinical observation trial in oncology. *Modern Pathol* 2016;29 (n2s):457a (1810) (United States and Canadian Academy of Pathology, Seattle, WA).
323. Toth LN, Amos CI, Dragnev KH, Tsongalis GJ, Tafe LJ. Janus kinase 3 (JAK3) aberrations in non-small cell lung cancer. *Modern Pathol* 2016;29 (n2s):485a (1928) (United States and Canadian Academy of Pathology, Seattle, WA).
324. Kelly K, Spotlow V, Ras A, Helm S, Malcolm J, Tsongalis GJ. Comparison of 5 methods for extraction of cell-free DNA. *Modern Pathol* 2016;29 (n2s):515a (2046) (United States and Canadian Academy of Pathology, Seattle, WA).
325. Stenquist DS, Bejarano S, Kennedy LS, Portillo S, Barrientos A, Burgos SP, Zelaya RAE, Averill C, Liu E, de Abreu F, Burchard P, Gallagher T, Goodrich M, Eliassen S, Weiss J, Mandujano C, Alford-Teaster J, Tsongalis GJ, Onega T, Chamberlin MD. Partnering for Success: Expanding

Breast and Cancer Screening in Rural Honduras One Clinic at a Time Global Oncology Symposium, 2016 (San Francisco, CA) (J Global Oncol).

326. Biernacka A, de Abreu FB, Peterson JD, Tafe LJ, Black CC, Gutmann EJ, Deharvengt SJ, Liu X, Amos CI, Tsongalis GJ. *TP53* and *LKB1/STK11* Mutation Status in *KRAS* Mutant Lung Adenocarcinoma – Implications for MEK Inhibition. *J Molec Diagn* 2016 (Nov);18:1000 (S11).
327. De Abreu FB, Peterson JD, Deharvengt SJ, Tafe LJ, Wells WA, Tsongalis GJ. Validation of the FusionPlex™ Solid Tumor Panel in routine clinical practice. *J Molec Diagn* 2016 (Nov);18:1024 (S109).
328. Deharvengt SJ, Tsongalis GJ, De Abreu FB. Evaluation of DNA quantification methods for amplicon-based library preparation from FFPE tissue. *J Molec Diagn* 2016 (Nov);18:1033 (TT13).
329. Deharvengt SJ, Turner SA, Kennedy LS, Tsongalis GJ. Multiplex Real-Time PCR Melting Curve Assay for Identifying HPV Types Using the Cepheid SmartCycler. *J Molec Diagn* 2016 (Nov);18:971 (ID13).
330. Deharvengt SJ, De Abreu FB, Peterson JD, Daber R, Ananda G, Sarsani VK, Spotlow V, Sims DJ, Harrington RD, Lih C, Williams PM, Harper KN, Bouk CH, Datta V, Konigshofer Y, Huang C, Dickens J, Ku A, Anekella B, Davis L, Garlick RK, Ferreira-Gonzalez A, Dumur CI, Fernandes H, Haralampu S, Tsongalis GJ. The Use of Biosynthetic Controls as Performance Standards for NGS Assays of Somatic Tumors: A Multi-laboratory study. *J Molec Diagn* 2016 (Nov);18:101031-1032 (TT06).
331. Dokus B, Steinmetz HB, Tsongalis GJ, Tafe LJ. Implementation of a BioView Fluorescence in-situ Hybridization (FISH) Automated Imaging and Analysis System. *J Molec Diagn* 2016 (Nov);18:1044-1045 (TT60).
332. Gallagher TL, de Abreu FB, Wells WA, Tsongalis GJ. Validation of EGFR Fragment Analysis by PerkinElmer LabChip GX Touch 24. *J Molec Diagn* 2016 (Nov);18:050 (TT83).
333. Jung HS, Bond JS, van Hoff J, Tsongalis GJ, Nguyen L, Linos K, Hickey WF, Lefferts JA. The OncoScan® FFPE Assay Diagnostically Confirmed a Rare Unclassifiable Myxoid Sarcoma Case. *J Molec Diagn* 2016 (Nov);18:1023 (S106).
334. Jung HS, Tsongalis GJ, Lefferts JA. Development of HLA-B*57:01 Genotyping Real-time PCR with Hydrolysis Probes. *J Molec Diagn* 2016 (Nov); 18:9450 (G56).
335. Jung HS, Tsongalis GJ, Lefferts JA. Concentration of Genomic DNA is Critical for the OncoScan® FFPE Assay. *J Molec Diagn* 2016 (Nov);18:1049 (TT79).
336. Liang L, Sanapareddy N, Patel F, Tan Q, Hussain W, Gaspard H, Goodell L, Bhagavathi S, Riedlinger G, Rosenfield J, Foran D, Rodriguez L, Tsongalis GJ, Turner SA, de Abreu FB, Steinmetz HB, Brooks A, Tischfield JA, Sahota A. Validation of a droplet PCR-based targeted gene panel for the detection of sequence variants in myeloid neoplasms. *J Molec Diagn* 2016 (Nov); 18:952-953 (H08).
337. Linnik YA, de Abreu FB, Peterson JD, Turner SA, Kaur P, Ornstein D, Tsongalis GJ, Loo E. Cohesin-complex Mutations are Diverse and Highly Associated with Secondary Acute Myeloid Leukemia.
338. Maloney NS, de Abreu FB, Deharvengt SJ, Peterson JP, Suriawinata AA, Tsongalis GJ. Gastrointestinal Stromal Tumor Mutation Analysis by Next Generation Sequencing. *J Molec Diagn* 2016 (Nov);18:1000-1001 (S12).

339. Olofson AM, de Abreu FB, Peterson JD, Deharvengt SJ, Hourdequin KC, Ripple GH, Lisovsky M, Suriawinata AA, Tsongalis GJ. Somatic Mutation Analysis of the RAS Gene Family in Colorectal Carcinoma. *J Molec Diagn* 2016 (Nov);18:1002 (S18).
340. Olofson AM, Liu X, Deharvengt SJ, de Abreu FB, Peterson JD, Suriawinata AA, Lisovsky M, Tsongalis GJ. Targeted Genomic Profiling of Rectal Carcinoma Using Next Generation Sequencing. *J Molec Diagn* 2016 (Nov);18:1002-1003 (S20).
341. Peterson JD, de Abreu FB, Wang Z, Wells WA, Tsongalis GJ. Evaluation of the Pillar NGS SLIMamp™ Lung and Colon Hot Spots Panel. *J Molec Diagn* 2016 (Nov);18:1017 (S82).
342. Peterson JD, Amos CI, de Abreu FB, Wells WA, Tsongalis GJ. Evaluation of the CLC Biomedical Genomics Workbench (BMGW) Platform for Targeted Clinical NGS Data Analysis. *J Molec Diagn* 2016 (Nov);18:990 (I16).
343. Pierce K, de Abreu FB, Peterson JD, Putra J, Deharvengt SJ, Liu X, Tsongalis GJ. Comparative Analysis of miRNA Expression and Next Generation Sequencing Results in Metastatic and Non-Metastatic Pancreatic Adenocarcinoma. *J Molec Diagn* 2016 (Nov);18:1001-1002 (S16).
344. Shajani-Yi Z, Nguyen LN, Hickey WF, Deharvengt SJ, de Abreu FB, Peterson JD, Gallagher TL, Erskine AJ, Lefferts JA, Tsongalis GJ. Frequency of *MGMT* Promoter Hypermethylation, 1p/19q Co-deletions and *IDH1* and *IDH2* Mutations in Gliomas. *J Molec Diagn* 2016 (Nov);18:1023 (S105).
345. Shajani-Yi Z, Cervinski MA, Palko Dinulos MB, Vallee SE, Wells WA, Tsongalis GJ. Molecular Test Utilization Improvements at Dartmouth-Hitchcock Medical Center. *J Molec Diagn* 2016 (Nov);18:996-997 (OTH05).
346. Toth LN, de Abreu FB, Peterson JD, Turner SA, Kaur P, Ornstein D, Tsongalis GJ, Loo E. Characterization of Clonal Hematopoiesis Identified in Non-Neoplastic Bone Marrow Biopsies. *J Molec Diagn* 2016 (Nov);18:954-955 (H16).
347. Turner SA, Deharvengt SJ, Plata J, LaRochelle EP, Bejarano S, Kennedy L, Tsongalis GJ. Evaluation of Methods for Point-of-Care Testing for High Risk HPV Screening in Low Resource Countries. *J Molec Diagn* 2016 (Nov);18:969-970 (ID06).
348. Turner SA, Jung HS, de Abreu FB, Peterson JD, Tsongalis GJ. Evaluation of the Qiagen GeneReader NGS System for the Detection and Reporting of Clinically Actionable Mutations in Solid Tumors. *J Molec Diagn* 2016 (Nov);18:1034 (TT14).
349. Vallee SE, Jung HS, Dokus BJ, Henne RA, Tafe LJ, Dinulos MBP, Tsongalis GJ, Lefferts JA. 15q11.2 BP1-BP2 Microdeletion syndrome: Clinical features and co-occurring copy number variants. *J Molec Diagn* 2016 (Nov); 18:948-949 (G51).
350. Toth LN, Peterson JD, de Abreu FB, Tsongalis GJ, Tafe LJ. Non-small cell lung cancer with isocitrate dehydrogenase (IDH1/IDH2) mutations. *J Molec Diagn* 2016 (Nov);18:1029 (S130).
351. Linos K, Peterson JD, Deharvengt SJ, de Abreu FB, Shirai K, Tsongalis GJ, Tafe LJ. Isocitrate Dehydrogenase 1 (IDH1) Mutations in Melanoma Frequently Co-occur with NRAS Mutations. (Accepted for presentation, USCAP annual meeting, 2017)
352. Nicka CM, de Abreu FB, Peterson JD, Tsongalis GJ, Tafe LJ. Characterization and Correlation of *ALK* Fusion Breakpoints in *ALK* FISH Rearranged Non-Small Cell Lung Cancer by Anchored Multiplex PCR and Next-Generation Sequencing (Accepted for presentation, USCAP annual meeting, 2017)
353. Studwell CM, Atkinson A, Kennedy L, Bejarano S, Plata Espinal JA, LaRochelle EPM, Lyons KD, Tsongalis GJ. Improving Cervical Cancer Outcomes in Rural Honduras with Low Cost HPV

Screening. J Assoc Genet Technol 2017;43(3):88, S2.

354. Allen SF, Airhart S, Bundy M, Gallagher TL, Jocoy E, Tsongalis GJ. STR analysis as a quality control measure for provenance of xenograft tumors. J Molec Diagn 2017; 1047 (TT12).
355. Atkinson AA, Studwell CM, LaRochelle EP, Kennedy LS, Deharvengt SJ, Espinal JA, Bejarano S, Tsongalis GJ. Molecular-based HPV screening in resource limited countries. J Molec Diagn 2017; 976 (ID15).
356. Atkinson AA, Studwell CM, Tafe LJ, Tsongalis GJ. HPV genotyping of solid tumors using real time PCR and multi-color melt curve analysis. J Molec Diagn 2017; 1017 (ST41).
357. Atkinson AA, Zhang R, Peterson JD, de Abreu FB, Yuan Y, Lei M, Tsongalis GJ. Real time PCR assessment of actionable mutations in non-small cell lung cancer. J Molec Diagn 2017; 1016 (ST38).
358. De Abreu FB, Petersen JD, Deharvengt SJ, Huang C, Bharath A, Ryder M, Garlick R, Tsongalis GJ. Evaluation of Seraseq FFPE tumor fusion RNA reference material for use in routine clinical NGS testing. J Molec Diagn 2017; 1039 (ST130).
359. De Abre FB, Petersen JD, Deharvengt SJ, Tafe LJ, Wells WA, Tsongalis GJ. Evaluation of a 170 gene NGS panel for the detection of RNA and DNA based variants in FFPE solid tumor samples. J Molec Diagn 2017; 1040 (ST133).
360. De Abreu FB, Petersen JD, Dugan B, Wang Z, Tsongalis GJ. Evaluation of the Pillar NGS SLIMamp cancer hotspot panel. J Molec Diagn 2017; 1039 (ST131).
361. Linnik Y, Allen SF, Cook LJ, Kilbourn JL, Studwell CM, Nakorchevsky AA, Loo EY, Tsongalis GJ, Lefferts JA. Comparison of a MALDI-TOF-based SNP panel with STR analysis for chimerism testing. J Molec Diagn 2017; 962(H36).
362. Nicka C, de Abreu FB, Peterson JD, Tsongalis GJ, Tafe LJ. Routine use of the FusionPlex solid tumor panel identifying clinically actionable gene rearrangements in lung adenocarcinoma. J Molec Diagn 2017; 1034 (ST108).
363. Olofson AM, Liu X, Deharvengt SJ, de Abreu FB, Peterson JD, Suriawinata AA, Lisovsky M, Tsongalis GJ. Targeted mutational analysis of predictive and prognostic biomarkers in colorectal cancer. J Molec Diagn 2017; 1019 (ST41).
364. Rajagopal A, Yurk D, de Abreu FB, Shin C, Tombrello T, Fraser S, Tsongalis GJ. Multiplexing method for significantly increasing the bandwidth of qPCR instrumentation. J Molec Diagn 2017; 1046 (TT09).
365. Sidiropoulos N, Babcock M, de Abreu FB, Dufresne S, Hampel K, Lebel K, Loo EY, Peterson JD, Scott C, Seward D, Skacel M, Steinmetz HB, Tafe LJ, Tsongalis GJ, Lefferts JA. The Northern New England Genomics Consortium. J Molec Diagn 2017; 1007 (OTH08).
366. Tadimety A, Zhang Y, Tsongalis GJ, Zhang JX. Screening circulating nucleic acids of pancreatic ductal adenocarcinoma using a plasmonic nanosensor. J Molec Diagn 2017; 1050 (TT24).
367. France J, Jung HS, Tsongalis G, Loo EY, Lefferts J. Development and assessment of a droplet digital RT-PCR method for BCR-ABL1 monitoring. Mod Pathol 2018;31(2s):805 (2246).
368. Nicka C, Peterson J, de Abreu F, Shirai K, Tsongalis G, Dragnev KH, Tafe L. Compound EGFR mutations frequently occur on the same allele (in Cis) and define a unique subset of EGFR mutant non-small cell lung cancer. Mod Pathol 2018;31(2s):745 (2080).
369. Tadimety A, Zhang Y, Palinski TJ, Cheng GC, Tsongalis GJ, Zhang JXJ. Plasmonic Gold Nanorods With Sequence Specific Conjugation for Circulating Tumor DNA Screening. 2018 International Conference on Optical MEMS and Nanophotonics (OMN), Lausanne, 2018, pp. 1-5.
370. Al-Turkmani MR, Suriawinata MA, Black CC, Shirai K, Dragnev KH, Tsongalis GJ. Rapid EGFR Mutation Testing in Lung Cancer Tissue Samples Using a Fully Automated System and Single-Use Cartridge. J Molec Diagn 2018 (Nov); 20(6):1007 (ST125).
371. Al-Turkmani MR, Rizzo EJ, Schutz SN, Tsongalis GJ. Stat EGFR Mutation Detection in Fresh Lung Cancer Tissue Specimens Using Touch Preparation and the Idylla™ System. J Molec Diagn 2018 (Nov); 20(6):1034 (TT060).

372. Al-Turkmani MR, Gallagher TL, Cervinski MA, Tsongalis GJ, Lefferts JA. Effect of Plasma Separation Time After Blood Collection on the Concentration and Integrity of Circulating Cell-Free DNA. *J Molec Diagn* 2018 (Nov); 20(6):1036 (TT066).
373. Atkinson A, Al-Turkmani MR, de Abreu F, Tsongalis GJ, Lefferts JA. Clinical Evaluation of the Pillar Bioscience ONCOReveal Multi-Cancer Panel. *J Molec Diagn* 2018 (Nov); 20(6):1006 (ST123).
374. de Abreu FB, Deharvengt SJ, Austermler B, Morrison T, Tsongalis GJ, Lefferts JA. Spike-in NGS Controls for Copy Number Assessment and Improved LOD and VAF Confidence. *J Molec Diagn* 2018 (Nov); 20(6):1027 (TT037).
375. Deharvengt SJ, Tsongalis GJ. NGS Library Quantification Using the Quantabio Q and PerfeCTa NGS Quantification Kit. *J Molec Diagn* 2018 (Nov); 20(6):1017 (TT005).
376. Green DC, Peterson JD, Tafe LJ, de Abreu F, Tsongalis GJ, Lefferts JA. Evaluation of SOPHiA DDM v4 for NGS analysis of Ampliseq Cancer Hotspot Panel. *J Molec Diagn* 2018 (Nov); 20(6):962 (I020).
377. Hughes EG, Barney R, Deharvengt SJ, Kilborn J, Green DC, Peterson JD, Erskine AJ, Tafe LJ, Lefferts JA, Tsongalis GJ, de Abreu FB. Molecular genetic profiling of gliomas in routine clinical practice. *J Molec Diagn* 2018 (Nov); 20(6):991 (ST075).
378. Johnston MA, Allen S, Steinmetz HB, Tsongalis GJ, Lefferts JA. Quantification of CMV Using the m2000 RealTime CMV Assay. *J Molec Diagn* 2018 (Nov); 20(6):951 (ID056).
379. Maloney NS, Green DC, Al-Turkmani MR, Liu X, Tsongalis GJ, Ren B. Biocartis Idylla™ Cartridge-Based Microsatellite Instability Assay Shows High Concordance with Immunohistochemical Analysis for Mismatch Repair Status in Colorectal Cancer. *J Molec Diagn* 2018 (Nov); 20(6):1032 (TT054).
380. Nicka CM, Green DC, Tsongalis GJ, Tafe LJ. Detection of Microsatellite Instability in Endometrial Carcinoma using the novel Idylla™ MSI Assay. *J Molec Diagn* 2018 (Nov); 20(6):1008 (ST127).
381. Strait AM; Cook LJ; Palisoul SM; Ren B; Tsongalis GJ; Liu X. MSI Status in Primary Pancreatic Carcinoma: A Pilot Study of a New England Cohort. *J Molec Diagn* 2018 (Nov); 20(6):993 (ST081).
382. Hughes E, Al-Turkmani MR, Griffin C, Tsongalis GJ, Lefferts JA. Confirming somatic variant allele fractions in novel circulating tumor DNA (ctDNA) control material. *J Molec Diagn* 2018 (Nov); 20(6):1029 (TT043).

Presented at International Meetings:

1. Carter TH, Kaufmann WK, Tsongalis GJ, Blackmon RH, Sun I and Tang S. Activation of a DNA dependent protein kinase in human cells by DNA damage and viral transformation. AACR: Cellular Responses to Environmental DNA Damage, Banff, Alberta, Canada, 1991.
2. Tsongalis GJ, Rezukey WN, Wu AH. An epidemiological study to evaluate the incidence of activated protein C resistance in the general population using a PCR-mediated RFLP assay. IFCC, International Congress of Clinical Chemistry, Wembley, London, 1996.
3. Joshi VV, Tsongalis GJ. Correlation between morphologic and non-morphologic prognostic markers in neuroblastomas (NB). Pediatric Oncology Group Meeting, Budapest, 1996.
4. Tsongalis GJ. The state of molecular pathology testing. 3rd International Meeting of the Athena Society. Samos, Greece, 2003.

5. Wishart H, McDonald B, McAllister T, Kasper L, Bauman T, Fadul C, Flashman L, Ryan K, Mamourian A, Rhodes H, Tsongalis G, Saykin A. Regional grey matter concentration and brain activity in relapsing-remitting MS: effects of BDNF genotype. 21th Congress of the European Committee / 10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, Thessaloniki, Greece, 2005.
6. Tsongalis GJ. Microarray technologies for the clinical laboratory. 4th International Meeting of the Athena Society. Mykonos, Greece, 2006
7. UEGW/WCOG GASTRO 2009, London, November 24, 2009.
8. Turner S, Studwell C, Deharvengt S, Lyons KD, Plata JA, LaRochelle EPM, Zapata AM, Kennedy L, Tsongalis GJ, Bejarano S. High risk HPV genotypes identified in northern Honduras: Evidence for prevention. World Congress/UICC, 2018, Malaysia.
9. Flynn TG, Dunaway CM, LaRochelle EPM, Zuniga J, Campos RJB, García HSR, Cervinski MA, Spaller MR, Romano M, Kennedy LS, Bejarano S, Lyons KD, Tsongalis GJ, Huyck KL. Reducing dermal exposure to agrochemical carcinogens using a fluorescent dye-based intervention among subsistence farmoers in riral Honduras. World Congress/UICC, 2018, Malaysia.
10. Kennedy L, LaRochelle EPM, Bejarano S, Tsongalis GJ. An organized approach to multi-organ screening in rural Honduras. World Congress/UICC, 2018, Malaysia.

XIX. Personal Statement:

Training as a molecular pathologist prepared me well for the post-genome era of science and medicine, including the recent explosion of information for novel diagnostics and therapeutics in oncology. My laboratories have been at the cutting edge of developing new diagnostic assays in the field of genomic medicine and in implementing new clinical applications based on the human genome. Some of our accomplishments include being the first to offer molecular monitoring for BCR-ABL in CML patients using a rapid qPCR technology, the first to develop an association of miRNA expression and pancreatic cancer, the first to develop pharmacogenetic testing for UGT1A1 polymorphisms and the first to offer next generation sequencing for solid and liquid tumor analysis in a clinical setting with more than 3,000 patient tumors now tested. Our interest in human cancers stems from the aggressiveness of the disease, lack of adequate biomarkers to diagnose and monitor progression of disease and use of molecular profiling to select the most appropriate therapy. This has not only been a very rewarding endeavor but it has also allowed me to be involved in some very exciting translational science that has also led to new patient-centric applications.